

## CURRICULUM VITAE

**Bruce Raymond Bacon, M.D.**

### **CURRENT POSITION:**

*James F. King MD Endowed Chair in Gastroenterology*  
Professor of Internal Medicine  
Division of Gastroenterology and Hepatology

### **CURRENT ADDRESSES:**

**Office:** Saint Louis University School of Medicine  
3635 Vista Avenue at Grand Boulevard  
P.O. Box 15250  
St. Louis, MO 63110-0250  
Phone: (314) 577-8764  
Fax: (314) 577-8125  
Cell: (314) 791-7349  
E-mail: [baconbr@slu.edu](mailto:baconbr@slu.edu)

### **EDUCATION AND TRAINING:**

1967-1971 B.A., College of Wooster, Wooster, OH  
1971-1975 M.D., Case Western Reserve University School of Medicine, Cleveland, OH  
1975-1978 Intern, Junior and Senior Assistant Resident, Internal Medicine, Cleveland Metropolitan General Hospital, Cleveland, OH  
1978-1979 Chief Resident, Internal Medicine and Fellow in Hematology, Cleveland Metropolitan General Hospital, Cleveland, OH  
1979-1981 Fellow in Gastroenterology, Cleveland Metropolitan General Hospital, Cleveland, OH  
1980-1982 NIH Research Trainee in Gastroenterology/Hematology, Case Western Reserve University at Cleveland Metropolitan General Hospital, Cleveland, OH

**PROFESSIONAL APPOINTMENTS:**

1978-1982	Teaching Fellow, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
1982-1987	Assistant Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
1987-1988	Associate Professor of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH
1982-1988	Staff Gastroenterologist, Cleveland Metropolitan General Hospital, Cleveland, OH
1988-1990	Associate Professor of Medicine and Physiology and Biophysics; Chief, Section of Gastroenterology and Hepatology, Louisiana State University School of Medicine, Shreveport, LA
1990-2010	Professor of Internal Medicine; Director, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO
1990-pres	Professor of Internal Medicine, Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, St. Louis, MO

**HONORS AND AWARDS:**

1971	The James Kendall Cunningham Memorial Prize, premedical studies
1971	The William A. Galpin Award for general excellence in college work, second place, men
1974	Alpha Omega Alpha
1980	Upjohn Research Award
1981-1984	Teaching and Research Scholar, American College of Physicians
1981	Postdoctoral Research Fellow, American Liver Foundation
1981	Peter A. J. Adam Award for Excellence in Research
1985-1988	NIH New Investigator Research Award
1989	Marcel Simon Award for best research in hemochromatosis by a young investigator
1993	American Society for Clinical Investigation
1998	Outstanding Chapter Leadership Award, American Liver Foundation
1999-2003	Chair, Subspecialty Board on Gastroenterology, American Board of Internal Medicine
2000-2002	Councilor, American Association for the Study of Liver Diseases
2000	James F. King MD Endowed Chair in Gastroenterology, Saint Louis University
2003	President-elect, American Association for the Study of Liver Diseases
2004	AGA/Miles and Shirley Fiterman Foundation "Hugh R. Butt" Clinical Research Award in Hepatology
2004	President, American Association for the Study of Liver Diseases
2004-2010	Chair, Certificate of Added Qualification Board on Transplant Hepatology, American Board of Internal Medicine
2005-2008	Member, Advisory Committee for the National Institutes of Health's Commission on Digestive Diseases
2010	AASLD Distinguished Service Award

**BOARD CERTIFICATION:**

National Board of Medical Examiners

Diplomate

American Board of Internal Medicine

Diplomate in Internal Medicine

Diplomate in Gastroenterology

Recertified

Diplomate in Transplant Hepatology

**LICENSURE:**

Ohio State Board of Medical Examiners  
Missouri Board of Registration for the Healing Arts  
Illinois Department of Professional Regulation

**MEMBERSHIP IN PROFESSIONAL SOCIETIES:**

Alpha Omega Alpha Honor Medical Society, 1974--present  
American College of Physicians, 1979--present, Fellow 1987  
Member, Gastroenterology MKSAP II Committee, 1993--1996  
Post-graduate Course Director, Missouri-ACP, 1995, 1996  
American Federation for Clinical Research, 1980--present  
American Association for the Advancement of Science, 1980--present  
American Liver Foundation, 1981--present  
Post-doctoral research fellow, 1981-1982  
Grants Review Committee, 1991--1997  
Chairman, Grants Review Committee, 1995--1997  
Chairman, Patient and Professional Education Committee, 1994--1997  
Board of Directors, member, 1996--2000; vice chair, Medical Affairs, 1997--2000  
American Association for the Study of Liver Diseases, 1983--present  
Co-chairman, Breakfast Working Conference: Hepatotoxicity, 1987, 1990  
Co-chairman, Breakfast Working Conference: Metabolic Liver Diseases, 1988  
Co-chairman, Early Morning Workshop: Approach to Pathogenesis and Management of Steatohepatitis, 1996  
Co-chairman, Early Morning Workshop: Steatohepatitis: Pathogenesis, Diagnosis and Management, 1997  
Co-chairman, Early Morning Workshop: Pathogenesis of Nonalcoholic Steatohepatitis, 1998  
Abstract Selection Committee: Cell Injury, Hepatotoxicity, 1987--1990, 1991, 1992  
Abstract Selection Committee: Inflammation/Fibrosis, 1995, 1996, 1997; Chairman, 1995, 1996  
Publications Committee, 1988--1990  
Program Evaluation Committee, 1988--1991  
Faculty, AASLD Postgraduate Course, 1988, 1990, 1991, 1992, 1994, 1995, 1997, 1998, 1999  
Session Co-chairman: Hepatotoxicity, 1990; Hepatotoxicity, Cytokines, and Fibrogenesis, 1996  
Nominating Committee, 1992--1993  
Health Care Policy Committee, 1994  
Public Policy Committee, 1997-2000  
Training and Workforce Committee, 1997-1999  
Councilor, 2000-2002  
President-elect – 2003  
President – 2004  
Past-President – 2005  
Governing Board – 2000-2005  
American Gastroenterological Association, 1984--present  
Gastroenterology Research Group, 1984--present  
Society for Free Radical Research, 1986--present  
Midwest Gut Club, 1984--1988, 1990--present  
Councilor, 1992-1995  
Host Institution, 1994  
American Society for Gastrointestinal Endoscopy, 1987--present  
Central Society for Clinical Research, 1987--present  
Abstract Selection Committee: Gastroenterology, 1991  
Session Co-chairman: Gastroenterology, 1991  
Councilor, Gastroenterology section, 1993-1996  
The Oxygen Society, 1988--present  
American College of Gastroenterology, Fellow, 1988--present  
Faculty, ACG Postgraduate Course, 1993, 1995, 1996, 1997, 2005  
Public Relations Committee, 1993--1998  
Governor, State of Missouri, 1996--1998  
Southern Society for Clinical Investigation, 1989--present  
International Association for the Study of the Liver, 1989--present  
St. Louis Society of Internal Medicine, 1992--present

The International Association for the Study of Disorders of Iron Metabolism, 1992--present  
 Secretary/Treasurer, 1992--1998  
 American Board of Internal Medicine  
 Gastroenterology Self-Evaluation Process (SEP) Committee, member: 1993--1995  
 Subspecialty Board on Gastroenterology, member: 1997-1999; Chair, 1999--2003  
 Board of Directors, member: 1999—2003  
 CAQ Board on Transplant Hepatology; Chair, 2004-present  
 American Society for Clinical Investigation, 1993--present  
 American Medical Association, Hepatitis Advisory Committee, 1993  
 Accreditation Council for Graduate Medical Education, subspecialty program prereviewer, 1994—2000  
 Chair, Gastroenterology Expert Committee, Council of Experts, U.S. Pharmacopeia – 2006-2007  
 Member, Advisory Committee for the National Institutes of Health's Commission on Digestive Diseases, 2005-2008

### **REVIEWER FOR SCIENTIFIC JOURNALS:**

*Gastroenterology*  
*Hepatology*  
*The Journal of Laboratory and Clinical Medicine*  
*Biochimica et Biophysica Acta*  
*The Journal of Clinical Investigation*  
*The American Journal of Gastroenterology*  
*New England Journal of Medicine*  
*The International Journal of Psychiatry in Medicine*  
*Toxicology and Applied Pharmacology*  
*Archives of Biochemistry and Biophysics*  
*Journal of Hepatology*  
*Digestive Diseases and Sciences*  
*American Journal of Physiology*  
*Lipids*  
*Annals of Internal Medicine*  
*Journal of the American Geriatrics Society*  
*Free Radical Biology and Medicine*  
*Laboratory Investigation*  
*The American Journal of the Medical Sciences*  
*Alcoholism: Clinical and Experimental Research*  
*American Journal of Kidney Diseases*  
*Pediatrics Research*  
*Journal of Pediatrics*  
*The Journal of Rheumatology*  
*Viral Hepatitis Reviews*  
*Carcinogenesis*  
*American Journal of Clinical Nutrition*  
*Liver International*  
*Digestive Diseases*

### **REVIEWER FOR GRANTING AGENCIES:**

1986-1991	Field Reader, Food and Drug Administration, Orphan Products Development
1990-1995	Research Grant Reviewer, U.S. Veterans Administration
1991-1997	Grants Review Committee, American Liver Foundation; Chairman: 1995-1997
1993	NIH Special Review Committee, "Hemochromatosis in African Americans"
1994,1995	NIH GMA-2 Study Section, Ad Hoc reviewer
1995-1999	NIH GMA-2 Study Section, member
1995-pres.	Research Grant Reviewer, National Health and Medical Research Council, Commonwealth of Australia

**EDITORIAL BOARD APPOINTMENTS:**

1987-1992	<i>The Journal of Laboratory and Clinical Medicine</i>
1990-1999	<i>Hepatology</i>
1994-1996	<i>Hepatology Elsewhere</i> , Advisory Committee
1990-1998	<i>The American Journal of the Medical Sciences</i>
1992-1997	<i>The American Journal of Gastroenterology</i> , Assistant Editor for Liver Diseases
1997- 1998	<i>The American Journal of Gastroenterology</i> , Associate Editor for Liver Diseases
1998-2004	<i>The American Journal of Gastroenterology</i> , Senior Associate Editor for Liver Diseases
1998-2006	<i>Postgraduate Medicine</i>
1998-2006	<i>Journal of Clinical Gastroenterology</i>
1999-pres.	<i>Current Gastroenterology Reports</i> , Editor for Liver
2004-pres.	<i>Current Hepatitis Reports</i> , Editor-in-Chief
2006-2010	<i>Gastroenterology</i> , Associate Editor
2011-pres.	<i>Clinical Liver Disease</i> , Deputy Editor

**RESEARCH SUPERVISORY ROLES:**

Case Western Reserve University, Cleveland Metropolitan General Hospital

1982	Jodi Nunnari, AGA Summer Research Scholar
1983	Jodi Nunnari, Chester Summer Scholar
1984-1985	Gary Peterson, Independent study, College of Wooster
1986	Thomas Giordano, Chester Summer Scholar
1986-1987	Diane Gorgas, Chester Summer Scholar
1986-1987	Christopher J. Magiera, M.D., NIH Trainee
1987	Patty Smanik, Chester Summer Scholar
1983-1987	James Dolak, Ph.D. candidate, Physiology and Biophysics

Louisiana State University School of Medicine in Shreveport

1988	Susan Broussard, Student Summer Research Scholar
1988	Barbara Dixon, Ph.D., Student Summer Research Scholar
1989	Chris Pendola, Student Summer Research Scholar

Saint Louis University School of Medicine

1991	A. Joseph Tector, AGA Summer Research Scholar
1991-1993	Yoshimasa Kobayashi, M.D., Ph.D., Postdoctoral Research Fellow
1992-1993	John K. Olynyk, M.B.B.S., Postdoctoral Research Fellow
1992-1994	Grant A. Ramm, Ph.D., Postdoctoral Research Fellow, American Liver Foundation
1993	Mohammad J. Farahvash, M.D., Postdoctoral Research Fellow
1993-1996	Kyle E. Brown, M.D., NIH NRSA Trainee
1994-1995	John A. Poulos, M.D., Postdoctoral Research Fellow
1994-1995	Joseph M. Bellezzo, B.S., Howard Hughes Medical Institute Medical Student Research Training Fellowship
1994-1996	Lin Li, M.D., Postdoctoral Research Fellow
1995-1997	Lynda Brady, M.D., NIH NRSA Trainee
1996-1997	Lynda Brady, M.D., American Liver Foundation Liver Scholar Award
1996-1998	John A. Poulos, M.D., NIH NRSA Trainee
1997-1998	John A. Poulos, M.D., American Liver Foundation, Postdoctoral Research Fellow
1997-1998	Shuang Chen, M.D., Postdoctoral Research Fellow
1999-2001	Kim R. Bridle, Ph.D., American Liver Foundation, Postdoctoral Research Fellow

**UNIVERSITY/HOSPITAL COMMITTEES:**

## Case Western Reserve University, Cleveland Metropolitan General Hospital

1981	Phase II Hematology Teaching Committee, Case Western Reserve University School of Medicine
1982-1988	Director, Gastrointestinal Endoscopy Unit Cleveland Metropolitan General Hospital
1982, 84-86	Chairman, Housestaff Scientific Contest, CMGH
1983-1988	Phase II Gastroenterology Teaching Committee, CWRU
1984-1988	Ambulatory Procedures Committee, CMGH
1984-1985	Chester Summer Scholar Selection Committee, CMGH
1985-1988	Chairman, Animal Resource Committee, CMGH
1985	Ambulatory Referrals Committee, CMGH
1985-1988	Institutional Animal Care and Use Committee, CWRU
1985-1988	Internship Selection Committee, CMGH
1986-1988	Emergency Services Committee, CMGH
1987	Chairman, Student Research Day, CWRU
1987	Faculty Council, At-large Clinical Representative, CWRU

## Louisiana State University School of Medicine in Shreveport

1988-1989	Medical Record Committee
1988-1990	Research Advisory Committee
1988-1990	Faculty Council, elected clinical member
1988	Ad Hoc Committee for Department of Medicine Self-study
1988-1990	Facility Wide Safety Committee
1989-1990	Utilization Review Committee
1989-1990	Chairman, Committee on Medical Student Research
1989-1990	Ad Hoc Committee for M.D. - Ph.D. Program

## Saint Louis University School of Medicine

1990-pres.	Member, Endoscopy Committee
1992-1995	Chairman, Endoscopy Committee
1990-1992	Member, Chairman of Pediatrics Search Committee
1992-pres.	Member, Department of Internal Medicine Executive Committee
1992-1994	Member, Patient Services Committee of the Medical Staff
1992-1994	Member, Chairman of Radiology Search Committee
1993-1994	Chairman, Working Group on Medical Records
1993-1995	Member, Graduate Medical Education Committee
1993-1998	Elected member, Governing Board, University Medical Group (UMG); Executive Committee, UMG
1993-1997	Secretary, Governing Board, UMG
1993-1995	Member, Chairman of Surgery Search Committee
1994-1996	Chairman, Chairman of Pathology Search Committee
1996-1998	Appointed member, SLUCare Governing Council
2000-2001	Chairman, Director of Division of Pulmonology and Pulmonary Occupational Medicine Search Committee
2003-2005	UMG Finance Committee
2005-pres	UMG Faculty Compensation Committee
2007-pres	Transplant Advisory Council, Chair

**SOURCES OF RESEARCH SUPPORT:****Past:**

1. NIH Grant No. T32-HL-07147 Hematology Training Grant; principal investigators: O.D. Ratnoff, M.D. and J.W. Harris, M.D.; support for trainee: 07/01/80-06/30/82; \$34,932, salary.
2. Research Initiation Grant, Case Western Reserve University; principal investigators: Bruce R. Bacon, Gary M. Brittenham, M.D. Period of support: 06/01/81-05/31/82; \$2,210.
3. American Liver Foundation Postdoctoral Research Fellowship; period of support: 07/01/81-06/30/82; \$7,500, salary.
4. American College of Physicians Teaching and Research Scholarship; period of support: 07/01/81-06/30/84; \$45,000, salary.
5. FDA Grant No. R01-FD-226-83-0004, "Carbonyl iron therapy for iron deficiency anemia"; principal investigator: Gary M. Brittenham, M.D.; effort 5%; entire period of support: 04/01/84-03/31/85; total direct costs: \$33,921.
6. NIH Grant No. R01-AM-31505, "Hepatotoxicity in a new animal model of iron overload"; principal investigator: Anthony S. Tavill, M.D.; effort 50%; entire period of support 07/01/82-06/30/85; total direct costs: \$305,299.
7. NIH New Investigator Research Award. R23-DK-35469, "Hepatic mitochondrial function in iron overload"; principal investigator: Bruce R. Bacon, M.D.; effort 50%; entire period of support: 08/01/85-12/31/88; total direct costs: \$107,500.
8. NIH Grant No. R01-DK-31505, "Hepatotoxicity in a new animal model of iron overload"; principal investigator: Bruce R. Bacon, M.D.; effort 40%; entire period of support: 07/01/86-06/30/90; total direct costs: \$342,884.
9. BRSF - Saint Louis University, "Hepatotoxicity in a new animal model of iron overload"; principal investigator: Bruce R. Bacon, M.D.; effort 10%; entire period of support: 11/01/90-10/31/91; total direct costs: \$15,000.
10. NIH Grant No. R01-DK-41816, "Hepatotoxicity of experimental hemochromatosis"; principal investigator: Bruce R. Bacon, M.D.; effort 30%; entire period of support: 09/30/92-09/29/95; total direct costs: \$385,361.
11. NIH Grant No. R01-DK-41816-04, "Hepatic fibrogenesis in experimental hemochromatosis"; principal investigator: Bruce R. Bacon, M.D.; effort 30%; entire period of support: 04/01/96-03/31/00; total direct costs: all 4 years: \$602,800.
12. NIH Grant No. R43-DK-55904-01, "Mucosal iron uptake and transfer in hemochromatosis"; principal investigator: Mort Janghorbani, Ph.D.; effort 10%; entire period of support: 03/01/99-02/28/2000; total direct costs: 1 year: \$78,770.
13. NIH Grant No. R01-DK-41816-04, "Hepatic fibrogenesis in experimental hemochromatosis"; principal investigator: Bruce R. Bacon, M.D.; effort 30%; entire period of support: 04/01/00-03/31/01 total direct costs: 1 year: \$50,000.
14. NIH Grant No. RO1-DK-53405-01, "Studies of the gene defective in hereditary hemochromatosis"; principal investigator: William S. Sly, M.D.; effort 5%; entire period of support: 12/01/97-11/30/02; total direct costs, all 5 years: \$927,787.
15. NIH Grant No. R01-DK-56924-01A2, "Multicenter randomized trial of high dose URSO in PSC"; effort 5%; entire period of support: 09/01/01-08/31/02; total direct costs for 1 year: \$28,674.

16. Saint Louis University-2000 Center of Excellence Award; principal investigator: Adrian M. Di Bisceglie, M.D.; effort 10%; entire period of support: 01/01/02-12/31/04; total direct costs, all 3 years: \$498,480.
17. NIH Grant No. RO1-DK-41816-08, "Signaling pathways in hepatic fibrogenesis"; principal investigator: Bruce R. Bacon, M.D.; effort 30%; entire period of support: 07/01/01- 06/30/06; total direct costs, all 5 years: \$1,000,000.
18. NIH Contract No. N01-DK-9-2324, "Hepatitis C clinical trial clinical center: Prevention of cirrhosis, hepatic decompensation, and hepatocellular carcinoma in patients with chronic hepatitis C"; principal investigator: Adrian M. Di Bisceglie, M.D.; effort 10%; entire period of support: 05/01/99 - 04/30/07, direct costs, all 8 years: \$2,497,000.
19. NIH/NIDDK Grant No. 5U01DK061718-07 "Hyperinsulinemia and the pathogenesis of NASH" principal investigator: Brent Neuschwander-Tetri, M.D., effort 2.5%; entire period of support 2004-2009; total direct costs, all 7 years: \$3,366,223.

**Current:**

1. NIH R01-DK-5-6924 "Randomized Trial of High-Dose URSO in PSC" principal investigator: Keith Lindor, M.D., effort 1% entire period of support 2001-2012; total direct costs, all 11 years \$226,062.

**INVITED PRESENTATIONS:**

1. "Hepatotoxicity of chronic iron overload: Role of lipid peroxidation". International Meeting on Free Radicals in Liver Injury, Torino, Italy, June, 1985.
2. "Hemochromatosis" and "Hepatotoxicity of chronic iron overload". Visiting professor, Department of Medicine, Wayne State University School of Medicine, Detroit, MI, October, 1986.
3. "Lipid peroxidation and iron overload". Winter meeting of The Society for Free Radical Research, London, England, December, 1986.
4. "Hemochromatosis" and "Hepatotoxicity of chronic iron overload". Visiting professor, Department of Medicine, University of Illinois School of Medicine, Chicago, IL, January, 1987.
5. "Lipid peroxidation in experimental hemochromatosis". The First International Conference on Hemochromatosis, New York, NY, April, 1987.
6. "Pathophysiology of tissue injury and hepatocellular neoplasia caused by iron overload". Presented at the American Gastroenterological Association symposium, "Hemochromatosis: More Common Than We Think", Chicago, IL, May, 1987.
7. "Hepatotoxicity of iron overload". Presented at the NIH workshop, "Toxic Oxygen and the Liver", Bethesda, MD, September, 1987.
8. "Mechanisms of hepatotoxicity in metal storage diseases". Postgraduate course of the American Association for the Study of Liver Diseases, Chicago, IL, November, 1988.
9. "The role of iron in potentiating free radical formation". Presented at the American Thoracic Society annual meeting symposium on, "The Role of Nutrients in Pulmonary Responses to Oxidant Stress", Cincinnati, OH, May, 1989.



10. "Lipid peroxidation in experimental haemochromatosis". The Second International Conference on Haemochromatosis, Gold Coast, Australia, July, 1989.
11. "Mechanisms of hepatotoxicity in iron overload". The Ninth International Conference on Proteins of Iron Storage and Transport, Brisbane, Australia, July, 1989.
12. "Hepatotoxicity of iron overload" and "Metal storage diseases". Visiting professor, Division of Gastroenterology, The University of Texas Health Science Center of Houston, Houston, TX, September, 1989.
13. "Hepatotoxicity of iron overload". Visiting scientist, Department of Medicine, University of Oklahoma, Oklahoma City, OK, October, 1989.
14. "Hemochromatosis: The most common genetic disorder that causes liver disease". "Meet the Researchers", sponsored by the American Liver Foundation at Digestive Disease Week, San Antonio, TX, May, 1990.
15. "Controversies in screening for iron overload". Luncheon workshop, International Association for the Study of the Liver, Gold Coast, Australia, September, 1990.
16. "Lipid peroxidation and associated hepatic organelle dysfunction in iron overload". President's premeeting, "Free Radicals and the Liver", Twenty-fifth meeting of the European Association for the Study of the Liver, Budapest, Hungary, October, 1990.
17. "Hemochromatosis". Visiting professor, Department of Medicine, University of Louisville School of Medicine, Louisville, KY, October, 1990.
18. "Hemochromatosis: Diagnosis and treatment". Meet-the-Professor Luncheon, American Association for the Study of Liver Diseases, postgraduate course, Chicago, IL, November, 1990.
19. "Hemochromatosis". Visiting professor, Department of Medicine, University of Kentucky School of Medicine, Lexington, KY, February, 1991.
20. "Diagnosis and management of chronic hepatitis" and "Masqueraders of chronic hepatitis". Visiting professor, Bethany Medical Center, Kansas City, KS, April, 1991.
21. "Mechanisms of iron toxicity". The Third International Conference on Hemochromatosis, Dusseldorf, Germany, July, 1991.
22. "Hemochromatosis: Diagnosis and management" and "Hepatotoxicity of experimental iron overload". Visiting professor, Humana Michael Reese Hospital, University of Illinois School of Medicine, Chicago, IL, October, 1991.
23. "Analysis of iron and copper in liver tissue". Postgraduate course of the American Association for the Study of Liver Diseases, Chicago, IL, November, 1991.
24. "Diagnosis and management of chronic hepatitis", "Hemochromatosis: Diagnosis and management", and "Hepatotoxicity of experimental iron overload". Visiting professor, Loyola University Medical Center, Chicago, IL, November, 1991.
25. "Diagnosis and management of chronic hepatitis". Visiting professor, University of Missouri, Columbia, MO, December, 1991.
26. "Hemochromatosis" and "Wilson's disease". Clinical Aspects of Liver Disease, University of Missouri - Kansas City, School of Medicine symposium, Kansas City, MO, May, 1992.

27. "Hepatotoxicity of experimental hemochromatosis". Plenary session, Sixth Biennial Meeting of the International Society for Free Radical Research, Torino, Italy, June, 1992.
28. "Mechanisms of cellular iron toxicity". Symposium on "Metals and the liver" at the Twenty-seventh Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria, August, 1992.
29. "Hemochromatosis" and "Management of chronic hepatitis". Visiting professor, Michigan State University School of Medicine, Lansing, MI, October, 1992.
30. "Hemochromatosis". Meet-the-Professor Luncheon, American Association for the Study of Liver Diseases, postgraduate course, Chicago, IL, November, 1992.
31. "Hemochromatosis". Visiting professor, Columbia Hospital, Milwaukee, WI, January, 1993.
32. "Hemochromatosis: Diagnosis and management" and "Hepatotoxicity of experimental hemochromatosis". Visiting professor, G.I. Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA, February, 1993.
33. "Pathophysiology of iron toxicity". Keynote presentation, Fourth International Conference on Hemochromatosis and Clinical Problems in Iron Metabolism and Eleventh International Conference on Iron and Iron Proteins, Jerusalem, Israel, May, 1993.
34. "Management of chronic hepatitis". Visiting professor, The Faulkner Hospital, Boston, MA, August 1993.
35. "Iron and copper overload". American College of Gastroenterology, postgraduate course, New York, NY, October, 1993.
36. "Hemochromatosis: Diagnosis and management". Visiting professor, Medical College of Ohio, Toledo, OH, October, 1993.
37. "Hepatotoxicity of experimental hemochromatosis" and "Hemochromatosis: Diagnosis and management". Visiting professor, Duke University Medical Center, Durham, NC, January, 1994.
38. "Iron and hepatitis C". Invited speaker, Boston Inter-Hospital Liver Group, Boston, MA, January, 1994.
39. "Hemochromatosis: Diagnosis and management" and "Iron and hepatitis C". Visiting professor, Henry Ford Hospital, Detroit, MI, January, 1994.
40. "Advances in hepatitis screening and treatment". Invited speaker, 1994 National Osteopathic Health Conference, St. Louis, MO, March, 1994.
41. "Mechanisms of hepatic fibrogenesis in response to tissue injury". Invited speaker, symposium on "Cellular Response to Injury", American Association of Anatomists, Experimental Biology Meeting, Anaheim, CA, April, 1994.
42. "Chronic hepatitis C: Problems with therapy", Panel discussant; "Iron and the liver", Meet-the-Professor Luncheon; "Metal overload disorders of the liver", Early morning workshop, American Association for the Study of Liver Diseases, postgraduate course, Chicago, IL, November, 1994.
43. "Iron and hepatitis C". Invited speaker, Southern California Society of Gastroenterology, Los Angeles, CA, December, 1994.
44. "Hemochromatosis: Diagnosis and management" and "Iron and hepatitis C". Visiting professor, University of Maryland, Baltimore, MD, March, 1995.

45. "Iron and hepatitis C", "Hemochromatosis: Diagnosis and management", and "Hepatic fibrogenesis in experimental hemochromatosis". Visiting professor, Louisiana State University School of Medicine, Shreveport, LA, May, 1995.
46. "Metals and the liver". American Association for the Study of Liver Diseases single topic conference on "Oxidant Injury and the Liver", Arlie, VA, June, 1995.
47. "Diagnosis and treatment of hemochromatosis and other iron overload syndromes". Postgraduate Course; "Cholestasis" Learning luncheon, American College of Gastroenterology, New York, October, 1995.
48. "Newer concepts of diagnosis and treatment of hereditary hemochromatosis". Invited speaker; "Hemochromatosis", Meet-the-Professor luncheon, Post-graduate Course, American Association for the Study of Liver Diseases, Chicago, IL, November, 1995.
49. "Iron and hepatitis C". Visiting professor, University of Wisconsin - Milwaukee, November, 1995.
50. "Hemochromatosis", "Iron and hepatitis C". "Mechanisms of tissue injury in iron overload". Visiting professor, University of Alabama - Birmingham, December, 1995.
51. "Hemochromatosis: Diagnosis and management". Visiting professor, Southern Illinois University School of Medicine, Springfield, IL, January, 1996.
52. "Hemochromatosis", "Steatosis, nonalcoholic steatohepatitis". American College of Gastroenterology Governor's Postgraduate Course, Phoenix, AZ, February, 1996.
53. "Hemochromatosis: Diagnosis and treatment". Visiting professor, University of Louisville, KY, April, 1996.
54. "New aspects of diagnosis and treatment for hereditary hemochromatosis". Speaker and moderator for the Clinical Symposium "Metals and the Liver", American Gastroenterological Association, San Francisco, May, 1996.
55. "Diagnosis of hereditary hemochromatosis in the 1990's: Screening with serum chemistry panels", "Liver biopsy - Why is it necessary?". Speaker and symposium chairman, 14th Annual Iron Overload Diseases Symposium, St. Louis, MO, June, 1996.
56. "Nonalcoholic steatohepatitis". American Gastroenterological Association Fall Postgraduate Course, Chicago, IL, September, 1996.
57. "An update on phlebotomy in chronic liver disease - From hemochromatosis to hepatitis C". Postgraduate Course; "Treatment of hepatitis C" Literature Journal Club Luncheon, American College of Gastroenterology, Seattle, October, 1996.
58. "Approach to pathogenesis and management of steatohepatitis" early morning workshop; "Presence of the hemochromatosis genotype in patients with liver disease", speaker and symposium organizer, "Recent Advances in Hereditary Hemochromatosis"; "Evaluation of liver tests", SGNA Hepatology Special Interest Group, at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November, 1996.
59. "Hemochromatosis: Impact of gene discovery". Visiting professor, Cleveland Clinic Foundation, Cleveland, OH, January, 1997.
60. "Update on treatment advances in hepatitis C". New England Consensus Conference on Hepatitis C, Stowe, VT, March, 1997.

61. "Hepatic fibrogenesis and experimental hemochromatosis". Visiting professor, University of Illinois at Chicago, and "Iron and hepatitis C," Chicago Society of Gastroenterology, Chicago, IL, March, 1997.
62. "Iron overload in liver disease," Symposium on "New Treatments in Chronic Liver Disease", Scripps Clinic and Research Foundation, La Jolla, CA, April, 1997.
63. "Iron and hepatitis C," "Hemochromatosis: Diagnosis and management". Visiting professor, University of Arizona School of Medicine, Tucson, AZ, April, 1997.
64. "Suboptimal responses to interferon treatment". HCV working session, American Digestive Health Foundation, Dallas, Texas, April, 1997.
65. "Hemochromatosis". Meet-the-Professor Luncheon, Digestive Disease Week, Washington, DC, May, 1997.
66. "Viral hepatitis". Bi-State Regional Infectious Diseases Conference, St. Louis, Missouri, September, 1997.
67. "Retinoids and oxyradicals in fibrogenesis: Therapeutic Implications". 2nd International Meeting on Therapy in Liver Diseases, Barcelona, Spain, September, 1997.
68. "The hemochromatosis gene and other news in hemochromatosis" Meet-the-Professor Luncheon; "Steatohepatitis: Pathogenesis, diagnosis, and management", early morning workshop; "Long-term treatment of hepatitis C patients with early cirrhosis", presented at satellite workshop entitled, "To Treat Or Not To Treat: The Challenge Of Hepatitis B And Hepatitis C", co-host: First annual awards banquet of the AASLD/ALF, at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November, 1997.
69. "Hepatic fibrogenesis in experimental hemochromatosis" and "Hereditary hemochromatosis: Impact of recent discovery of a candidate gene". Visiting professor, Mayo Medical Center, Rochester, Minnesota, December, 1997.
70. "Hemochromatosis". American College of Gastroenterology Governor's Conference, Phoenix, AZ, January, 1998.
71. "Hepatotoxicity of experimental hemochromatosis". 10th Gordon Research Conference on Oxygen Radicals in Biology, Ventura, CA, February, 1998.
72. "Haemochromatosis". International State-of-the-Art Lecture, British Society of Gastroenterology, Harrowgate, England, March, 1998.
73. "Hereditary hemochromatosis: Impact of recent gene discovery" and "Hepatic fibrogenesis in experimental hemochromatosis". Michigan Society of Gastrointestinal Endoscopy and David M. Bull, M.D. Visiting Professor, Wayne State University School of Medicine, March, 1998.
74. "Hemochromatosis: Diagnosis and management in the 1990s", "Nonalcoholic steatohepatitis (NASH)- Pathogenesis, diagnosis, and treatment" and "Hereditary hemochromatosis - Impact of recent gene discovery". Visiting professor, the University of Iowa College of Medicine, Iowa City, Iowa, April, 1998.
75. "Manuscript preparation and the peer review process: An editorial board perspective". ASGE Young Investigator's Conference, Santa Monica, CA, April, 1998.
76. "Hemochromatosis in 1998", "Research directions in hemochromatosis", NIDDK Hemochromatosis Symposium on Molecular Medicine and Hemochromatosis: At the Crossroads, Bethesda, MD, May, 1998.

77. "The hemochromatosis gene and other news in hemochromatosis", Meet-the-Professor Luncheon, "Hemochromatosis", Focused Clinical Update, American Gastroenterological Association, New Orleans, LA, May, 1998.
78. "Iron and hepatitis C and alcoholic liver disease" and "Pathophysiology of hereditary hemochromatosis". Quadrennial meeting of the World Congress of Gastroenterology, Vienna, Austria, September, 1998.
79. "Drug and metabolic liver disease" session moderator, Post-graduate course; "Screening for hemochromatosis" Meet-the-Professor luncheon; "Pathogenesis of non-alcoholic steatohepatitis" early morning workshop; participant, Annual awards banquet AASLD/ALF; all at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November, 1998.
80. "Available options for treatment of interferon non-responders", Invited speaker, Emerging and Re-Emerging Issues in Infectious Diseases - Hepatitis C: A Meeting Ground for the Generalist and the Specialist, sponsored by the National Institutes of Health/Foundation for Advanced Education in the Sciences, Bethesda, MD, December, 1998.
81. "What is NASH? Overview", Invited speaker and co-moderator of "Pathophysiology of steatosis and liver injury" session at the Non-Alcoholic Steatohepatitis Conference, NIH, NIDDK, Bethesda, MD, December, 1998.
82. "Iron and the liver", New York Gastroenterology Association, New York, NY, January, 1999.
83. "Hemochromatosis" presented at "Gastroenterology, 1999: New approaches to old problems" Baylor College of Medicine, Houston, TX, and "Hemochromatosis: Diagnosis and management in 1999" and "Pathophysiology of hereditary hemochromatosis". Hilda Raphael Schwartz visiting professor, Baylor College of Medicine, Houston, TX, February, 1999.
84. "Pathophysiology of hereditary hemochromatosis" and "Hereditary hemochromatosis: Diagnosis and management in 1999". Visiting professor, University of Chicago, Chicago, IL, March, 1999.
85. "Hemochromatosis: Diagnosis and management in 1999" and "Pathophysiology of hereditary hemochromatosis". Visiting professor, University of Texas - Southwestern, Dallas, TX, March, 1999.
86. "The gene(s) for hemochromatosis: Their role in diagnosis" presented at the University of Toronto Hepatology Update 1999 and "Pathophysiology of hereditary hemochromatosis". 1999 Sheila Sherlock Lecturer at Liver Research Day, Toronto, Canada, April, 1999.
87. "Recent developments in hemochromatosis and iron overload syndromes". 30th Annual Nathan W. Chaikin Lecture in Gastroenterology, New York Medical College, Valhalla, New York, May, 1999.
88. "Iron and the liver" State-of-the-Art Lecture; "Pathophysiology of hereditary hemochromatosis" State-of-the-Art Symposium on the Genetic Basis of Intestinal Disorders; "Treatment of chronic hepatitis C in patients who have failed to respond to interferon monotherapy" evening symposium on Combination Therapy: The New Standard of Treatment for Hepatitis C, all presented at the American Gastroenterological Association annual meeting, Orlando, Florida, May, 1999.
89. "Diagnosis of hereditary hemochromatosis". participant in EASL International Consensus Conference on Hemochromatosis; plenary session chair "Iron toxicity: From basic aspects to therapeutical interventions", at the World Congress on Iron Metabolism, BioIron '99, Sorrento, Italy, May, 1999.
90. "Hereditary hemochromatosis: Diagnosis and management" and "Pathophysiology of hereditary hemochromatosis". Visiting professor, Division of Gastroenterology, Northwestern University, Chicago, IL, July, 1999.

91. "Herbal medicine 861 has direct antiproliferative effects on hepatic stellate cells". Presented at NIH Symposium on Complementary and Alternative Medicine in Chronic Liver Disease, Bethesda, MD, August, 1999.
92. "Hemochromatosis: Diagnosis and management for the new millennium" and "Pathophysiology of iron absorption". Visiting professor, Ochsner Clinic, New Orleans, LA, October, 1999.
93. "Hemochromatosis: Diagnosis and management in 1999" and "Pathophysiology of hemochromatosis". Visiting professor, Oregon Health Sciences University, Portland, OR, October, 1999.
94. "Hemochromatosis: Pathogenesis and diagnosis". Presented at Falk Symposium No. 115, Basel, Switzerland, October, 1999.
95. "Pathophysiology of hereditary hemochromatosis in mouse and man". Presented at the Ninth Annual Irwin M. Arias, M.D. Symposium "Bridging Basic Science and Liver Disease", Boston, MA, November, 1999.
96. "Genetic screening" speaker; "Genetic screening for liver disease" Co-moderator for Meet the Professor Session; "Molecular basis of hemochromatosis" co-moderator for the Early Morning Workshop, all at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, TX, November, 1999.
97. "Hereditary hemochromatosis: Diagnosis and management", "Hepatic fibrogenesis in experimental hemochromatosis" and "Pathophysiology of hereditary hemochromatosis". Visiting professor at Medical College of Virginia, Richmond, VA, December, 1999.
98. "The molecular basis for hemochromatosis". Visiting professor, University of Arkansas, Little Rock, AK, January, 2000.
99. "Advances in hemochromatosis" and "Hereditary hemochromatosis: Diagnosis and management". Visiting professor, University of Oklahoma, Oklahoma City, OK, February, 2000.
100. "Current management of chronic hepatitis C". Visiting professor, University of Tennessee, Memphis, TN, March, 2000.
101. "Hereditary hemochromatosis: Implications of gene discovery", Pittsburgh Gut Club, and "Hereditary hemochromatosis: Diagnosis and management in 2000". Visiting professor, University of Pittsburgh, Pittsburgh, PA, March, 2000.
102. "Hereditary hemochromatosis: Update for 2000" and "Iron overload disorders: Practical considerations". Visiting professor at Inova Fairfax Hospital and Georgetown University, Fairfax, VA, April, 2000.
103. "Current and future therapies for hepatitis B". Visiting professor, Medical College of Wisconsin, and "Hemochromatosis: Pathogenesis and diagnosis", guest speaker; Milwaukee GI Society, Milwaukee, WI, April, 2000.
104. "Hemochromatosis", speaker, Meet-the-Professor Luncheon, "Hemochromatosis", moderator Luncheon Breakout Session, at the American Gastroenterological Association annual meeting, San Diego, CA, May, 2000.
105. "Hemochromatosis: Diagnosis and genetic testing". Guest speaker, Current Topics in Gastroenterology and Hepatology, Lahey Clinic CME Course, Burlington, MA, July, 2000.
106. "Screening for hemochromatosis and Wilson disease". Guest speaker, 7th Annual World Congress of Pediatrics, Pediatric Gastroenterology, Hepatology, and Nutrition, Postgraduate Course 2000, Boston, MA, August, 2000.

107. "Hemochromatosis". Visiting professor, UC San Diego Medical Center, San Diego, CA, August, 2000.
108. "Hereditary hemochromatosis: Update in 2000". Visiting professor, Allegheny General Hospital, Pittsburgh, PA, September, 2000.
109. "A patient with hepatitis C and normal ALT: Treatment should be offered" and "Use of molecular markers in liver disease". Guest speaker, 36th Annual Gastroenterology Update, The Cleveland Clinic Foundation, September, 2000.
110. "Hepatitis C and the normal ALT patient" and "Hepatitis C: Update on diagnosis and management". Visiting professor, University of Florida, Jacksonville, FL, September, 2000.
111. "Hepatitis C" and "Hemochromatosis". Guest speaker, Internal Medicine Gastroenterology Update, Presbyterian Hospital of Dallas, Dallas, TX, October, 2000.
112. "Management of hemochromatosis" and "Molecular basis of hemochromatosis" Moderator, Early Morning Workshop, "Iron and hepatitis C" Moderator, Meet-the-Professor Luncheon, at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, TX, October, 2000.
113. "Pathophysiology of hereditary hemochromatosis" and "Hereditary hemochromatosis". Louis Zetzel Visiting professor, Beth Israel Deaconess Medical Center, Boston, MA, January, 2001.
114. "Hemochromatosis: Impact of gene discovery" and "Treatment of chronic hepatitis C with pegylated interferon". Guest speaker, 6th Annual Stanford Hepatitis Update, Palo Alto, CA, January, 2001.
115. "Non-alcoholic steatohepatitis" and "Hemochromatosis". Guest speaker, University of Miami School of Medicine's 14th biannual course Hepatobiliary Diseases in Clinical Practice, Miami, FL, March, 2001.
116. "Hereditary hemochromatosis". Guest speaker, Scripps Clinic 16th Annual Conference, New Treatments in Chronic Liver Disease, La Jolla, CA, March, 2001.
117. "Approach to HCV patients with normal ALT levels". Guest speaker, American College of Gastroenterology Clinical Implications in Hepatitis Symposium, Dallas, TX, April, 2001.
118. "Pathophysiology of hereditary hemochromatosis" and "Update in hemochromatosis". Visiting professor, Brooke Army Medical Center, San Antonio, TX, April, 2001.
119. "Hereditary hemochromatosis: Implications of gene discovery". Visiting professor, The University of Vermont, Burlington, VT, June, 2001.
120. "Genetics of hemochromatosis". Guest speaker, Irish Society of Gastroenterology Meeting, The Genetic Basis of Gastrointestinal and Liver Disease: Implications for the Clinician, Cork, Ireland, June, 2001.
121. "Strategies to minimize hepatic injury and fibrosis". Session chair, American Association for the Study of Liver Disease Single Topic Conference, Chicago, IL, June, 2001.
122. "Treatment of chronic hepatitis C with pegylated interferon and ribavirin". Speaker, Paducah Gut Club, Paducah, KY, July, 2001.
123. "Hemochromatosis". Visiting professor, Georgetown University, Washington, D.C., September, 2001.
124. "Advances in the treatment of chronic hepatitis B and C". Guest speaker at Update in Digestive Diseases and Visiting professor, SIU School of Medicine, Springfield, IL, September, 2001.

125. "Hereditary hemochromatosis: Implications of gene discovery in clinical practice". Grand Rounds, St. John's Mercy Medical Center, St. Louis, MO, September, 2001.
126. "Chronic hepatitis C: New treatments to improve outcome", "NASH: A potentially serious common liver disease", and "Hereditary hemochromatosis: Implication of gene discovery in the clinical practice". Guest speaker at the 3rd Annual Red River Gastrointestinal Conference and Shreveport Gut Club, Shreveport, LA, September, 2001.
127. "Pathophysiology of hereditary hemochromatosis" and "Hereditary hemochromatosis: Impact of gene discovery on diagnosis and management". Schiff Professor and Visiting professor, University of Cincinnati, Cincinnati, OH, October, 2001.
128. "Complimentary and alternative medicine and liver disease", panelist, "HCV: PEG interferons: When to use them"; Panelist, "Hereditary hemochromatosis: Implications of gene discovery on pathophysiology and clinical practice". Baker Presidential Lecturer, American College of Gastroenterology annual meeting, Las Vegas, NV, October, 2001.
129. "Iron and HCV infection". Guest speaker, 3<sup>rd</sup> International Hepatitis C Update for the New Millennium, University of Texas, Houston, TX, November/December, 2001.
130. "Hereditary hemochromatosis: Impact of gene discovery on diagnosis and management". Guest speaker, Medical Grand Rounds, St. Luke's Hospital, St. Louis, MO, December, 2001.
131. "Pathophysiology of hereditary hemochromatosis". Guest speaker and visiting professor, Update on Hepatitis, Mount Sinai School of Medicine, New York, NY, December, 2001.
132. "GI core curriculum and the training directors: Do we understand what is expected of us?". Guest speaker, GI Training Director's Workshop, Gastroenterology: Training in the New Era, Chicago, IL, March, 2002.
133. "Hereditary hemochromatosis: Impact of gene discovery in clinical practice". Visiting professor, University of Pennsylvania, Pittsburgh, PA, March, 2002.
134. "Hereditary hemochromatosis" and "HCV: Update and therapy". Guest speaker, A Day in The Gut XI, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, April, 2002.
135. "Hemochromatosis". Guest speaker, Annual Digestive Disease and Nutrition Centers Symposium, Washington University School of Medicine, St. Louis, MO, April, 2002.
136. "Conditions that may accelerate the progression of HCV disease: Iron overload". Moderator/Co-Chair, 2002 AASLD Single Topic Conference, Chicago, IL, April, 2002
137. "Hemochromatosis/Wilson's disease". Visiting professor, Allegheny General Hospital, May, 2002.
138. "Hepatitis C: Advances in research". Guest speaker, SoLUtions Clinical Research Coordinators Educational Symposium, St. Louis, MO, May, 2002.
139. "Natural history of NASH" and "Pathophysiology and treatment of NASH". Guest speaker, AASLD NASH Clinical Symposia at Digestive Disease Week, May, 2002.
140. "Hereditary hemochromatosis: Implications of gene discovery on clinical practice" and "Pathophysiology of hereditary hemochromatosis". Visiting professor, Massachusetts General Hospital, Boston, MA, May, 2002.
141. "HCV: Update in therapy". Speaker, Tulsa Gut Club, Tulsa, OK, July, 2002.



142. "NASH: clinical features, confounding factors, and clinical trials" and "Screening for hemochromatosis". Speaker, Eighth Annual Hepato-Biliary Update, Johns Hopkins University, Ocean City, MD, August, 2002.
143. "Hereditary hemochromatosis: Implications of gene discovery on clinical practice" and "NAFLD and NASH". Guest Speaker, Biennial Mackinac Island Symposium, Wayne State University School of Medicine, Mackinac Island, MI, September, 2002.
144. "HCV: Update in therapy". Visiting professor, University of Oklahoma, Oklahoma City, OK, September, 2002.
145. "Hereditary hemochromatosis". Visiting professor, Presbyterian Hospital of Dallas, Dallas, TX, October, 2002.
146. "Hemochromatosis: Pathophysiologic mechanisms", Speaker, "Iron and hepatitis C", Moderator, Meet the Professor Luncheon, "Diagnosis and management of hemochromatosis". Moderator, Early Morning Workshop, 53<sup>rd</sup> Annual Meeting of the American Association for the Study of Liver Disease, November, 2002.
147. "Update on viral hepatitis". Speaker, Practical Anatomy Workshop, Saint Louis University, St. Louis, MO, November, 2002.
148. "Update in the treatment of hepatitis C". Visiting professor, The University of Tennessee, Memphis, TN, December, 2002.
149. "HCV: Update in therapy". Speaker, Portsmouth Naval Hospital, Norfolk, VA, January, 2003.
150. "Hereditary hemochromatosis: Implications of genetic testing". Visiting Professor, University of Colorado Health Sciences Center, Denver, CO, January, 2003.
151. "Diagnosis and genetic screening of inherited diseases of the liver: Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis" and "Treatment of hereditary liver disease". Speaker, XIV Digestive Diseases at the Caribbean, San Juan, PR, March, 2003.
152. "Certification" and "Certificate of added qualification (CAQ) in transplant hepatology". Speaker, 2003 Training Directors' Workshop: *Advancing GI Fellowship Training*, Chicago, IL, March, 2003.
153. "Hereditary hemochromatosis: Implications of gene discovery on clinical practice". The Mayo Clinic Hugh Butt Fellows' Choice Visiting Professor, Rochester, MN, March, 2003.
154. "Hereditary hemochromatosis: Implications of gene discovery on clinical practice". Visiting professor, Scott & White Hospital, Austin, TX, April, 2003.
155. "HCV: Update in therapy". Speaker, St. Mary's Health Center Grand Rounds, St. Louis, MO, April, 2003.
156. "Hereditary hemochromatosis: Implications of gene discovery on clinical practice". Visiting professor, Middle Georgia Hospital, Atlanta, GA, April, 2003.
157. "Hemochromatosis". Visiting professor, Lankenau Hospital, Bryn Mawr, PA, April, 2003.
158. "Iron as a cofactor in disease". Chairperson, International BioIron Society, Bethesda, MD, May, 2003.
159. "HCV: Update in therapy". Visiting professor, Henry Ford Hospital, Detroit, MI, June, 2003.
160. "Hemochromatosis". Gateway Hemophilia Association, St. Louis, MO, June, 2003.

161. "Hemochromatosis: A clinical update". First Annual Duke Liver Disease Update and Symposium, Durham, NC, September, 2003.
162. "Hemochromatosis", "NASH", and "Update on Hepatitis C". Visiting professor, Central Mississippi Gut Club, Jackson, MS, September, 2003.
163. "Hemochromatosis" and "Therapeutic Management of GI Disorders". Visiting professor, University of Tennessee – Memphis, Memphis, TN, October, 2003.
164. "Pegylated interferons: Management of patients with hepatitis C", and "Retreatment strategies for the relapsing patient". Speaker, ACG Symposium, Baltimore, MD, October, 2003.
165. Course Director, Postgraduate Course, "Role of liver biopsy in 2003" and "Clinico-Pathological Correlation – CPC". Chair, Postgraduate Course. Moderator, Presidential Plenary Session II. 54<sup>th</sup> Annual Meeting of the American Association for the Study of Liver Disease, November, 2003.
166. "Screening and prevention of gastrointestinal cancer: recent development and current guidelines". Moderator. 2<sup>nd</sup> Annual Gastrointestinal Cancers: An Update on Advances in Diagnosis and Management, St. Louis, MO, November, 2003.
167. "Hemochromatosis: Genotypes and Phenotypes". Visiting professor, University of Michigan, Ann Arbor, MI, November, 2003.
168. "Hemochromatosis: Implications of gene discovery on clinical practice". Visiting professor, University of Nebraska – Omaha, NE., December, 2003.
169. "Hereditary hemochromatosis: implications of gene discovery on clinical practice". Visiting professor, Cleveland Clinic, Cleveland, OH, January 2004.
170. "Nonalcoholic fatty liver disease". Speaker, 4<sup>th</sup> Annual Gastroenterology Update, Key Biscayne, Florida, January, 2004.
171. "Hemochromatosis: Clinical update". Speaker, Mayo Clinic Winter Gastroenterology Meeting: Gastroenterology *Linked* to Endoscopy and Hepatology. Scottsdale, AZ, February, 2004.
172. "Hemochromatosis". Speaker, Mayo Clinic GI and Hepatology 2004: Advances and Controversies, Orlando, FL, March, 2004.
173. "Advances in treatment options for hepatitis C virus". Speaker, Gastroenterology and Hepatology Spring Update 2004, St. Louis, MO, March, 2004.
174. "Comparison of the natural history of alcoholic and nonalcoholic fatty liver". Speaker, Biennial Scientific Meeting of the International Association for the Study of the Liver (IASL), Salvador, Brazil, March, 2004.
175. "Iron and hepatitis C". Visiting professor and speaker, 2003-2004 Center for the Study of Hepatitis C Seminar Series, Rockefeller University, New York, NY, March, 2004.
176. "Current and emerging concepts in the management of hepatitis C and hepatitis B". Visiting professor, University of Arkansas for Medical Sciences, Little Rock, AR, April, 2004.
177. "Hemochromatosis". Visiting professor, MetroHealth Medical Center, Cleveland, OH, May, 2004.
178. "Advances in the Treatment of Hepatitis C". Speaker, Saint Louis University CME Dinner Meeting, St.

Louis, MO, October, 2005.

179. "Hepatocellular Carcinoma: To Biopsy or Not? Moderator, GI Cancers Symposium, St. Louis, MO, October 2005.
180. "Program Wrap Up". Speaker, South Texas Liver Update 2005. San Antonio, TX, October 2005.
181. "Inherited Liver Diseases". Panelist; "Is it safe to Use Immunosuppressive Drugs in the Patient with Viral Hepatitis?", Moderator and Panelist; "Use of Non-Invasive Markers of Fibrosis: Will We Need Liver Biopsy in the Future?", Panelist; Hereditary Hemochromatosis: What We Have Learned Since the Discovery of *HFE*", the J. Edward Berk Lecturer; "Liver" Speaker, American College of Gastroenterology 70<sup>th</sup> Annual Scientific Meeting & Postgraduate Course, Honolulu, HI, October 2005.
182. "NASH: Diagnosis and Management", 25<sup>th</sup> Annual Waldo B. Edwards Seminar, St. Joseph Hospital of Kirkwood, St. Louis, MO, November, 2005.
183. "Best of the AASLD", Speaker, "Phoenix GI Society", Phoenix, AZ, December, 2005.
184. "Hepatitis C: Current Management", Speaker, St. Mary's OB/GYN Grand Rounds, St. Louis, MO, January, 2006.
185. "Hereditary Hemochromatosis." Speaker, AASLD Pediatric Single Topic Conference, Atlanta, GA, January, 2006.
186. "Update on Hemochromatosis", Speaker, John Cochran VA Grand Rounds, St. Louis, MO, January, 2006.
187. "Iron Metabolism and the Liver", Speaker and Visiting Professor, The Annual Leon Schiff Lectureship at the University of Miami School of Medicine, Miami, FL, February, 2006.
188. "Drug-Induced Hepatitic Injury", Speaker, The Johns Hopkins University School of Medicine 23<sup>rd</sup> Annual Meeting Medical and Surgical Gastroenterology: A Multidisciplinary Approach, Snowmass, CO, February, 2006.
189. "Challenges in Hepatitis C Therapy", Speaker, Valley Gut Club, Fresno, CA, February, 2006.  
"Progress in Treating Liver Disease", Moderator and Speaker, Saint Louis University Grand Vision Lecture Series, Gut Feelings: Topics in Gastroenterology and Hepatology, St. Louis, MO, March, 2006.
190. "Iron Metabolism and Liver Disease", Speaker and Visiting Professor, Hennepin County Medical Center, Minneapolis, MN, March, 2006.
191. "Hepatitis" Speaker and Visiting Professor, Drexel University College of Medicine, Philadelphia, PA, March, 2006.
192. "Hereditary Hemochromatosis: What We Have Learned Since the Discovery of *HFE*", Speaker and Visiting Professor, University of Wisconsin Medical School, Madison, WI, March, 2006.
193. "NAFLD and NASH" and "Drug-induced Hepatotoxicity", Speaker, Martin Memorial Health System Gastroenterology Symposium, Stuart, FL, March, 2006.
194. "Hemochromatosis: From Screening to Pathogenesis to Therapy", Moderator, Meet-the-Professor Luncheon, Digestive Disease Week, Los Angeles, CA, May, 2006.
195. "Diagnosing and Managing the Iron Related Liver Disease" and "HCV: The Issues about Interferon Therapies for Our Patients", Speaker and Visiting Professor, University of Cincinnati College of Medicine, UC Liver

- Forum, Cincinnati, OH, June, 2006.
196. "Hepatitis C and Iron Overload", Speaker and Visiting Professor, University of Pennsylvania School of Medicine, Philadelphia, PA June, 2006.
  197. EASL - AALSD Monothematic Conference On Genetic Liver Diseases. Speaker/moderator "Genotype Phenotype in Classic *HFE* Hemochromatosis", Modena, Italy, July, 2006.
  198. Lahey Clinic GI Symposium. Speaker, "Hereditary Hemochromatosis: 2006", Boston, MA, July, 2006.
  199. Saint Louis University Internal Medicine Grand Rounds. Speaker, "Hepatitis: Update in Diagnosis and Management". St. Louis, MO, September, 2006.
  200. Cleveland Clinic Viral Hepatitis Summit. Speaker, "Debate: Weight-Base Dosing is Important – Pro", "Growth Factors for the Intolerant Patient", Cleveland, OH, August, 2006.
  201. USP Council of Experts. Moderator. Washington, DC, August, 2006
  202. Methodist Hospital Grand Rounds, Speaker, "New Concepts in the Treatment of Hepatitis C, Update in GI for Primary Care. Brooklyn, NY, September, 2006.
  203. Fairview Hospital Grand Rounds. Speaker, "Hereditary Hemochromatosis: New Information Since the Discovery of *HFE*". Cleveland, OH , October, 2006.
  204. Dallas Fellows Symposium. Speaker, "Inherited Liver Diseases". Dallas, TX, October, 2006.
  205. 2006 Regal Awards. Award presenter. Chicago, IL , October, 2006.
  206. American Association for the Study of Liver Diseases Annual Meeting. Moderator for the 2006 Career Development Workshop, "4<sup>th</sup> Year Fellowship/CAQ", Moderator Early Morning Workshop, "Iron-Overload Disorders", October, 2006.
  207. National Commission on Digestive Diseases. Bi-Annual Meeting. Washington, DC, November, 2006.
  208. Saint Louis University CME Program. Speaker, "Best of the AASLD – Hepatitis", "Best of the AASLD – Metabolic Liver Diseases", St. Louis, MO, December, 2006.
  209. Saint Louis University Pathology Conference. Speaker, "Hereditary Hemochromatosis: New Information Since the Discovery of *HFE* – 2007", St. Louis, MO, January, 2007.
  210. Maimonides Medical Center Grand Rounds. Speaker, "Treatment Strategies for HCV Nonresponders", February, 2007.
  211. Albert Einstein Medical Center Grand Rounds Lecture. Speaker, "Iron Overload Disorders: Diagnosis and Management in 2007", March, 2007.
  212. University of Connecticut Grand Rounds. Speaker, "Hereditary Hemochromatosis: New Information Since the Discovery of *HFE*", March, 2007.
  213. 18<sup>th</sup> Annual Update in Internal Medicine, NEOUCOM College of Medicine, "Management of Chronic Viral Hepatitis", May, 2007.
  214. AGA 2007 Spring Post Graduate Course. Moderator, Luncheon Breakout Session, "Hemochromatosis", May, 2007.

215. National Commission on Digestive Disease Bi-Annual Meeting. Washington, DC, June, 2007.
216. Clinical Research Single Topic Conference “Hemochromatosis: What has happened after *HFE*?”. Course Director and presenter, “Opening remarks”, “Overview of non-*HFE* iron loading disorders”. Atlanta, GA, September, 2007.
217. Fellow’s Hepatology Update 2007. “Hemochromatosis and Wilson Disease”, Fort Worth, TX, October, 2007.
218. Raine Visiting Professor , Australian Gastrointestinal Endoscopy Association presenter, “Hemochromatosis: What we have learned since the discovery of *HFE*”, “HCV, fat and iron – implications for disease progression”, “Hepatitis C: Diagnosis and treatment”; Warren Jones Oration presenter “Hemochromatosis: What we have learned since the discovery of *HFE*”; session moderator “Iron and Brain Meetings”, Perth, Australia, October, 2007.
219. American Association for the Study of Liver Diseases Annual Meeting. Presenter for the 2007 Career Development Workshop, “4<sup>th</sup> Year Advanced Hepatology Fellowship: Who needs it and why?”, Boston, MA, November, 2007.
220. National Commission on Digestive Disease Meeting. Chicago, IL, November, 2007.
221. American Association for the Study of Liver Diseases Future Trends Meeting. Presenter “Training in hepatology: Current structure and proposed”, Washington, DC, January, 2008.
222. The Baylor College of Medicine GI and Liver Course 2008. Panelist, Meet-the-Professor Luncheon, presenter “Treating the HCV non-responder – retreatment and maintenance”, “Hemochromatosis and other causes of iron storage disease”, Houston, TX, February, 2008.
223. Gastroenterology and Hepatology Linked to Endoscopy: Mayo Clinic’s 6<sup>th</sup> Annual Winter Course. Presenter, “Hereditary hemochromatosis, Scottsdale, AZ, February, 2008.
224. NYU Medicine Grand Rounds, Visiting professor and speaker, “Hereditary hemochromatosis: New information since the discovery of *HFE*”, New York, NY April, 2008.
225. Virginia Commonwealth University Medical Center. Visiting professor and speaker, “Hereditary hemochromatosis: What have we learned since the discovery of *HFE*?”, Richmond, VA, April, 2008.
226. Saint Louis University CME Program, “Controversies and Consensus in the Treatment of Hepatitis B”. Course director and moderator, St. Louis, Missouri, May, 2008
227. AGA 2008 Spring Postgraduate Course. Speaker, “Iron overload syndromes: Genetic testing, hepcidin and beyond. Digestive Disease Week, San Diego, CA, May, 2008.
228. ACG Regional Course. Speaker, Chicago, IL, June, 2008.
229. 4th Annual Southwest Liver Update 2008, participated in “Metabolic Liver Disease Roundtable” Breakout Session “Hereditary Hemochromatosis”, Hepatitis C Roundtable “Discussion”, and Wrap-Up session. San Antonio, TX, August 15-16, 2008.
230. DFW Liver & Gut Club, invited speaker, “Iron Overload Syndrome and the Impact of Iron as a Co-Factor in other Liver Diseases. Dallas, TX, October 8, 2008.
231. 3rd Annual Liver Disease Symposium, invited speaker, “Hemochromatosis: Diagnosis and Treatment”. Phoenix, AZ, November 14-15, 2008.

232. 59th Annual AASLD Meeting, Meet-the-Professor Luncheon, “HFE and Beyond: New Mutations and Phenotypic Expression in Genetic Hemochromatosis”, Moderator Postgraduate Course “Genetics and Genomics Meet Hepatology”. San Francisco, CA, October 3, 2008.
233. Resnick Lecturer, invited speaker, “Iron and Liver Disease” and “Hemochromatosis: Diagnosis and Management”, Boston, MA, January 28-29, 2009.
234. 2009 Training Directors Workshop, invited speaker, “Improving Training in GI & Hepatology: A Design to Meet the Needs of all Stakeholders. Orlando, FL, February 27-28, 2009.
235. Walter Reed Symposium, invited speaker, “Hemochromatosis”. McLean, Virginia, March 20-21, 2009.
236. 3rd Public Health Update invited speaker, “Evaluation and Management of Patients with Elevated Liver Tests and Treatment of Chronic Hepatitis C”, Springfield, IL, March 25, 2009.
237. Tufts Medical Center, invited speaker, “Hereditary Hemochromatosis: Diagnosis and Management”, Boston, MA, April 8, 2009.
238. Lahey Clinic, invited speaker, “Hepatitis C: Diagnosis and Treatment”, Burlington, MA, April 9, 2009.
239. “NAFLD: Who, When and What Next?”, Speaker, American College of Gastroenterology, Kansas City, MO, August 2009.
240. “Hemochromatosis 2009: When to Check, How to Confirm, and Treat”, Speaker, American College of Gastroenterology Annual Post Graduate Course. San Diego, CA, October 2009.
241. “Hereditary Hemochromatosis: Diagnosis and Treatment of a Common Genetic Disorder”, Moderator, Luncheon Breakout Session, American College of Gastroenterology Annual Post Graduate Course. San Diego, CA, October 2009.
242. “Present & Future Treatment Options for Hepatitis C Patients”, Grand Rounds, Visiting professor, University of Connecticut, October 2009
243. “Treatment Options for Hep-C patients with Liver Transplant, Renal Transplant or HIV Co-infection”, Grand Rounds, Visiting professor, Yale University, October 2009.
244. “New Trends in the Treatment of HCV”, Grand Rounds, Dallas Methodist Liver Transplant, Dallas, TX, October 2009.
245. “Hemochromatosis – a New Disease Paradigm”, Moderator, Leon Schiff State-of-the-Art Lecture, 60<sup>th</sup> Annual Meeting, Boston, October 2009.
246. “Practical Strategies for Improving Outcomes in Patients with Chronic Hepatitis C Virus Infection”, Grand Rounds, St. Mary’s Health Center, St. Louis, MO, January 2010.
247. “Practical Strategies for Improving Outcomes in Patients with Chronic Hepatitis C Virus Infection”, Grand Rounds, St. John’s Mercy Medical Center, St. Louis, MO, January, 2010.
248. “Current Therapy for Hepatitis C”, and “HCV Infection: Management of Relapsers and Non-Responders”, Presenter, AGA Clinical Congress, Las Vegas, NV, January 2010.
249. “HH: Pathophysiology, Diagnosis, and Treatment”, and “Iron and Liver Disease” Edward Moor Lecturship Visiting professor and Grand Rounds, Vanderbilt University Medical Center, Nashville, TN, February 2010.

250. "Practical Strategies For Improving Outcomes In Patients With Chronic Hepatitis C Virus Infection." University of Miami, Miller School of Medicine, Grand Rounds, Miami, FL, April, 2010.
251. "Pathogenesis and Evaluation of Fibrosis in the Digestive System Translation Symposium" Moderator, American Gastroenterological Association Annual Post Graduate Course, New Orleans, LA, May, 2010.
252. "Dealing With Genetic Liver Diseases: Hemochromatosis and Wilson Disease", Moderator, Luncheon Breakout Session, American Gastroenterological Association Annual Post Graduate Course, New Orleans, LA, May 2010.
253. "Liver Urgencies and Emergencies: What you Need to Know" Moderator, ACG Postgraduate Course, Combined Clinical Symposium, American Gastroenterological Association Annual Post Graduate Course, New Orleans, LA, May, 2010.
254. "Hepatitis C: The Next Revolution in Management", invited speaker, American College of Gastroenterology Regional Postgraduate Course, St. Louis, MO, August, 2010.
255. "Hemochromatosis Diagnosis and Management", invited speaker, Annual GI Teaching Day, Vassar Brothers Medical Center, Poughkeepsie, NY, September, 2010.
256. "Controversies in Non-Viral Liver Disease", Moderator, "Iron Overload: Beyond the Classic C282Y Mutation", invited speaker, American College of Gastroenterology Postgraduate Course, San Antonio, TX, October, 2010.
257. "Pathogenesis and Genetics of Hemochromatosis", Moderator, Early Morning Workshop, Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October, 2010.
258. "Iron Overload Syndromes" invited speaker, "Non-alcoholic Fatty Liver Disease: New Treatment Options" invited speaker Break-out session, American Gastroenterological Association Clinical Congress, Miami, FL, January, 2011.
259. "Hepatology Update", invited speaker, Digestive Disease Week (DDW) 2011 Highlights, The University of Kansas Medical Center, Kansas City, KS, May, 2011.
260. "State of the Art: Advances in Hepatitis Management", invited speaker, Association of Physicians of Pakistani-Descent of North America, St. Louis, MO, June 2011.
261. "HCV Treatment - 2011" and "Adverse Effects of HCV and HBV Antiviral Therapy", invited speaker, Chilean Society Meeting, Santiago, Chile, August, 2011.
262. "Hepatitis C Roundtable Case Discussion", invited speaker, National Liver Conference 2011, San Antonio, TX, September, 2011.
263. "Hereditary Hemochromatosis", invited speaker, Liver Diseases Research Seminar, Mount Sinai School of Medicine, New York, NY, October, 2011.
264. "Management of Hepatitis C", invited speaker, Gastroenterology Grand Rounds, Temple University, Philadelphia, PA, October, 2011.
265. "Hepatitis C: A New Era in Treatment and its Implications for RA Patients", invited speaker, St. Louis Rheumatology Association, October, 2011.
266. "The Road to an Integrated Gastroenterology and Transplant Hepatology Fellowship", invited speaker, Competency Training Workshop at the Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA, November, 2011.

**Original Basic and Clinical Investigations:**

1. Goodman AM, Bacon BR, Hines JD. Deoxyuridine suppression studies in bone marrow in primary refractory sideroblastic anemia. *American Journal of Hematology* 5:43-49, 1979.
2. Bacon BR, Rothman SA, Ricanati ES, Rashad FA. Renal artery stenosis with erythrocytosis following renal transplantation. *Archives of Internal Medicine* 140:1206-1211, 1980.
3. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation *in vivo* in rats with chronic iron overload. *Journal of Clinical Investigation* 71:429-439, 1983.
4. Aisen ML, Bacon BR, Goodman AM, Chester EM. Retinal abnormalities associated with anemia. *Archives of Ophthalmology* 101:1049-1052, 1983.
5. Stark DD, Bass NM, Moss AA, Bacon BR, McKerrow JH, Cann CE, Brito A, Goldberg HI. Nuclear magnetic resonance imaging of experimentally induced liver disease. *Radiology* 148:743-751, 1983.
6. Bacon BR, Brittenham GM, Tavill AS, McLaren CE, Park CH, Recknagel RO. Hepatic lipid peroxidation *in vivo* in rats with chronic dietary iron overload is dependent on hepatic iron concentration. *Transactions of the Association of American Physicians* 96:146-154, 1983.
7. Marino LR, Bacon BR, Hines JD, Halpin TC. Parietal cell function of full term and premature infants: Unstimulated gastric acid and intrinsic factor secretion. *Pediatric Gastroenterology and Nutrition* 3:23-27, 1984.
8. Bacon BR, Park CH, Fowell EM, McLaren CE. Hepatic steatosis in rats fed diets with varying concentrations of sucrose. *Fundamental and Applied Toxicology* 4:819-826, 1984.
9. Stark DD, Moseley ME, Bacon BR, Moss AA, Goldberg HI, Bass NM, James TL. Magnetic resonance imaging and spectroscopy of hepatic iron overload. *Radiology* 154:137-142, 1985.
10. Bacon BR, Bailey-Newton RS, Connors AF. Pleural effusions after endoscopic variceal sclerotherapy. *Gastroenterology* 88:1910-1914, 1985.
11. Bailey-Newton RS, Connors AF, Bacon BR. Effect of endoscopic variceal sclerotherapy on gas exchange and hemodynamics in humans. *Gastroenterology* 89:368-373, 1985.
12. Bacon BR, Park CH, Brittenham GM, O'Neill R, Tavill AS. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. *Hepatology* 5:789-797, 1985.
13. Mostow ND, O'Neill R, Noon DL, Bacon BR. Determination of alpha-tocopherol in rat liver by high performance liquid chromatography utilizing ultraviolet detection. *Journal of Chromatography, Biomedical Applications* 344:137-143, 1985.
14. Bacon BR, Marshall JB. A randomized, prospective double-blind clinical trial comparing butorphanol and meperidine in patients undergoing upper gastrointestinal endoscopy. *Clinics in Anesthesiology* 4(suppl):67-75, 1986.
15. Stassen WN, McCullough AJ, Bacon BR, Gutnik SH, Wadiwala IM, McLaren C, Kalhan SC, Tavill AS. Immediate diagnostic criteria for bacterial infection of ascitic fluid: Evaluation of ascitic fluid polymorphonuclear leukocyte count, pH and lactate concentration alone and in combination. *Gastroenterology* 90:1247-1254, 1986.



16. Bacon BR, Healey JF, Brittenham GM, Park CH, Nunnari J, Tavill AS, Bonkovsky HL. Hepatic microsomal function in rats with chronic dietary iron overload. *Gastroenterology* 90:1844-1853, 1986.
17. Connors AF, Bacon BR, Miron S. Sodium morrhuate delivery to the lung during endoscopic variceal sclerotherapy. *Annals of Internal Medicine* 105:539-542, 1986.
18. Bacon BR, O'Neill R, Park CH. Iron-induced peroxidative injury to isolated rat hepatic mitochondria. *Journal of Free Radicals in Biology and Medicine* 2:339-347, 1986.
19. Bacon BR, Stark DD, Park CH, Saini S, Groman EV, Hahn PF, Compton CC, Ferrucci JT. Ferrite particles: A new MRI contrast agent. Lack of acute or chronic hepatotoxicity following intravenous administration. *Journal of Laboratory and Clinical Medicine* 110:164-171, 1987.
20. Park CH, Bacon BR, Brittenham GM, Tavill AS. Pathology of dietary carbonyl iron overload in rats. *Laboratory Investigation* 57:555-563, 1987.
21. Bonkovsky HL, Healey JF, Lincoln B, Bacon BR, Bishop DF, Elder GH. Hepatic heme synthesis in a new model of experimental hemochromatosis: Studies in rats fed finely-divided elemental iron. *Hepatology* 7:1195-1203, 1987.
22. Bacon BR, Marshall JB. A randomized, prospective, double-blind clinical trial comparing butorphanol and diazepam in patients undergoing upper gastrointestinal endoscopy. *Acute Care* 12(suppl 1):57-62, 1988.
23. Andorn AC, Bacon BR, Nguyen-Hunh AT, Parlato SJ, Stitts JA. Guanyl nucleotide interactions with dopaminergic binding sites labeled by [<sup>3</sup>H]spiroperidol in human caudate and putamen: Guanyl nucleotides enhance ascorbate-induced lipid peroxidation and cause an apparent loss of high affinity binding sites. *Molecular Pharmacology* 33:155-162, 1988.
24. Weissleder R, Stark DD, Englestad B, Bacon BR, Compton CC, Jacobs P, Lewis J. Superparamagnetic iron oxide: Pharmacokinetics and toxicity. *American Journal of Roentgenology* 152:167-173, 1989.
25. Bacon BR, Britton RS, O'Neill R. Effects of vitamin E deficiency on hepatic mitochondrial lipid peroxidation and oxidative metabolism in rats with chronic dietary iron overload. *Hepatology* 9:398-404, 1989.
26. Feldman ES, Bacon BR. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. *Hepatology* 9:686-692, 1989.
27. Kvietyts PR, Inauen W, Bacon BR, Grisham MB. Xanthine oxidase-induced injury to endothelium: Role of intracellular iron and hydroxyl radical. *American Journal of Physiology* 257:H1640-H1646, 1989.
28. Britton RS, O'Neill R, Bacon BR. Hepatic mitochondrial malondialdehyde metabolism in rats with chronic iron overload. *Hepatology* 11:93-97, 1990.
29. Britton RS, Ferrali M, Magiera CJ, Recknagel RO, Bacon BR. Increased prooxidant action of hepatic cytosolic low-molecular-weight iron in experimental iron overload. *Hepatology* 11:1038-1043, 1990.
30. Sharma BK, Bacon BR, Britton RS, Park CH, Magiera CJ, O'Neill R, Dalton N, Smanik P, Speroff T. Prevention of hepatocyte injury and lipid peroxidation by iron chelators and  $\alpha$ -tocopherol in isolated iron-loaded rat hepatocytes. *Hepatology* 12:31-39, 1990.

31. Marshall JB, Schreiber H, Kolozsi W, Vasudeva R, Bacon BR, McCullough AJ, Holt S. A prospective, multi-center clinical trial of the Taylor intragastric balloon for the treatment of morbid obesity. *The American Journal of Gastroenterology* 85:833-837, 1990.
32. Gholson CF, Provenza JM, Silver RC, Bacon BR. Endoscopic retrograde cholangiography in the swine: A new model for endoscopic training and hepatobiliary research. *Gastrointestinal Endoscopy* 36:600-603, 1990.
33. Britton RS, O'Neill R, Bacon BR. Chronic dietary iron overload results in impaired calcium sequestration by hepatic mitochondria and microsomes. *Gastroenterology* 101:806-811, 1991.
34. Gholson CF, Provenza JM, Doyle JT, Bacon BR. Endoscopic retrograde sphincterotomy in the swine. *Digestive Diseases and Sciences* 36:1406-1409, 1991.
35. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurement of iron status in patients with chronic hepatitis. *Gastroenterology* 102:2108-2113, 1992.
36. Kamimura S, Gaal K, Britton RS, Bacon BR, Triadafilopoulos G, Tsukamoto H. Increased 4-hydroxynonenal levels in experimental alcoholic liver disease: Association of lipid peroxidation with liver fibrogenesis. *Hepatology* 16:448-453, 1992.
37. Bacon BR, O'Neill R, Britton RS. Hepatic mitochondrial energy production in rats with chronic iron overload. *Gastroenterology* 105:1134-1140, 1993.
38. Olynyk JK, O'Neill R, Britton RS, Bacon BR. Determination of hepatic iron concentration in fresh and paraffin-embedded tissue: Diagnostic implications. *Gastroenterology* 106:674-677, 1994.
39. Olynyk JK, Matuschak GM, Lechner AJ, Britton RS, Tredway TL, O'Neill R, Bacon BR. Differential production of TNF by Kupffer cells after phagocytosis of *E. coli* and *C. albicans*. *American Journal of Physiology* 267 (*Gastrointestinal and Liver Physiology* 30):G213-G219, 1994.
40. Ramm GA, Britton RS, O'Neill R, Bacon BR. Identification and characterization of a receptor for tissue ferritin on activated rat lipocytes. *Journal of Clinical Investigation* 94:9-15, 1994.
41. Matuschak GM, Munoz C, Epperly NA, Britton RS, Walsh D, Schilly DR, Tredway TL, Khan TA, Bacon BR, Lechner AJ. TNF-alpha and IL-6 expression in perfused rat liver after intraportal candidemia vs. *E. coli* or *S. aureus* bacteremia. *American Journal of Physiology* 267 (*Regulatory Integrative Comparative Physiology* 36): R446-R454, 1994.
42. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. *Gastroenterology* 107:1103-1109, 1994.
43. Sokol RJ, Twedt D, McKim JM, Devereaux MW, Karrer FM, Kam I, Von Steigman G, Narkewicz MR, Bacon BR, Britton RS, Neuschwander-Tetri BA. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis. *Gastroenterology* 107:1788-1798, 1994.
44. Di Bisceglie, AM, Bacon BR, Kleiner DE, Hoofnagle JH. Increase in iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. *Journal of Hepatology* 21:1109-1112, 1994.
45. Ramm GA, Li SCY, Li L, Britton RS, O'Neill R, Kobayashi Y, Bacon BR. Chronic iron overload causes activation of rat lipocytes *in vivo*. *American Journal of Physiology* 268 (*Gastrointestinal and Liver Physiology* 31):G451-G458, 1995.

46. Olynyk JK, Reddy RK, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. *Gastroenterology* 108:1104-1109, 1995.
47. Kowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keefe EB, Sorrell MF, Bacon BR, Weber FL, Tavill AS. Primary liver cancer and survival in patients undergoing liver transplantation for hemochromatosis. *Transplantation and Liver Surgery* 1:237-241, 1995.
48. Ramm GA, Britton RS, O'Neill R, Blaner WS, Bacon BR. Vitamin A-poor lipocytes: A novel desmin-negative lipocyte subpopulation, which can be activated to myofibroblasts. *American Journal of Physiology* 269 (*Gastrointestinal and Liver Physiology* 32):G532-G541, 1995.
49. Tector AJ, Olynyk JK, Britton RS, Janney CG, O'Neill R, Bacon BR. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in iron-loaded rats fed ethanol. *Journal of Laboratory and Clinical Medicine* 126:597-602, 1995.
50. Ramm GA, Britton RS, O'Neill R, Kohn HD, Bacon BR. Rat liver ferritin selectively down-regulates the expression of alpha-smooth muscle actin in cultured rat lipocytes. *American Journal of Physiology* 270 (*Gastrointestinal and Liver Physiology* 33):G370-G375, 1996.
51. Parkkila S, Niemelä O, Britton RS, Brown KE, Ylä-Herttuala S, O'Neill R, Bacon BR. Vitamin E decreases hepatic levels of aldehyde-derived peroxidation products in rats with iron overload. *American Journal of Physiology* 270 (*Gastrointestinal and Liver Physiology* 33):G376-G384, 1996.
52. Bellezzo JM, Britton RS, Bacon BR, Fox ES. LPS-mediated NF- $\kappa$ B activation in rat Kupffer cells can be induced independently of CD14. *American Journal of Physiology* 270 (*Gastrointestinal and Liver Physiology* 33):G956-G961, 1996.
53. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo Jr R, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer MC, Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RK. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. *Nature Genetics* 13:399-408, 1996.
54. Andorn AC, Britton RS, Bacon BR. Ascorbate-stimulated lipid peroxidation in human brain is dependent on iron but not on hydroxyl radical. *Journal of Neurochemistry* 67:717-722, 1996.
55. Bonkovsky HL, Ponka P, Bacon BR, Drysdale J, Grace ND, Tavill AS. An update on iron metabolism. Summary of the Fifth International Conference on Disorders of Iron Metabolism. *Hepatology* 24:718-729, 1996.
56. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi VK, Carey WD. Performance characteristics of a large scale screening program for viral hepatitis and risk factors associated with exposure to viral hepatitis B and C. Results of the National Hepatitis Screening Survey. *Hepatology* 24:979-986, 1996.
57. Neuschwander-Tetri BA, Bellezzo JM, Britton RS, Bacon BR, Fox ES. Thiol regulation of endotoxin-induced release of tumor necrosis factor- $\alpha$  from isolated rat Kupffer cells. *Biochemical Journal* 320:1005-1010, 1996.
58. Brown KE, Poulos JE, Li L, Soweid AM, Ramm GA, O'Neill R, Britton RS, Bacon BR. Effect of vitamin E supplementation on hepatic fibrogenesis in chronic dietary iron overload. *American Journal of Physiology* 272:G116-G123, 1997.
59. Parkkila S, Waheed A, Britton RS, Feder JN, Tsuchihashi Z, Schatzman RC, Bacon BR, Sly WS. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals

- unique pattern of expression in gastrointestinal tract. *Proceedings of the National Academy of Sciences, USA* 94:2534-2539, 1997.
60. Bacon BR, Sadiq SA. Hereditary hemochromatosis: Presentation and diagnosis in the 1990s. *American Journal of Gastroenterology* 92:784-789, 1997.
  61. Poulos JE, Weber JD, Bellezzo JM, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Fibronectin and cytokines increase JNK, ERK, AP-1 activity, and transin gene expression in rat hepatic stellate cells. *American Journal of Physiology* 273 (*Gastrointestinal and Liver Physiology* 36):G804-G811, 1997.
  62. Waheed A, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, Schatzman RC, Britton RS, Bacon BR, Sly WS. Hereditary hemochromatosis: Effects of C282Y and H63D mutations on association with beta<sub>2</sub>-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. *Proceedings of the National Academy of Sciences, USA* 94:12384-12389, 1997.
  63. Parkkila S, Waheed A, Britton RS, Bacon BR, Zhou XY, Tomatsu S, Fleming RE, Sly WS. Association of the transferrin receptor in human placenta with HFE, the protein defective in hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 94:13198-13202, 1997.
  64. Olynyk JK, Yeoh GC, Ramm GA, Clarke SL, Hall PM, Britton RS, Bacon BR, Tracy TF. Gadolinium chloride suppresses hepatic oval cell proliferation in rats with biliary obstruction. *American Journal of Pathology* 152:347-352, 1998.
  65. Bellezzo JM, Leingang KA, Bulla GA, Britton RS, Bacon BR, Fox ES. Modulation of lipopolysaccharide-mediated activation in rat Kupffer cells by antioxidants. *Journal of Laboratory and Clinical Medicine* 131:36-44, 1998.
  66. Andorn AC, Britton RS, Bacon BR, Kalaria RN. Ascorbate-stimulated lipid peroxidation and non-heme iron concentrations in Alzheimer disease. *Molecular and Chemical Neuropathology* 33:15-26, 1998.
  67. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Jiang J, Fei Y, Brunt EM, Ruddy DA, Prass CE, Schatzman RC, O'Neill R, Britton RS, Bacon BR, Sly WS. *HFE* gene knockout produces mouse model of hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 95:2492-2497, 1998.
  68. Olynyk JK, Luxon BA, Britton RS, Bacon BR. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements. *The American Journal of Gastroenterology* 93:346-350, 1998.
  69. Thomas W, Fullan A, Loeb DB, McClelland EE, Bacon BR, Wolff RK. A haplotype and linkage disequilibrium analysis of the hereditary hemochromatosis gene region. *Human Genetics* 102:517-525, 1998.
  70. Farrell GC, Bacon BR, Goldin RD, and The Clinical Advisory Group for the Hepatitis C Comparative Study. Lymphoblastoid interferon-alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon-alfa-2b: Results of an international randomized controlled trial. *Hepatology* 27:1121-1127, 1998.
  71. Shaheen NJ, Bacon BR, Grimm IS. Clinical characteristics of hereditary hemochromatosis patients who lack the C282Y mutation. *Hepatology* 28:526-529, 1998.
  72. Fiel MI, Schiano TD, Bodenheimer Jr HC, Thung SN, King TW, Varma CR, Miller CM, Brunt EM, Starnes S, Prass C, Wolff RK, Bacon BR. Hereditary hemochromatosis in liver transplantation. *Liver Transplantation and Surgery* 5:50-56, 1999.

73. Waheed A, Parkkila S, Saarnio J, Fleming RE, Zhou XY, Tomatsu S, Britton RS, Bacon BR, Sly WS. Association of HFE protein with transferrin receptor in cryptal enterocytes of human duodenum. *Proceedings of the National Academy of Sciences, USA* 96:1579-1584, 1999.
74. Fleming RE, Migas MC, Zhou XY, Britton RS, Brunt EM, Tomatsu S, Waheed A, Bacon BR, Sly WS. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: Increased duodenal expression of the iron transporter DMT1. *Proceedings of the National Academy of Sciences, USA* 96:3143-3148, 1999.
75. Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK. *HFE* genotype in patients with hemochromatosis and other liver diseases. *Annals of Internal Medicine* 130:953-962, 1999.
76. Bassett SE, Di Bisceglie AM, Bacon BR, Sharp RM, Govindarajan S, Hubbard GB, Brasky KM, Lanford RE. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. *Hepatology* 29:1884-1892, 1999.
77. Niemelä O, Parkkila S, Britton RS, Brunt E, Janney C, Bacon BR. Hepatic lipid peroxidation in hereditary hemochromatosis and alcoholic liver injury. *Journal of Laboratory and Clinical Medicine* 133:451-460, 1999.
78. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. *American Journal of Gastroenterology* 94:2467-2474, 1999.
79. Tung BY, Farrell FJ, McCashland TM, Gish RG, Bacon BR, Keeffe EB, Kowdley KV. Long-term follow-up after liver transplantation in patients with hepatic iron overload. *Liver Transplantation and Surgery* 5:369-374, 1999.
80. Dahr S, Omran L, Bacon BR, Solomon H, Di Bisceglie AM. Liver transplantation in patients with chronic hepatitis C and alcoholism. *Digestive Diseases and Sciences* 44:2003-2007, 1999.
81. Olynyk JK, Britton RS, Stephenson AH, Leicester KL, O'Neill R, Bacon BR. An *in vitro* model for the study of phagocytosis of damaged hepatocytes by rat Kupffer cells. *Liver* 19:418-422, 1999.
82. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. *Hepatology* 30:847-850, 1999.
83. Fleming RE, Migas MC, Holden CC, Waheed A, Britton RS, Tomatsu S, Bacon BR, Sly WS. Transferrin receptor 2: Continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 97:2214-2219, 2000.
84. Nowicki MJ, Bacon BR. Hereditary hemochromatosis in siblings: Diagnosis by genotyping. *Pediatrics* 105:426-429, 2000.
85. Parkkila S, Parkkila AK, Waheed A, Britton RS, Zhou XY, Fleming RE, Tomatsu S, Bacon BR, Sly WS. Reduced expression of the HFE protein on cell surface of epithelial cells, macrophages and circulating monocytes in hereditary hemochromatosis. *Haematologica* 85:340-345, 2000.
86. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multi-center; prospective, randomized, controlled trial. *Hepatology* 32:135-138, 2000.
87. Brunt EM, Olynyk JK, Britton RS, Janney CG, Di Bisceglie AM, Bacon BR. Histological evaluation of iron in liver biopsies: Relationship to *HFE* mutations. *American Journal of Gastroenterology* 95:1788-1793, 2000.

88. Ramm GA, Carr SC, Bridle KR, Li L, Britton RS, Crawford DH, Vogler CA, Bacon BR, Tracy Jr TF. Morphology of liver repair following cholestatic liver injury: Resolution of ductal hyperplasia, matrix deposition and regression of myofibroblasts. *Liver* 20:387-396, 2000.
89. Sponseller CA, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine. *Liver Transplantation* 6:715-720, 2000.
90. Khan MA, Poulos JE, Brunt EM, Li L, Solomon H, Britton RS, Bacon BR, Di Bisceglie AM. Hepatic  $\alpha$ -smooth muscle actin expression in hepatitis C patients before and after interferon therapy. *Hepato-Gastroenterology* 48:212-215, 2001.
91. Di Bisceglie AM, Thompson J, Smith-Wilkaitis N, Brunt EM, Bacon BR. Combination of interferon and ribavirin in chronic hepatitis C: Re-treatment of nonresponders to interferon. *Hepatology* 33:704-707, 2001.
92. Fleming RE, Holden CC, Tomatsu S, Waheed A, Brunt EM, Britton RS, Bacon BR, Roopenian DC, Sly WS. Mouse strain differences determine severity of iron accumulation in *HFE* knockout model of hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 98:2707-2711, 2001.
93. Sproule TJ, Jazwinska EC, Britton RS, Bacon BR, Fleming RE, Sly WS, Roopenian DC. Naturally variant autosomal and sex-linked loci determine the severity of iron overload in  $\beta$ 2-microglobulin-deficient mice. *Proceedings of the National Academy of Sciences, USA* 98:5170-5174, 2001.
94. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. *American Journal of Gastroenterology* 96:2468-2472, 2001.
95. Pianko S, McHutchison JG, Gordon SC, Heaton S, Goodman ZD, Patel K, Cortese CM, Brunt EM, Bacon BR, Blatt LM. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. *Journal of Interferon and Cytokine Research* 22:483-489, 2002.
96. Waheed A, Grubb JH, Zhou XY, Tomatsu S, Fleming RE, Costaldi E, Britton RS, Bacon BR, Sly WS. Regulation of transferrin-mediated iron uptake by *HFE*, the protein defective in hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 99:3117-3122, 2002.
97. Diwarkaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. *Journal of Hepatology* 36:687-691, 2002.
98. Olynyk JK, Khan NA, Ramm GA, Brown KE, O'Neill R, Britton RS, Bacon BR. Aldehydic products of lipid peroxidation do not directly activate rat hepatic stellate cells. *Journal of Gastroenterology and Hepatology* 17:785-790, 2002.
99. Fleming RE, Ahmann JR, Migas MC, Waheed A, Koeffler HP, Kawabata H, Britton RS, Bacon BR, Sly WS. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 99:10653-10658, 2002.
100. Ahmad KA, Ahmann JR, Migas MC, Waheed A, Britton RS, Bacon BR, Sly WS, Fleming RE. Decreased liver hepcidin expression in the *HFE* knockout mouse. *Blood Cells and Molecular Disease* 29:361-366, 2002.
101. Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use of complementary and alternative medicine in patients with liver disease. *American Journal of Gastroenterology* 97:2391-2397, 2002.

102. Ramm GA, Li L, Britton RS, O'Neill R, Bacon BR. Effect of protein kinase C activation and inhibition on rat hepatic stellate cell activation. *Digestive Diseases and Sciences* 48:790-796, 2003.
103. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: A case series. *American Journal of Gastroenterology* 98:926-930, 2003.
104. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Sponseller CA, Hampton K, Bacon BR. Interim results of a pilot study demonstrating the early effects of the PPAR-gamma ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with nonalcoholic steatohepatitis. *Journal of Hepatology* 38:434-440, 2003.
105. Hannuksela J, Parkkila S, Waheed A, Britton RS, Fleming RE, Bacon BR, Sly WS. Human platelets express hemochromatosis protein (HFE) and transferrin receptor 2. *European Journal of Haematology* 70:201-206, 2003.
106. Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. *Modern Pathology* 16:49-56, 2003.
107. Li J, Hu W, Baldassare JJ, Bora PS, Chen S, Poulos JE, O'Neill R, Britton RS, Bacon BR. The ethanol metabolite, linolenic acid ethylester, stimulates mitogen-activated protein kinase and cyclin signaling in hepatic stellate cells. *Life Sciences* 73:1083-1096, 2003.
108. Shaheen NJ, Lawrence LB, Bacon BR, Barton JC, Barton NH, Galanko J, Martin CF, Burnett CK, Sandler RS. Insurance, employment, and psychosocial consequences of a diagnosis of hereditary hemochromatosis in subjects without end organ damage. *American Journal of Gastroenterology* 98:1175-1180, 2003.
109. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR- $\gamma$  ligand rosiglitazone. *Hepatology* 38:1008-1017, 2003.
110. Tomatsu S, Orii KO, Fleming RE, Holden CC, Waheed A, Britton RS, Gutierrez MA, Velez-Castrillon S, Bacon BR, Sly WS. Contribution of the H63D mutation in HFE to murine hereditary hemochromatosis. *Proceedings of the National Academy of Sciences, USA* 100:15788-15793, 2003.
111. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. *Journal of Clinical Gastroenterology* 38:68-71, 2004.
112. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Gräff A, Gusmirovic I, Solomon H, Luxon BA, Bacon BR, Fimmel CJ. Disease and cell-specific expression of GP73 in human liver disease. *American Journal of Gastroenterology* 99:1087-1095, 2004.
113. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. CD14-positive hepatic monocytes/macrophages increase in hereditary hemochromatosis. *Liver International*. 24:446-451, 2004.
114. Hassan H, Joh JH, Bacon BR, Bastani B. Evaluation of serum anion gap in patients with liver cirrhosis of diverse etiologies. *The Mount Sinai Journal Of Medicine* 71:281-284, 2004.
115. Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. *Human Pathology* 35:1070-1082, 2004.

116. Olynyk JK, St. Pierre TG, Britton RS, Brunt EM, Bacon BR. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: A new role for magnetic resonance imaging. *American Journal of Gastroenterology* 100:837-841,2005.
117. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. *Clinical Gastroenterology and Hepatology* 3:604-609, 2005.
118. Kowdley KV, Brandhagen DJ, Gish RG, Bass N, Weinstein J, Schilsky ML, Fontana RJ, McCashland T, Cotler SJ, Bacon BR, Keeffe E, Gordon F, Polissar N, the National Hemochromatosis Transplant Registry. Survival after liver transplantation among patients with hepatic iron overload: the National Hemochromatosis Transplant Registry. *Gastroenterology* 129:494-503, 2005.
119. Chang T, Gish RG, Hadziyannis S, Cianciara J, Rizzetto M, Schiff ER, Pastore G, Bacon BR, Poynard T, Joshi S, Kleszczewski KS, Thiry A, Rose RE, Colonno RJ, Hindes RG. A dose ranging study of the efficacy and tolerability of entecavir in lamivudine refractory chronic hepatitis B patients. *Gastroenterology* 129:1198-1209, 2005.
120. Bridle KR, Li L, O'Neill R, Britton RS, Bacon BR. Coordinate activation of intracellular signaling pathways by insulin-like growth factor-1 and platelet-derived growth factor in rat hepatic stellate cells. *Journal of Laboratory and Clinical Medicine* 147:234-241, 2006.
121. Hayashi PH, Mehia C, Reimers J, Solomon HS, Bacon BR. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. *Journal of Clinical Gastroenterology* 40:740-744, 2006.
122. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. Differential findings for CD14-positive hepatic monocytes/macrophages in primary biliary cirrhosis, chronic hepatitis C and nonalcoholic steatohepatitis. *Liver International* 26:559-565, 2006.
123. Drake SF, Morgan EH, Herbison CE, Graham RM, Chua ACG, Leedman PJ, Bacon BR, Fleming RE, Olynyk JK, Trinder D. Iron absorption and hepatic iron uptake are increased in a transferrin receptor 2 (Y245X) mutant mouse model of hemochromatosis type 3. *American Journal of Physiology (Gastrointestinal and Liver Physiology)* 292:G323-8, 2007.
124. Rodriguez A, Hilvo M, Kytomaki L, Fleming RE, Britton RS, Bacon BR, Parkkila S. Effects of iron loading on muscle: Genome-wide mRNA expression profiling in the mouse. *BMC Genomics* 8:379, 2007.
125. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Al-adhami M, Morris ML, Lektrom-Himes JA, Efler SM, Davis HL. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. *Hepatology* 46:1341-1349, 2007.
126. Kobayashi Y, Bridle KR, Ramm GA, O'Neill R, Bacon BR. Effect of phorbol esters and platelet-derived growth factor on protein kinase C in rat hepatic stellate cells. *Liver International* 27:1066-1075, 2007.
127. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S, ACCELERATE Investigators. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *New England Journal of Medicine* 357:124-134, 2007.
128. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST. Clinical Trial: Randomized controlled trial of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. *Alimentary Pharmacology & Therapeutics* 28:886-894, 2008.
129. George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: A 5-year follow-up of 150 patients.



*Hepatology* 49:729-738, 2009

130. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis GN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. Peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for the treatment of chronic hepatitis C genotype 1 infection. *New England Journal of Medicine* 361:580-593, 2009.
131. Bacon BR, Shiffman ML, Mendes F, Ghalib R, Hassanein T, Morelli G, Joshi S, Rothstein K, Kwo P, Gitlin N. Retreating Chronic Hepatitis C with Daily Interferon Alfacon-1/Ribavirin After Nonresponse to Pegylated Interferon/Ribavirin: DIRECT Results. *Hepatology* 49:1838-1846, 2009.
132. Hänninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR. Expression of iron-related genes in human brain and brain tumors. *BMC Neuroscience* 10:36-45, 2009.
133. Rodriguez A, Luukkonen H, Luukkala T, Fleming RE, Britton RS, Bacon BR, Parkkila S. Global transcriptional response to *Hfe* deficiency and dietary iron overload in mouse kidney, *PLoSOne* 4:9, 2009.
134. Kanwal F, Kramer J, Asch SM, El-Serag H, Spiegel BM, Edmundowicz S, Sanyal AJ, Dominitz JA, McQuaid KR, Martin P, Keeffe EB, Friedman LS, Ho SB, Durazo F, Bacon BR. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. *Clinical Gastroenterology and Hepatology* 8:709-717, 2010.
135. Chua A, Roheeth D, Morgan E, Herbison C, Tirnitz-Parker J, Ross G, Fleming R, Britton RS, Bacon BR, Olynyk J, Trinder D. Iron uptake from plasma transferrin by a transferrin receptor 2 mutant mouse model of haemochromatosis. *Journal of Hepatology* 52:425-431, 2010.
136. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu MD, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Albinterferon Alfa-2b was not inferior to pegylated interferon- $\alpha$  in a randomized trial of patients with chronic hepatitis C virus genotype 1. *Gastroenterology* 139:1257-66, 2010.
137. Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype 1 hepatitis C non-responders and relapsers after failing Interferon and ribavirin combination therapy. *Alimentary Pharmacology and Therapeutics* 32:969-83, 2010.
138. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection. *Annals of Internal Medicine* 153:231-239, 2010.
139. Poordad F, Lawitz E, Hassanein T, Shiffman M, Bacon BR, Godofsky E, Heise J, Halliman D, Chun E, Hammond J. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naïve patients with genotype 1 chronic hepatitis C. *Hepatology* 52:1208-1215, 2010.
140. Bacon BR. Clinical trial report: Treatment of nonalcoholic steatohepatitis with vitamin E. *Current Gastroenterology Reports* 13:1-2, 2011.
141. Poordad F, McCone Jr. M, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P. Boceprevir for untreated chronic HCV genotype 1 infection. *New England Journal of Medicine* 364:1195-1206, 2011.
142. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, for the HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. *New England Journal of Medicine* 364:1207-1217, 2011.

143. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR. Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir. *Gastroenterology* 2012 [epub ahead of print].
144. Kanwal F, Kramer JR, Buchanan P, Asch SM, Assioun Y, Bacon BR, Li J, El-Serag HB. The quality of care provided to patients with cirrhosis and ascites in the department of veterans affairs. *Gastroenterology* 143:70-77, 2012.
145. Chhatwal J, Ferante SA, Brass C, El Khoury AC, Burroughs M, Bacon BR, Estaban-Mur R, Elbasha EH. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. (submitted), 2012.
145. Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Mason AL, Myers RP, Milkiewicz P, Odin JA, Luketic VA, Bacon BR, Bodenheimer H, Liakina V, Vincent C, Levy C, Franke A, Gregerson PK, Annese V, Gershwin ME, deAndrade M, Amos CI, Lazaridis KN, Seldin MF, Siminovitch KA. Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. 2012 (submitted).

#### **Reviews, Chapters in Books or Proceedings, Editorials:**

1. Bacon BR, Brittenham GM, Tavill AS, McLaren CE, Park CH. Hepatic mitochondrial and microsomal lipid peroxidation in rats with chronic dietary iron overload is dependent on iron concentration. In: Urushizaki I, Aisen P, Listowsky I, Drysdale J, eds. *Structure and Function of Iron Storage and Transport Proteins*. Amsterdam: Elsevier Science Publishers; 1983:489-492.
2. Bacon BR, Tavill AS. Role of the liver in normal iron metabolism. *Seminars in Liver Disease* 4:181-192, 1984.
3. Bacon BR, Brittenham GM, Park CH, Tavill AS. Hepatic mitochondrial and microsomal function in experimental chronic iron overload. In: Spik G, Montreuil J, Crichton RR, Mazurier J, eds. *Proteins of Iron Storage and Transport*. Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division); 1985:313-316.
4. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatotoxicity of chronic iron over-load. Role of lipid peroxidation. In: Poli G, Cheeseman KH, Dianzani MU, Slater TF, eds. *Free Radicals in Liver Injury*. Oxford, England: IRL Press Limited; 1985:49-57.
5. Bacon BR, Tavill AS. Inherited metabolic diseases of the liver. In: Spittell JA, ed. *Clinical Medicine*, Vol. 10, Chapter 30. Philadelphia, PA: Harper and Row Publishers; 1985:1-15.
6. Tavill AS, Bacon BR. Hemochromatosis: How much iron is too much? (Editorial) *Hepatology* 6:142-145, 1986.
7. Bacon BR, Tavill AS, Recknagel RO. Lipid peroxidation and experimental iron overload. In: Fillastre JP, ed. *Hepatotoxicity of Drugs*. Publications of the University of Rouen (Editions INSERM); 1986:63-74.
8. Gordeuk VR, Bacon BR, Brittenham GM. Iron overload: Causes and consequences. *Annual Review of Nutrition* 7:485-508, 1987.
9. Bacon BR, Tavill AS, Recknagel RO. Lipid peroxidation and iron overload. In: Rice-Evans C, ed. *Free Radicals, Oxidant Stress and Drug Action*. London: Richelieu Press; 1987:259-275.

10. Britton RS, Bacon BR, Recknagel RO. Lipid peroxidation and associated hepatic organelle dysfunction in iron overload. *Chemistry and Physics of Lipids* 45:207-239, 1987.
11. Bacon BR, Tavill AS. Metal storage diseases. In: Gitnick G, ed. *Principles and Practice of Gastroenterology and Hepatology*, Chapter 92. New York: Elsevier Science Publishing Co.; 1988:1383-1401.
12. Bacon BR, Brittenham GM, Park CH, Tavill AS. Lipid peroxidation in experimental hemochromatosis. *Annals of the New York Academy of Sciences* 526:155-163, 1988.
13. Bonkovsky HL, Healey JF, Lincoln B, Bacon BR, Bishop DF. Decreased hepatic 5-aminolevulinic acid dehydratase in experimental hemochromatosis. *Annals of the New York Academy of Sciences* 526:365-368, 1988.
14. Bacon BR. Gastrointestinal and hepatic systems. In: Adler SN, Lam M, Gasbarra DB, Connors AF, eds. *A Pocket Manual of Differential Diagnosis*. Boston: Little, Brown and Co.; 1988:129-171.
15. Bacon BR. Mechanisms of hepatotoxicity in metal storage diseases. *AASLD Postgraduate Course Syllabus*, 1988:114-131.
16. Bacon BR. Hemochromatosis: Much more common than we thought. *Medicine in Small Doses*. LSUMC-S, 12:1, 1989.
17. Bacon BR. Joseph H. Sheldon and hereditary hemochromatosis: Historical highlights. *Journal of Laboratory and Clinical Medicine* 113:761-762, 1989.
18. Bacon BR, Britton RS. Hepatic injury in chronic iron overload: Role of lipid peroxidation. *Chemico-Biological Interactions* 70:183-226, 1989.
19. Nichols GM, Bacon BR. Hereditary hemochromatosis: Pathogenesis and clinical features of a common disease. *The American Journal of Gastroenterology* 84:851-862, 1989.
20. Tavill AS, Bacon BR. Hemochromatosis: Iron metabolism and the iron overload syndromes. In: Zakim D, Boyer TD, eds. *Hepatology. A Textbook of Liver Disease*, Chapter 48. Philadelphia: W. B. Saunders; 1990:1273-1299.
21. Bacon BR, Britton RS. The pathology of hepatic iron overload: A free radical-mediated process? *Hepatology* 11:127-137, 1990.
22. Tavill AS, Sharma BK, Bacon BR. Iron and the liver: Genetic hemochromatosis and other hepatic iron overload disorders. *Progress in Liver Diseases* 9:281-305, 1990.
23. Gholson CF, Provenza JM, Bacon BR. Hepatologic consideration in patients with parenchymal liver disease undergoing elective surgery. *The American Journal of Gastroenterology* 85:487-496, 1990.
24. Bacon BR. Evaluation and management of iron storage diseases. *Practical Gastroenterology* 14:41-49, 1990.
25. Edling JE, Bacon BR. Pleuropulmonary complications of endoscopic variceal sclerotherapy. *Chest* 99:1252-1257, 1991.
26. Bacon BR. Managing chronic hepatitis. *Postgraduate Medicine* 90:103-112, 1991.
27. Bacon BR. Analysis of iron and copper in liver tissue. Liver biopsy interpretation for the 1990s: Clinicopathologic correlations in liver disease. *AASLD postgraduate course syllabus*, 1991:457-478.

28. Bacon BR. Hemochromatosis: Diagnosis and management. *Resident and Staff Physician* November 1991:21-27.
29. McClain CJ, Marsano L, Burk RF, Bacon BR. Trace metals in liver disease. *Seminars in Liver Disease* 11:321-339, 1991.
30. Gholson CF, Bacon BR. Metabolic and systemic diseases. In: Gitnick G, LaBrecque DR, Moody FG, eds. *Diseases of the Liver and Biliary Tract*. St. Louis: Mosby-Year Book, Inc.; 1992:489-523.
31. Bacon BR. Causes of iron overload. (Editorial) *New England Journal of Medicine* 326:126-127, 1992.
32. Nichols GM, Bacon BR. Iron metabolism and disorders of iron overload. In: Kaplowitz N, ed. *Liver and Biliary Diseases*. Baltimore: Williams and Wilkins; 1992:309-321.
33. Bacon BR, Joshi SN, Granger DN. Ischemia, congestive failure, Budd-Chiari syndrome and veno-occlusive disease. In: Kaplowitz N, ed. *Liver and Biliary Diseases*. Baltimore: Williams and Wilkins; 1992:421-431.
34. Bacon BR, Britton RS, O'Neill R. Lipid peroxidation and associated hepatic organelle dysfunction in iron overload. In: Csmos G, Feher J, eds. *Free Radicals and the Liver*. Berlin: Springer Verlag; 1992:63-76.
35. Bacon BR. Hemochromatosis. In: Rakel RE, ed. *Conn's Current Therapy*. New York: W. B. Saunders Co.; 1993:381-383.
36. Becherer PR, Bacon BR. Hepatitis C testing: Interpretation, implications, and counseling. *Missouri Medicine* 90:31-35, 1993.
37. Gholson CF, Bacon BR. The liver in anesthesia and surgery. In: Rustgi K, Van Thiel DH, eds. *The Liver in Systemic Disease*. New York: Raven Press, Ltd.; 1993:145-165.
38. Bacon BR, Britton RS, O'Neill R, Li SCY, Kobayashi Y. Hepatotoxicity of experimental hemochromatosis. In: Poli G, Albano E, Dianzani MU, eds. *Free Radicals: From Basic Science to Medicine*. Basel, Switzerland: Birkhauser Verlag; 1993:242-254.
39. Bacon BR, Fried MW, Di Bisceglie AM. A 39-year-old man with elevated serum aminotransferases and ferritin values and a family history of hemochromatosis. *Seminars in Liver Disease* 13:101-105, 1993.
40. Bacon BR. Hereditary hemochromatosis: Early diagnosis, good prognosis. *IM: Internal Medicine*, November 1993, pp. 14-26.
41. Westblom U, Bacon BR. *Helicobacter pylori*: A decade later. (Editorial) *American Journal of the Medical Sciences* 306:393-394, 1993.
42. Bacon BR, Li SCY. Metabolic liver diseases. In: Lewis JH, ed. *A Pharmacologic Approach to Gastrointestinal Disease*. Baltimore: Williams and Wilkins; 1994:359-376.
43. Britton RS, Tavill AS, Bacon BR. Mechanisms of iron toxicity. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. *Iron Metabolism in Health and Disease*. London: W. B. Saunders; 1994:311-351.
44. Bacon BR, Tavill AS. Metal storage diseases. In: Gitnick G, ed. *Principles and Practice of Gastroenterology and Hepatology*, 2nd edition. New York: Elsevier Science Publishing Co.; 1994:951-966.
45. Olynyk J, Bacon BR. Hereditary hemochromatosis: Detecting and correcting iron overload. *Postgraduate Medicine* 96:151-165, 1994.

46. Dana F, Becherer PR, Bacon BR. Hepatitis C virus: What recent studies can tell us. *Postgraduate Medicine* 95:121-130, 1994.
47. Clarkston WK, Bacon BR. Gastrointestinal and hepatic systems. In: Adler SN, Lam M, Gasbarra DB, Connors AF, eds. *A Pocket Manual of Differential Diagnosis*, 3rd edition. Boston: Little, Brown and Co.; 1994:153-199.
48. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. *Hepato-Gastroenterology* 41:343-348, 1994.
49. Britton RS, Ramm GA, Olynyk J, Singh R, O'Neill R, Bacon BR. Pathophysiology of iron toxicity. In: Hershko C, ed. *Advances in Experimental Medicine and Biology*. New York: Plenum Publishing Corp.; 356:239-254, 1994.
50. Olynyk JK, Bacon BR. Hepatitis C: Recent advances in understanding and management *Postgraduate Medicine* 98:79-94, 1995.
51. Kobayashi Y, Britton RS, Ramm GA, O'Neill R, Bacon BR. Protein kinase C in rat lipocytes. In: Wisse E, Knook DL, Wake K, eds. *Cells of the Hepatic Sinusoid*. Volume 5. Leiden: The Kuppfer Cell Foundation; 1995:5:351-353.
52. Bacon BR. Hemochromatosis. In: Snape WJ, ed. *Consultations in Gastroenterology*. Philadelphia: W.B. Saunders; 1996:808-813.
53. Bacon BR. Hemochromatosis and Wilson's disease. In: Maddrey WC, ed. *The Liver, Volume I in Gastroenterology and Hepatology. The Comprehensive Visual Reference*. Philadelphia: Current Medicine; 1996:8.1-8.16.
54. Bacon BR, Tavill AS. Hemochromatosis and the iron overload syndromes. In: Zakim D, Boyer TD, eds. *Hepatology. A Textbook of Liver Disease*. Philadelphia: W. B. Saunders; 1996:1439-1472.
55. Tavill AS, Bacon BR. Guest editors. "Metals and free-radical-induced liver injury". *Seminars in Liver Disease* 16:1-101, 1996.
56. Brunt EM, Tavill AS, Bacon BR. A 49-year-old man with alpha-1-antitrypsin deficiency and abnormal iron study results. *Seminars in Liver Disease* 16:97-101, 1996.
57. Bacon BR. Hemochromatosis and Wilson's disease. In: Maddrey WC, ed. *Current Practice of Medicine: Hepatology*. New York: Churchill Livingstone; 1996:XIV:11.1-11.8.
58. Bacon BR. Inheritable forms of liver disease. In: McNally PR, ed. *GI/Liver Secrets*. Philadelphia: Hanley and Belfus, Inc.; 1996:215-221.
59. Bacon BR, Brown KE. Iron metabolism and disorders of iron overload. In: Kaplowitz N, ed. *Liver and Biliary Diseases*. 2nd edition. Baltimore: Williams and Wilkins; 1996:349-362.
60. Bacon BR, Joshi SN, Granger DN. Ischemia, congestive failure, Budd-Chiari syndrome and veno-occlusive disease. In: Kaplowitz N, ed. *Liver and Biliary Diseases*. 2<sup>nd</sup> edition. Baltimore: Williams and Wilkins; 1996:469-481.
61. Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis. *Medical Clinics of North America*, 80:1147-1166, 1996.
62. Long GS, Bacon BR, Di Bisceglie AM. Interpretation of serological tests for hepatitis C virus infection. *Cleveland Clinic Journal of Medicine* 63:264-268, 1996.

63. Poulos JE, Bacon BR. Liver transplantation for hereditary hemochromatosis. *Digestive Diseases* 14:316-322, 1996.
64. Neuschwander-Tetri BA, Bacon BR. Viral hepatitis. In: Conn RB, Borer WZ, Snyder JW, eds. *Current Diagnosis*, 9th edition. Philadelphia: W. B. Saunders; 1997:644-650.
65. Neuschwander-Tetri BA, Bacon BR. Fatty liver and nonalcoholic steatohepatitis. In: Friedman LS, Keefe E, eds. *Handbook of Liver Disease*. London: Churchill Livingstone; 1997:95-102.
66. Soweid A, Bacon BR. Nutritional disorders and the liver. In: Gitlin N, ed. *The Liver and Systemic Disease*. London: Churchill Livingstone; 1997:209-228.
67. Bacon BR. Iron and hepatitis C. (Editorial) *Gut* 41:127-128, 1997.
68. Bacon BR. Diagnosis and management of hemochromatosis. *Gastroenterology* 113:995-999, 1997.
69. Bacon BR, Britton RS. Hereditary hemochromatosis. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. *Sleisenger & Fordtran's Gastrointestinal and Liver Disease*. 6th edition. Philadelphia: W. B. Saunders; 1997:1097-1103.
70. Britton RS, Bacon BR. Retinoids and oxyradicals in fibrogenesis: Therapeutic implications. In: Arroyo V, Bosch J, Bruguera M, Rodes J, eds. *Therapy in Liver Diseases*, Barcelona: Masson S.A.; 1997:163-171.
71. Bacon BR. Iron overload states. In: Rosen H, Martin P, eds. *Liver Clinics of North America*. Philadelphia: W. B. Saunders; 2:63-75, 1998.
72. Petersen PF, Bacon BR. Iron and liver disease. *Practical Gastroenterology*, March, 1998, pp 10-20.
73. Bacon BR, Ramrakhiani S. When jaundice strikes. *Cortlandt Forum*, April, 1998, pp 7-8.
74. Ramrakhiani S, Bacon BR. Hemochromatosis: Advances in molecular genetics and clinical diagnosis. *Journal of Clinical Gastroenterology* 27:41-46, 1998.
75. Bacon BR. Hereditary hemochromatosis: Prevalence, diagnosis, and use of recently developed tests. *Current Practice of Medicine Reports* 1:93-95, 1998.
76. Bacon BR. Hemochromatosis. In: Reinius J, Brandt L, eds. *Clinical Practice of Gastroenterology*. Philadelphia: Current Medicine; 1999:943-947.
77. Bacon BR, Powell LW, Adams PC, Kresina TF, Hoofnagle JH. Molecular medicine and hemochromatosis: At the crossroads. *Gastroenterology* 116:193-207, 1999.
78. Bacon BR, Schilsky M. New knowledge of the genetic pathogenesis of hemochromatosis and Wilson disease. *Advances in Internal Medicine* 44:91-116, 1999.
79. Ramrakhiani S, Bacon BR. Alcohol and chronic hepatitis C: Cofactors in the pathogenesis of liver disease. *Advances in Gastroenterology, Hepatology, and Clinical Nutrition* 3:315-316, 1999.
80. Bacon BR. Hemochromatosis and Wilson disease. In: Maddrey WC, ed. *Current Practice of Medicine: Hepatology* 2:77-85, 1999.
81. Bacon BR. The discovery of *HFE*. *Current Gastroenterology Reports* 1:7, 1999.
82. Bacon BR. Advances in treatment of chronic hepatitis C. *Current Gastroenterology Reports* 1:8, 1999.

83. Bacon BR. Hemochromatosis. *Current Treatment Options in Gastroenterology* 2:58-60,1999.
84. Britton RS, Bacon BR. Intracellular signaling pathways in stellate cell activation. *Alcoholism: Clinical and Experimental Research* 23:922-925, 1999.
85. Di Bisceglie AM, Bacon BR. The unmet challenges of hepatitis C. *Scientific American* 281:80-85, 1999.
86. Bacon BR. Available options for treatment of interferon non-responders. *American Journal of Medicine* 107::675-705, 1999.
87. Bacon BR. Hereditary hemochromatosis. In: Bacon BR, Di Bisceglie AM, eds. *Liver Disease: Diagnosis and Management*. Philadelphia, Churchill Livingstone; 2000:140-149.
88. Clarkston WK, Bacon BR. Gastrointestinal and hepatic systems. In: Adler SN, Gasbarra DB, Adler-Klein D, eds. *A Pocket Manual of Differential Diagnosis*. 4th edition. Philadelphia: Lippincott Williams & Wilkins; 2000:151-202.
89. Brown KE, Bacon BR. Iron metabolism in hemochromatosis. In: Barton JC, Edwards CQ, eds. *Hemochromatosis*. Cambridge: Cambridge University Press; 2000:157-162.
90. Bacon BR. Hemochromatosis and Wilson's disease. In: Maddrey WC, ed. *Atlas of the Liver*, second edition Volume I in *Gastroenterology and Hepatology. The Comprehensive Visual Reference*. Philadelphia: Current Medicine; 2000:8.1-8.16.
91. Olynyk JK, Bacon BR. Hepatitis C and iron. In: Liang TJ, Hoofnagle JH, eds. *Hepatitis C*. New York: Academic Press; 2000:415-426.
92. Bacon BR. Metabolic, granulomatous, and infiltrative disorders of the liver. In: Humes HD, et al, eds. *Kelley's Textbook of Internal Medicine*. 4th Edition. Philadelphia: Lippincott Williams & Wilkins; 2000:1011-1016.
93. Ramrakhiani S, Bacon BR. Hepatology in the new millennium: Advances in viral hepatitis, hepatic disorders, and liver transplantation. *Medical Clinics of North America* 84:1085-1105, 2000.
94. Bridle KR, Li L, O'Neill R, Britton RS, Bacon BR. Insulin-like growth factor-1 activates extracellular signal - regulated kinase, phosphatidylinositol 3-kinase and p70-S6 kinase pathways involved in rat hepatic stellate cell proliferation. In: Wisse E, et al., eds. *Cells of the Hepatic Sinusoid*. Volume 8. Leiden: Kupffer Cell Foundation; 2001:250-253.
95. Bacon BR. Hemochromatosis: Diagnosis and management. *Gastroenterology* 120:718-725, 2001.
96. Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. *Hepatology* 34:595-603, 2001.
97. Parkkila S, Niemela O, Britton RS, Fleming RE, Waheed A, Bacon BR, Sly WS. Molecular aspects of iron absorption and HFE expression. *Gastroenterology* 121:1489-1496, 2001.
98. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. HFE. In: Templeton DM, ed. *Molecular and Cell Iron Transport* 2001;8:189-205.
99. Britton RS, Bacon BR. Hereditary hemochromatosis and alcohol: A fibrogenic cocktail. (Editorial) *Gastroenterology* 122:563-565, 2002.

100. Britton RS, Fleming RE, Parkkila S, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis: Genetics and beyond. *Seminars in Gastrointestinal Disease* 13:68-79, 2002.
101. Bacon BR, Britton RS. Hereditary hemochromatosis. In: Feldman M, Friedman LS, Sleisenger MH (eds). *Sleisenger and Fordtran's Gastrointestinal and Liver Disease*. 7th Edition. Philadelphia: Harcourt Health Sciences; 2002;2:1261-1268.
102. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferase levels. *Hepatology* 36:S179-S184, 2002.
103. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. *International Journal of Hematology* 76:219-228, 2002.04.
104. Cohen S, Bacon BR, Berlin JA, Fleischer D, Hecht GA, Loehrer PJ Sr, McNair AE Jr, Mulholland M, Norton NJ, Rabeneck L, Ransohoff DF, Sonnenberg A, Vannier MW. National Institutes of Health Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. *Gastrointestinal Endoscopy* 56:803-809, 2002.
105. Tavill AS, Bacon BR. Hemochromatosis and the iron overload syndromes. In: Zakim D, Boyer TD, eds. *Hepatology: A Textbook of Liver Disease*. Philadelphia: W.B. Saunders; 2003:1289-1316.
106. Harrison SA, Bacon BR. Hereditary hemochromatosis: Update for 2003. *Journal of Hepatology* 38:S14-S23, 2003.
107. Bacon BR. Treatment for chronic hepatitis C. *Current Gastroenterology Reports* 5:1-2, 2003.
108. Bacon BR. Hemochromatosis. In: Bodenheimer HC, ed. *Self-Assessment Colour Review of Hepatobiliary Medicine*. London: Manson Publishing; 2003.
109. Bacon BR, Britton RS. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrell MF, Maddrey WC, eds. *Diseases of the Liver*. 9th edition. Philadelphia: Lippincott Raven, 2003;1187-1205.
110. Bacon BR. Introduction for "Symposium on Chronic Hepatitis". *Postgraduate Medicine* 114:47, 2003.
111. Bacon BR. Hemochromatosis and Wilson disease. In: Maddrey W, ed. *Atlas of the Liver*. 3<sup>rd</sup> edition. Philadelphia: Current Medicine; 2003:189-204.
112. Bacon BR. Treatment of nonalcoholic steatohepatitis. *Current Gastroenterology Reports* 6:9, 2004.
113. Bacon BR. Iron overload (hemochromatosis). In: Goldman L, Ausiello D, ed. *Cecil Textbook of Medicine*, 22<sup>nd</sup> edition. Philadelphia: W. B. Saunders, 2004:1302-1306.
114. Bacon BR. Managing Hepatitis C. *The American Journal of Managed Care* 10:S30-S31, 2004.
115. Bacon BR. Treatment of the patient with normal liver tests. In: McHutchison JG, ed. *Management Issues in Hepatitis C Infection*. London: Science Press, 2004:98-100.
116. Bacon BR. How to initiate therapy. In: McHutchison JG, ed. *Management Issues in Hepatitis C Infection*. London: Science Press, 2004:53-55.
117. McHutchison JG, Bacon BR. Hepatitis C: A 20-year debt comes due. *American Journal of Managed Care* 10:S20, 2004.
118. Bacon BR. The HCV patient with normal ALT levels. In: McHutchison JG, ed., *Case Based Medicine, Teaching Series, Hepatitis C*, New York:McMahon Publishing Group, 2004:52-59.



119. Alter MJ, Seeff LB, Bacon BR, Thomas DL, Rigsby M, Di Bisceglie AM. Testing persons at an increased risk for hepatitis C virus infection. *Annals of Internal Medicine* 141:715-717, 2004.
120. Neuschwander-Tetri BA, Bacon BR. Fatty liver and nonalcoholic steatohepatitis. In: Friedman LS, Keefe E, eds. *Handbook of Liver Disease*. 2<sup>nd</sup> Edition. London: Churchill Livingstone; 2004:95-102.
121. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathogenesis of hereditary hemochromatosis. *Clinics in Liver Disease* 8:755-773, 2004.
122. Bacon BR. Chronic hepatitis C and normal ALT: considerations for treatment. (Editorial). *American Journal of Gastroenterology* 99:1706-1707, 2004.
123. Harrison SA, Bacon BR. Relation of hemochromatosis with hepatocellular carcinoma: Epidemiology, natural history, pathophysiology, screening, treatment and prevention. *Medical Clinics of North America* 89:391-409, 2004.
124. Bacon BR. Preface. In: Bacon BR, ed. *Metabolic Liver Diseases Clinics in Liver Disease*. Philadelphia, Elsevier, 2004, 8:xi-xii.
125. Bacon BR. Hereditary hemochromatosis. In: Krawy B, ed. *Hepatology: A Practical Approach*. The Netherlands, Elsevier Science BV 2004.
126. Bacon BR. Certificate of added qualification in transplant hepatology. *Liver Transplantation* 11:4-6, 2005.
127. Fleming RE, Bacon BR. Orchestration of iron homeostasis. *New England Journal of Medicine* 352:1741-1744, 2005.
128. Bacon BR. HCV treatment in difficult patients: Study one to four. *Current Gastroenterology Reports* 7:9-10, 2005.
129. Bacon BR. All hepatitis C patients should be offered liver biopsy and treatment. *AGA Perspectives* 1:4, 2005.
130. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathophysiology of hereditary hemochromatosis. *Seminars in Liver Disease*; 2005:411-419.
131. Bacon BR. Update on hemochromatosis as a genetic disease. Proceedings of the 12<sup>th</sup> Post-Graduate Course, "Advances in Gastroenterology and Hepatology". *Spanish Society of Digestive Disorders*, 109-115, 2005.
132. Bacon BR, McHutchison JG. Treatment issues with chronic hepatitis C: special populations and pharmacy strategies. *American Journal of Managed Care*. 11:S296-307, 2005.
133. McHutchison JG, Bacon BR. Chronic hepatitis C: an age wave of disease burden. *American Journal of Managed Care*. 11:S286-295, 2005.
134. Bacon BR. Inheritable forms of liver disease. In: McNally PR, 3<sup>rd</sup> Edition. *GI/Liver Secrets*. Philadelphia: Elsevier Mosby; 2006:287-295.
135. Bacon BR. Hereditary hemochromatosis. In: Bacon BR, O'Grady J, Di Bisceglie AM, Lake JR, eds. *Comprehensive Clinical Hepatology 2e*, London: Elsevier; 2006, 341-349.
136. Berg CL, Jonas MM, Bacon BR. Treatment of hereditary hemochromatosis, Wilson disease, and other metabolic disorders of the liver. In: Wolfe MM, Davis GL, Farrar FA, Grinnell RA, Malagelada JR, Steer ML. *Therapy of Digestive Disorders*. 2nd edition. London: Saunders Elsevier; 2006, 487-502.

137. Bacon BR. Screening for hemochromatosis. (Editorial) *Archives of Internal Medicine* 166:269-270, 2006.
138. Bacon BR. Screening for hemochromatosis. (Editorial) *Current Gastroenterology Reports* 8:5-6, 2006.
139. Bacon BR. Assessing evidence from clinical trials in chronic hepatitis C. *Journal of Viral Hepatitis* 2006;1:1-5.
140. Bacon BR, Britton RS. Hereditary hemochromatosis. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. *Sleisenger & Fordtran's Gastrointestinal and Liver Disease*. 8th edition. Philadelphia: W. B. Saunders, 2006, 1589-1599.
141. Bacon BR. Hemochromatosis and Wilson disease. In: Maddrey W, ed. *Atlas of the Liver*. 4th edition. Philadelphia: Current Medicine; 2006;215-232.
142. Bacon BR. Hepatology: Where do we go from here? *Gastroenterology* 131:1373-1374, 2006.
143. Bacon BR, Britton RS. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrell MF, Maddrey WC, eds. *Diseases of the Liver*. 10th edition. Baltimore: Lippincott, Williams, & Wilkins, 2007;1041-1061.
144. Pietrangelo A, Elferink RO, Prieto J, Bacon BR. Genetics in liver disease. *Journal of Hepatology* 46:1143-1148, 2007.
145. Bacon BR. The certificate of added qualification in transplant hepatology. *Gastroenterology & Hepatology* 3:523-524, 2007.
146. Bacon BR, Adams PC. Hepatology as a distinct specialty - born in the USA. *The Canadian Journal of Gastroenterology* 21:421, 2007.
147. Bacon BR. Iron overload (hemochromatosis). In: Goldman L, Ausiello D, ed. *Cecil Textbook of Medicine*, 23<sup>rd</sup> edition. Philadelphia: W. B. Saunders, 2007;1596-1600.
148. McHutchison JG, Bacon BR, Owens GS. Making it happen: managed care considerations in vanquishing hepatitis C. *American Journal of Managed Care*. 12:S327-340, 2007.
149. Bacon BR, McHutchison JG. Into the light: strategies for battling hepatitis C. *American Journal of Managed Care* 2007 12:S319-326, 2007.
150. Bacon BR, Grosso LJ, Freedman N. Subspecialty certification in transplant hepatology. *Liver Transplantation* 13:1479-1481, 2007.
151. Olynyk JK, Ombiga J, Trinder D, Bacon BR. Iron in chronic liver disease. In: Schattner Am, Knobler H, ed. *Metabolic Aspects of Chronic Liver Disease*. Nova Science Publishers, Inc., 2008;175-199.
152. Bacon BR. Hepatology: small steps forward. *Gastroenterology* 134:381, 2008.
153. Bacon BR, Britton RS. Clinical penetrance of hereditary hemochromatosis. *New England Journal of Medicine* 358:291-292, 2008.
154. Bacon BR. Cirrhosis and its complications. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine 17<sup>th</sup> edition*, McGraw-Hill Companies, Inc., 2008;1971-1979.
155. Bacon BR. Genetic, metabolic, and infiltrative diseases affecting the liver. . In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine 17<sup>th</sup> edition*, McGraw-Hill Companies, Inc., 2008;1980-1983.

156. Bacon BR. Treatment of hepatitis C genotype 2/3. *Current Gastroenterology Reports* 10:5-6, 2008.
157. Clarkston WK, Sanchez P, Bacon BR. Gastrointestinal and hepatic systems. In: Adler SN, Adler-Klein D, Gasbarra DB, eds. *A Pocket Manual of Differential Diagnosis*. 5th edition. Philadelphia: Lippincott Williams & Wilkins; 2008:115-170.
158. Bacon BR, Chang KM, Wells RG. End-stage liver disease in 2008: Finally a glass half full. *Gastroenterology* 134:1639-1640, 2008
159. Bacon BR. Workforce issues in hepatology: What is needed? *Hepatology* 47:1801-1804, 2008.
160. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. *Hepatology* 48:991-1001, 2008.
161. Bacon BR. Cirrhosis and its complications. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine 17<sup>th</sup> edition*, McGraw-Hill Companies, Inc., 2008;302:1971-1980.
162. Bacon BR. Genetic, Metabolic, and Infiltrative Diseases Affecting the Liver. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine 17<sup>th</sup> edition*, McGraw-Hill Companies, Inc., 2008;303:1980-1980-1983.
163. Bacon BR. Lack of efficacy of maintenance interferon: results of the HALT-C Trial. *Current Gastroenterology Reports* 11:1-2, 2009.
164. Rodriguez A, Luukkaala T, Fleming RE, Britton RS, Bacon BR, Parkkila S. Global transcriptional response to HFE deficiency and dietary iron overload in mouse liver and duodenum. *PLoS ONE* Vol. 4, Issue 9, 2009
165. Bacon BR. Training in hepatology: Where are we now? *Gastroenterology* 137:1557-1558, 2009.
166. Prather CM, Bacon BR. Moving the field of gastroenterology & hepatology forward. *Missouri Medicine* 106:337-338, 2009.
167. Bacon BR. Hemochromatosis. In: Rakel RE, ed. *Conn's Current Therapy 2009*. Philadelphia: Elsevier 2009;114:
168. Bacon BR. Inheritable forms of liver disease. In: McNally PR, ed. *GI/Liver Secrets*. Philadelphia: Hanley and Belfus, Inc.;1996:215-221.
169. Bacon BR. Inheritable forms of liver disease. In: McNally PR, *GI/Liver Secrets Plus*. Philadelphia: Mosby Elsevier; 2010;32:233-238
170. Bacon BR. Cirrhosis and its complications. In: Longo DL, Fauci AS. *Harrison's Gastroenterology and Hepatology*. McGraw Hill 2010;41:419-433.
171. Bacon BR. Genetic, metabolic, and infiltrative diseases affecting the liver. In: Longo DL, Fauci AS. *Harrison's Gastroenterology and Hepatology*. McGraw Hill 2010;42:434-438.
172. Bacon BR. Clinical trial report: Treatment of nonalcoholic steatohepatitis with Vitamin E. *Current Gastroenterology Reports* 13:1-2, 2011.
173. Bacon BR. Optimizing long-term treatment strategies in chronic hepatitis B. *Gastroenterology & Hepatology* 7:10-12, 2011.

174. Bacon BR. Managed care considerations in the management of hepatitis C virus infection. *The American Journal of Managed Care* 17:S116-S122, 2011.
175. Bacon BR. Cirrhosis and its complications. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine* 18 ed. McGraw-Hill Companies, USA. 2011;308:2592-2602.
176. Bacon BR. Genetic, metabolic, and infiltrative diseases affecting the liver. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. *Harrison's Principles of Internal Medicine*, 18e. McGraw-Hill Companies, USA. 2011;309:2603-2606.
177. Bacon BR, Britton RS. Hemochromatosis and other iron storage disorders. In: Schiff ER, Sorrell MF, Maddrey WC, eds. *Diseases of the Liver*. 11th edition. Baltimore: Lippincott, Williams, & Wilkins, 2011;30
178. Khalid O, Bacon BR. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations. *Clinics in Liver Disease* 15:573-583, 2011.
179. Bacon BR, Khalid, O. New therapies for hepatitis C virus infection. *Missouri Medicine* 108:255-258, 2011.
180. Bacon BR. Inherited and Metabolic Disorders of the Liver. In:Goldman L, Schafer AI. *Goldman's Cecil Medicine*, 24<sup>th</sup> edition Philadelphia: Elsevier Saunders, 2011;153:984-985.
181. Bacon BR. Iron overload hemochromatosis. In:Goldman L, Schafer AI. *Goldman's Cecil Medicine*, 24<sup>th</sup> edition Philadelphia: Elsevier Saunders, 2011; 219:1373-1377.
182. Kanwal F, Bacon BR. Does Treatment Alter the Natural History of Chronic HCV? In: Shiffman ML. *Chronic Hepatitis C Virus: Advances in Treatment, Promise for the Future*. Springer Science+Business Media, 2011;9:103-112.
183. Britton RS, Bacon BR, Flemming RE. Mammalian models of iron homeostasis. In: Anderson GJ, McLaren GD. *Iron Physiology and Pathophysiology in Humans*. Humana Press part of Springer Science+Business Media, 2012;29:631-652.
184. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS; American Association for the Study of Liver Diseases. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. *Hepatology* 54:328-343, 2011.
185. Bacon BR, Khalid O. Triple therapy with boceprevir for HCV genotype 1 infection: phase III results in relapsers and nonresponders. *Liver International* 32 Suppl 1:51-53, 2012.
186. Bacon BR. Hemochromatosis: discovery of the HFE gene. *Missouri Medicine* 109:133-136, 2012.

#### **Textbooks/Symposia:**

1. Gholson CF, Bacon BR. *Essentials of Clinical Hepatology*. St. Louis: CV Mosby; 1993.
2. Tavill AS, Bacon BR (guest editors). Metals and free-radical-induced liver injury. *Seminars in Liver Diseases* 16:1-101, 1996.

3. Bacon BR, Di Bisceglie AM, eds. *Liver Disease: Diagnosis and Management*. Philadelphia: Churchill Livingstone; 2000.
4. Bacon BR (guest editor) Metabolic Liver Disease. *Clinics In Liver Disease* Vol. 8, No.4 Philadelphia: Elsevier, November, 2004.
5. Bacon BR. (guest editor) Iron and the Liver. *Seminars in Liver Disease* 25:379-380, 2005.
6. Bacon BR, O'Grady J, Di Bisceglie AM, Lake JR, eds. *Comprehensive Clinical Hepatology 2e*, London: Elsevier, 2006.
7. Barton JC, Edwards CQ, Phatak PD, Britton RS, Bacon BR, eds., *Handbook of Iron Overload Disorders*, New York Cambridge: Cambridge University Press; July, 2010.

### **Case Reports:**

1. Bacon BR, Ricanati ES. Severe and prolonged renal insufficiency: reversal in a patient with malignant hypertension. *Journal of the American Medical Association* 239:1159-1160, 1978.
2. Bacon BR, Treuhaft WH, Goodman AM. Azathioprine induced pancytopenia: occurrence in two patients with connective tissue diseases. *Archives of Internal Medicine* 141:223-226, 1981.
3. Gutnik SH, Bacon BR. Endoscopic appearance of gastric myeloma. *Gastrointestinal Endoscopy* 30:263-265, 1985.
4. Wadiwala IM, Bacon BR. A simplified technique for constructing a feeding jejunostomy from an existing gastrostomy. *Gastrointestinal Endoscopy* 32:288-290, 1986.
5. Bacon BR, Camara DS, Duffy MC. Severe ulceration and delayed perforation of the esophagus after endoscopic variceal sclerotherapy. *Gastrointestinal Endoscopy* 33:311-315, 1987.
6. Jackson RH, Payne DK, Bacon BR. Esophageal perforation due to nasogastric intubation. *The American Journal of Gastroenterology* 85:439-442, 1990.
7. Provenza JM, Bacon BR. Chylous ascites due to sarcoidosis. *The American Journal of Gastroenterology* 86:92-95, 1991.
8. Scott DA, Gholson CF, Netchvolodoff CV, Ray M, Gonzalez E, Bacon BR. Incidental microvesicular steatosis due to valproic acid anti-convulsant therapy. *The American Journal of Gastroenterology* 86:500-502, 1991.
9. Scott DA, Netchvolodoff CV, Bacon BR. Delayed subcapsular hematoma following percutaneous liver biopsy as a manifestation of warfarin toxicity. *The American Journal of Gastroenterology* 86:503-505, 1991.
10. Kane RE, Kotagel S, Bacon BR, Vogler CA. Valproate use associated with persistent hyperammonemia and mitochondrial injury in a child with Down's syndrome. *Journal of Pediatric Gastroenterology and Nutrition* 14:223-227, 1992.
11. Gholson CF, Solomon H, Bacon BR, Fairchild R. Unsuspected portal vein thrombosis associated with temporizing sclerotherapy prior to orthotopic liver transplantation. *Transplantation* 54:740-745, 1992.
12. Singh R, Clarkston WK, Zuckerman DA, Joist JH, Bacon BR. Transjugular intrahepatic portosystemic shunt (TIPS) for palliation of bleeding esophageal varices in a patient with severe hemophilia A, advanced HIV infection, and cirrhosis. *The American Journal of Gastroenterology* 88:2112-2114, 1993.

13. Farahvash MJ, Janney CG, Salimi Z, Majdi G, Bacon BR. "Jejunized colon": A rare complication of carcinoid tumor. *The American Journal of Gastroenterology* 89:429-433, 1994.
14. Combs C, Brunt EM, Solomon H, Bacon BR, Brantly M, Di Bisceglie AM. Rapid development of hepatic alpha-1-antitrypsin globules after liver transplantation for chronic hepatitis C. *Gastroenterology* 112:1372-1375, 1997.
15. Ramrakhiani S, Brunt EM, Bacon BR. Possible cholestatic injury from ranitidine with a review of the literature. *The American Journal of Gastroenterology* 93:822-826, 1998.
16. Mistry BM, Solomon H, Garvin PJ, Durham RM, Turnage S, Bacon BR, Galvin N, Varma CR. Spontaneous rupture of the liver upon revascularization during transplantation. *Transplantation* 69:2214-2218, 2000.
17. Kng C, Ng FH, Ng WF, Wong BCY, Grosso LE, Brunt EM, Bacon BR. A Chinese patient with non-*HFE*-linked iron overload. *Journal of Clinical Gastroenterology* 33:69-71, 2001.
18. Collins J, Ritter D, Bacon BR, Landt M, Creer MH. Macro-aspartate aminotransferase in a female with antibodies to hepatitis C virus. *Liver* 22:501-506, 2002.
19. Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: A case report and review of the literature. *American Journal of Gastroenterology* 98:201-204, 2003.
20. Kudva GC, Bacon BR. Iron deficiency anemia in hereditary hemochromatosis after gastric bypass surgery. *Annals of Hematology* 88:291-292, 2009.
21. Touma W, Nayak RP, Hussain Z, Bacon BR, Kudva GC. Epoprostenol-Induced Hypersplenism in Portopulmonary Hypertension. *American Journal of Medical Science* 2012. Jan 6 [Epub ahead of print].

#### **Correspondence, Book Reviews, Miscellaneous:**

1. Bacon BR, Connors AF. Pleural effusions following endoscopic variceal sclerotherapy. Reply. *Gastroenterology* 90:255-256, 1986.
2. Tavill AS, McCullough AJ, McLaren C, Bacon BR, Stassen WN. Linear discriminant analysis of ascitic fluid in hepatic cirrhosis. Reply. *Gastroenterology* 92:558-559, 1987.
3. Bacon BR. Hepatic transport and jaundice. Book review. *The American Journal of Gastroenterology* 84:1340, 1989.
4. Bacon BR, Nichols GM. Hereditary hemochromatosis. Reply. *The American Journal of Gastroenterology* 85:99-100, 1990.
5. Gholson CF, Bacon BR. Hepatobiliary disease and jaundice. Book review. *The American Journal of Gastroenterology* 85:337, 1990.
6. Bacon BR. Managing chronic hepatitis. Medifacts, Ltd., audio cassette, 1992.
7. Bacon BR. Hereditary hemochromatosis: Diagnosis and management. *Clinical Advances in Gastroenterology*, Vol. 3, No. 5, American College of Gastroenterology, audio cassette, 1992.
8. Gholson CF, Bacon BR. Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy. Reply. *The American Journal of Gastroenterology* 87:1226, 1992.

9. Bacon BR, Di Bisceglie AM. Aspartate aminotransferase and iron status - Lack of support for covariation. Reply. *Gastroenterology* 104:665, 1993.
10. Bacon BR, Britton RS. Medical and nutritional complications of alcoholism. Mechanisms and management. Book review. *Hepatology* 18:223, 1993.
11. Dies DF, Bacon BR. Hepatic encephalopathy. Book review. *The American Journal of Gastroenterology* 88:977, 1993.
12. Neuschwander-Tetri BA, Bacon BR. Portal hypertension: Varices and portal hypertension. Book review. *The American Journal of Gastroenterology* 88:1303, 1993.
13. Provenza JM, Bacon BR. Chyloperitoneum associated with sarcoidosis. Reply. *The American Journal of Gastroenterology* 88:1462-1463, 1993.
14. Luxon BA, Bacon BR. Hepatic transport and bile secretion: Physiology and pathophysiology. Book review. *The American Journal of Gastroenterology* 88:1805-1806, 1993.
15. Bacon BR. AGA Clinical Teaching Project Unit 8: Inherited liver disease. Book review. *The American Journal of Gastroenterology* 89:141-142, 1994.
16. Bacon BR. The Liver: Biology and Pathobiology. Book Review. *Gastroenterology* 108:1603, 1995.
17. Bacon BR, Neuschwander-Tetri BA. Prognosis in nonalcoholic steatohepatitis. Reply. *Gastroenterology* 109:1607, 1995.
18. Andorn AC, Britton RS, Bacon BR. Lipid peroxidation in brain homogenates: The role of iron and hydroxyl radicals. Reply. *Journal of Neurochemistry* 69:1330-1331, 1997.
19. Bacon BR, Britton RS, Olynyk JK. *HFE* genotype in patients with hemochromatosis and other liver diseases. Reply. *Annals of Internal Medicine* 132:246, 2000.
20. Ramrakhiani S, Bacon BR. Comment on prevalence of *HFE* genotype and their relation to iron overload in patients at a health appraisal clinic. *Evidence-based Gastroenterology* 2:36-37, 2001.
21. Bacon BR, Di Bisceglie AM. Letter to the Editor regarding "Hepatitis C Virus Infection" by Lauer and Walker. *New England Journal of Medicine* 345:1425-1426, 2001.
22. Kudva GC, Bacon BR. Letter to the Editor regarding "Iron deficiency anemia in hereditary hemochromatosis after gastric bypass surgery. *Annals of Hematology* 88:291-292, 2009.
23. Bacon BR. Genetics in liver disease. Book review. *Gastroenterology* 134:1265-1266.

### **Abstracts/Presentations:**

\* Designates presentation at regional, national, or international meetings.

1. Goodman AM, Bacon BR, Hines JD. Deoxyuridine suppression studies in bone marrow in primary refractory sideroblastic anemia. *Blood* 50: (Suppl) 93, 1977 and *Clin Res* 25:611A, 1977.

2. Aisen ML, Bacon BR, Goodman AM, Chester EM. Retinal abnormalities associated with anemia. *Clin Res* 29:328A, 1981.
- \*3. Gross TL, Bacon BR, Sokol RJ, Hines JD, Giroski PM. Vitamin B<sub>12</sub> binding in amniotic fluid (AF). Presented at the annual meeting of the Society of Perinatal Obstetricians, January 1981.
4. Bacon BR, Gross TL, Hines JD, Sokol RJ, Giroski PM. Vitamin B<sub>12</sub> binding proteins in amniotic fluid. *Clin Res* 29:329A, 1981.
- \*5. Bacon BR, Tavill AS, Recknagel RO, Brittenham GM. Evidence for subcellular localization of lipid peroxidation in experimental chronic iron overload. *Hepatology* 1:493, 1981. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1981.
6. Brittenham GM, Bacon BR, Park CH, Tavill AS. Iron overload: Parenchymal iron deposition in a new animal model with dietary carbonyl iron. *Blood* 58:24A, 1981.
7. Marino L, Bacon BR, Hines JD, Halpin TC. Intrinsic factor (IF) secretion as an indicator of parietal cell (PC) function in the newborn. *Ped Res* 16:298A, 1982.
8. Brittenham GM, Bacon BR, Park CH, Tavill AS. New model of iron overload: Hepatic parenchymal deposition with dietary carbonyl iron. *Clin Res* 30:501A, 1982.
- \*9. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic lipid peroxidation *in vivo* in a new animal model of iron overload. *Gastroenterology* 82:1221, 1982. Presented at the annual meeting of the American Gastroenterological Association, May 1982.
- \*10. Brittenham GM, Bacon BR. Single dose oral iron therapy for iron deficiency anemia. *Blood* 60:(Suppl) 27A, 1982. Presented at the annual meeting of the American Society of Hematology, December 1982.
- \*11. Stark DD, Bass NM, Moss AA, Bacon BR, McKerrow JH, Cann CE, Brito A, Goldberg HI. Assessment of experimentally induced liver disease by NMR imaging. Presented at the annual meeting of the Association of University Radiologists, March 1983.
- \*12. Bacon BR, Brittenham GM, Tavill AS, McLaren CE, Recknagel RO. Hepatic lipid peroxidation *in vivo* in rats with chronic dietary iron overload is dependent on hepatic iron concentration. *Clin Res* 31:530A, 1983. Presented at the annual meeting of the Association of American Physicians, May 1983.
13. Bacon BR, Healey JF, Brittenham GM, Tavill AS, Bonkovsky HL. Dietary iron overload decreases rat hepatic 5-aminolevulinate dehydrase and cytochrome P-450. *Gastroenterology* 84:1362, 1983.
- \*14. Bacon BR, Brittenham GM, Tavill AS, McLaren CE, Park CH. Hepatic mitochondrial and microsomal lipid peroxidation in rats with chronic dietary iron overload is dependent on iron concentration. Presented at the Sixth International Conference on Proteins of Iron Storage and Transport. Sapporo, Japan, July 1983.
- \*15. Stark DD, Moseley M, Young G, Bacon BR, Moss AA, Goldberg HI. NMR imaging and high resolution spectroscopy of hemochromatosis. Presented at the annual meeting of the Society of Magnetic Resonance in Medicine, San Francisco, CA, August 1983.
- \*16. Bacon BR, Tavill AS, Brittenham GM, Park CH, O'Neill R. Dietary iron overload decreases oxidative metabolism in rat hepatic mitochondria. *Hepatology* 3:813, 1983. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1983.
- \*17. Bacon BR, Healey JF, Brittenham GM, Tavill AS, Bonkovsky HL. Rat hepatic microsomal lipid peroxidation and cytochrome P-450 levels at increasing liver non-heme iron concentration. *Clin Res* 31:720A, 1983. Presented at the midwest section of the American Federation for Clinical Research, November 1983.



- \*18. Park CH, Bacon BR, Brittenham GM, Tavill AS, Petrelli M. Dietary iron overload in rats: Morphologic observations. *Lab Invest* 50:44-45A, 1984. Presented at the annual meeting of the United States/Canada Division of the International Academy of Pathologists, March 1984.
- \*19. Bacon BR, Bailey-Newton RS, Connors AF. Effects of endoscopic variceal sclerotherapy on hemodynamics and pulmonary gas exchange. *Gastrointestinal Endoscopy* 30:130-131, 1984. Presented at the annual meeting of the American Society for Gastrointestinal Endoscopy, May 1984.
- 20. Bacon BR, Healey JF, Brittenham GM, Nunnari J, Bonkovsky HL, Tavill AS. Hepatic microsomal lipid peroxidation in rats with dietary iron overload alters microsomal function. *Gastroenterology* 86:1310, 1984.
- \*21. Stassen W, Bacon BR, McCullough AJ, Gutnik S, Kalhan S, Tavill AS. Superior diagnostic value of ascitic fluid pH and lactate levels as immediate indicators of infected ascites. *Gastroenterology* 86:1341, 1984. Presented at the annual meeting of the American Gastroenterological Association, May 1984.
- 22. Bacon BR, Park CH. Effects of iron-induced lipid peroxidation *in vitro* on hepatic mitochondrial oxidative metabolism. *Hepatology* 4:1039, 1984.
- \*23. Bacon BR, Bailey-Newton RS, Connors AF. Exudative pleural effusions are common after endoscopic variceal sclerotherapy. *Hepatology* 4:1039, 1984. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1984.
- \*24. Gordeuk VR, Brittenham GM, Bacon BR, Keating LJ. Short-term oral carbonyl iron therapy for iron deficiency anemia. *Clin Res* 32:752A, 1984. Presented at the Midwest Section, American Federation for Clinical Research, November 1984.
- \*25. Stark DD, Moseley M, Bacon BR, Moss AA, Goldberg HI, James TL. Magnetic resonance imaging and spectroscopy of hepatic iron overload. Presented at the annual meeting of the Radiologic Society of North America, November 1984.
- \*26. Bacon BR, Marshall JM. Double-blind comparison of butorphanol and meperidine in patients undergoing gastrointestinal endoscopy. Presented at symposium "Butorphanol tartrate: The anesthetic uses of an agonist antagonist agent", April 1985.
- \*27. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic mitochondrial oxidative metabolism in experimental iron overload. Presented at the International Meeting on Free Radicals in Liver Injury, Torino, Italy, June 1985.
- \*28. Bacon BR, Tavill AS, Brittenham GM, Park CH, Recknagel RO. Hepatic mitochondrial oxidative metabolism in experimental iron overload. Presented at the Seventh International Congress on Proteins of Iron Metabolism, Villeneuve d'Ascq, France, July 1985.
- \*29. Bacon BR, Park CH, Stassen WN, Brittenham GM, Tavill AS. Hepatic fibrosis in rats with chronic dietary iron overload. Presented at the Seventh International Congress on Proteins of Iron Metabolism, Villeneuve d'Ascq, France, July 1985.
- \*30. Bacon BR, Park CH. Biochemical and morphologic effects of iron-induced lipid peroxidation *in vitro* on rat hepatic mitochondria. Presented at the Seventh International Congress on Proteins of Iron Metabolism, Villeneuve d'Ascq, France, July 1985.
- \*31. Bacon BR, Healey JF, Brittenham GM, Park CH, Bonkovsky HL, Tavill AS. Effects of experimental dietary iron overload on hepatic microsomal function. Presented at the Seventh International Congress on Proteins of Iron Metabolism, Villeneuve d'Ascq, France, July 1985.

- \*32. Felder R, Stark DD, Bacon BR, Lauffer R, Brady TJ. MR of systemic iron overload. Presented at the annual meeting of the Society of Magnetic Resonance in Medicine, August 1985.
- \*33. Felder R, Stark DD, Bacon BR, Lauffer R, Brady TJ. MR of systemic iron overload. Presented at the annual meeting of the Radiologic Society of North America, November 1985.
- \*34. Bacon BR, O'Neill R, Brittenham GM, Park CH, Tavill AS. Effects of vitamin E deficiency on hepatic mitochondrial oxidative metabolism in experimental dietary iron overload. *Hepatology* 5:950, 1985. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1985.
- \*35. Park CH, Stassen WN, Bacon BR, Brittenham GM, Louis L, Tavill AS. Hepatic fibrosis in rats with chronic dietary iron overload. *Hepatology* 5:950, 1985. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1985.
- \*36. Stassen WN, Park CH, Bacon BR, Brittenham GM, Louis L, Tavill AS. Hepatic fibrosis in rats with dietary iron overload. *Clin Res* 33:877A, 1985. Presented at the annual meeting of the Central Society for Clinical Research, November 1985.
- \*37. Stark DD, Bacon BR, Tager DM, Hahn PF, Ferrucci JT. Evaluation of hemolysis by MR: Splenic iron overload. Presented at the annual meeting of the American Roentgen Ray Society, April 1986.
- \*38. Connors AF, Bacon BR, Miron S. Quantitation of sodium morrhuate delivered to the lung during endoscopic variceal sclerotherapy. Presented at the annual meeting of the American Thoracic Society, May 1986.
- \*39. Bacon BR, O'Neill R. Characterization of iron-induced peroxidative injury to isolated hepatic mitochondria. *Gastroenterology* 90:1708, 1986. Presented at the annual meeting of the American Gastroenterological Association, May 1986.
- \*40. Feldman ES, Bacon BR, Brittenham GM. Hepatic mitochondrial oxidative metabolism and lipid peroxidation in experimental hexachlorobenzene-induced porphyria with dietary carbonyl iron overload. *Gastroenterology* 90:1725, 1986. Presented at the annual meeting of the American Gastroenterological Association, May 1986.
- \*41. Bonkovsky HL, Healey JF, Bacon BR, Desnick RJ, Elder GH. Hepatic heme synthesis in a model of experimental hemochromatosis. Studies in rats fed finely-divided elemental iron. *Gastroenterology* 90:1714, 1986. Presented at the annual meeting of the American Gastroenterological Association, May 1986.
- \*42. Bacon BR, Connors AF, Miron S. Quantitative estimate of sodium morrhuate delivery to the lung and effect on diffusing capacity during endoscopic variceal sclerotherapy. *Gastrointestinal Endoscopy* 32:146, 1986. Presented at the annual meeting of the American Society for Gastrointestinal Endoscopy, May 1986.
- \*43. Stark DD, Groman EV, Saini S, Hahn PF, Sullivan J, Bacon BR, Compton CC, Ferrucci JT. Ferrite: superparamagnetic contrast agent for MR imaging. Presented at the annual meeting of the Society of Magnetic Resonance in Medicine, August 1986.
- 44. Andorn AC, Stitts JM, Bacon BR. Guanyl nucleotides induce a reversible inhibition of high affinity [<sup>3</sup>H] spiroperidol binding in human caudate and putamen by a novel effect on lipid peroxidation. *Abstracts of the Society for Neuroscience* 12, 1986.
- \*45. Cheriyn A, Stassen WN, Malicky E, Bacon BR, Louis LN, Tavill AS. Hepatic prolyl hydroxylase activity fails to reflect fibrosis in an animal model of dietary iron overload. *Clin Res* 34:951A, 1986. Presented at the annual meeting of the Central Society for Clinical Research, November 1986.
- 46. Hill SR, Tavill AS, Malicky E, Bacon BR, Louis LN. Protective effects of deferoxamine on hypoxic injury to isolated perfused rat liver. *Hepatology* 6:1137, 1986.

- \*47. Bacon BR, Britton RS. Hepatic mitochondrial malondialdehyde metabolism in rats with chronic iron overload. *Hepatology* 6:1208, 1986. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1986.
- \*48. Magiera C, Britton RS, Ferrali M, Recknagel RO, Bacon BR. Increased pro-oxidant action of hepatic ultrafiltrates in experimental iron overload. *Hepatology* 6:1209, 1986. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1986.
- \*49. Britton RS, Ferrali M, Magiera C, Bacon BR, Recknagel RO. A bioassay to measure cytosolic low molecular weight iron which is catalytically active in stimulating lipid peroxidation. *Fed Proc* 86:411, 1987. Presented at the annual meeting of FASEB, March 1987.
- \*50. Magiera C, Britton RS, Recknagel RO, Bacon BR. Low molecular weight iron in hepatic cytosol is chelated by deferoxamine *in vivo*. *Fed Proc* 86:411, 1987. Presented at the annual meeting of FASEB, March 1987.
- \*51. Magiera CJ, Bacon BR. Iron-induced lipid peroxidation in isolated iron loaded hepatocytes. *Gastroenterology* 92:1753, 1987. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May 1987.
- \*52. Bacon BR, Britton RS, Magiera CJ, Recknagel RO. Hepatic ultrafiltrates in experimental iron overload show increased pro-oxidant action. Presented at the 8th International Conference on Proteins of Iron Transport and Storage, Montreal, May 1987.
- \*53. Bacon BR, O'Neill R. Lack of effect of vitamin E status on hepatic mitochondrial lipid peroxidation and oxidative metabolism in iron overload. Presented at the 8th International Conference on Proteins of Iron Transport and Storage, Montreal, Canada, May 1987.
- \*54. Bacon BR, Dalton N, O'Neill R. Effects of iron overload on hepatic mitochondrial cytochromes, oxidases/reductases and oxidative metabolism. *Hepatology* 7:1027, 1987. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 1987.
- \*55. Sharma BK, Dalton NT, Smanik PA, Bacon BR. Effects of iron chelators *in vitro* on isolated iron-loaded hepatocytes. *Hepatology* 7:1045, 1987. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 1987.
- \*56. Abounader P, Mahanty S, O'Neill R, Bacon BR. Effects of glutathione (GSH) depletion on hepatic lipid peroxidation in rats with dietary iron overload. *Hepatology* 7:1045, 1987. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 1987.
- 57. Abounader P, Bacon BR. Effects of glutathione depletion *in vivo* on hepatic lipid peroxidation *in vitro* in homogenates from iron-loaded rat liver. *Hepatology* 7:1089, 1987.
- \*58. Wadiwala I, Tavill AS, Louis L, Bacon BR, Brittenham GM, Varnes AW. Hepatobiliary iron excretion in dietary iron overload: Preferential biliary response to deferoxamine chelation. *Hepatology* 7:1107, 1987. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 1987.
- 59. Tsukamoto H, Bacon BR. Status of pro and antioxidants in ethanol-induced centrilobular liver necrosis. *Hepatology* 7:1078, 1987.
- \*60. Weissleder R, Stark DD, Bacon BR, Engelstad BL, Saini S, Hahn PF, Ferrucci JT. Ferrite particles: Evidence for biodegradability and safety as a tissue specific contrast agent for MR imaging. Presented at the annual meeting of the Radiological Society of North America, November 1987.

- \*61. Bacon BR, Britton RS, Dalton N, O'Neill R. Effects of iron overload on hepatic nucleotide levels and energy state. *Hepatology* 8:1240, 1988. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1988.
62. Bacon BR, Williams TR, Britton RS. Detection of hepatic free radicals *in vivo* in chronic dietary iron overload. *Hepatology* 8:1378, 1988.
- \*63. Britton RS, O'Neill R, Bacon BR. Hepatic mitochondrial and microsomal calcium sequestration is decreased in dietary iron overload. *Gastroenterology* 96:A579, 1989. Presented at the annual meeting of the American Gastroenterological Association, May 1989.
- \*64. Bacon BR, Britton RS, Sharma BK, Park CH, O'Neill R. Use of iron chelators in isolated iron-loaded hepatocytes to prevent hepatocellular lipid peroxidation and injury. Presented at the Second International Conference on Haemochromatosis, Gold Coast, Australia, July 1989.
- \*65. Britton RS, O'Neill R, Bacon BR. Chronic dietary iron overload results in impaired calcium sequestration by hepatic mitochondria and microsomes. Presented at the Ninth International Conference of Iron Storage and Transport, Brisbane, Australia, July 1989.
- \*66. Edling JE, Britton RS, Grisham MB, Bacon BR. Increased unwinding of hepatic double-stranded DNA (ds DNA) in rats with chronic dietary iron overload. *Gastroenterology* 98:A585, 1990. Presented at the annual meeting of the American Gastroenterological Association, May 1990.
67. Provenza JM, Netchvolodoff CV, Bacon BR. Safety of guidewire dilatation of the esophagus without fluoroscopy. *Gastrointestinal Endoscopy* 36:189, 1990.
- \*68. Andorn AC, Britton RS, Bacon BR. Evidence that lipid peroxidation and total iron are increased in Alzheimer's brain. *Neurobiology of Aging* 11:316, 1990. Presented at the Second International Congress on Alzheimer's Disease, Toronto, Canada, July 1990.
- \*69. Andorn AC, Britton RS, Bacon BR, Franko M, Hamazaki N, Kalaria RN. Nonheme iron is increased and ascorbate-stimulated lipid peroxidation is reduced in postmortem prefrontal cortex in Alzheimer's disease (AD): A comparison of findings in AD and normal age matched controls. *Abstracts of the Society for Neuroscience* 16:1875, 1990. Presented at the Society for Neuroscience, St. Louis, MO, 1990.
70. Allen DR, Britton RS, Rau JM, McCay PB, Bacon BR. Free radical production from hepatotoxic agents in isolated iron-loaded hepatocytes. *Hepatology* 12:1007, 1990.
- \*71. Britton RS, O'Neill R, Bacon BR. Inhibition of mitochondrial calcium cycling with ruthenium red maintains cell viability in isolated iron-loaded hepatocytes. *Hepatology* 12:931, 1990. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1990.
- \*72. Doyle JT, Britton RS, O'Neill R, Bacon BR. Verapamil and ruthenium red inhibit iron-dependent lipid peroxidation and reduce damage in isolated iron-loaded hepatocytes. *Gastroenterology* 100:737, 1991. Presented at the annual meeting of the American Gastroenterological Association, May 1991.
- \*73. Kamimura S, Gaal K, Britton RS, Bacon BR, Triadafilopoulos G, Tsukamoto H. Increased 4-hydroxynonenal levels in advanced alcoholic liver disease in rats. *Gastroenterology* 100:758, 1991. Presented at the annual meeting of the American Gastroenterological Association, May 1991.
74. Gholson CF, Provenza JM, Doyle JT, Bacon BR. Endoscopic retrograde sphincterotomy (ERS) in the swine. *Gastrointestinal Endoscopy* 37:271, 1991.

- \*75. Britton RS, Edling JE, Grisham MB, Bacon BR. Hepatic DNA damage in rats with chronic dietary iron overload. Presented at the Third International Conference on Hemochromatosis, Dusseldorf, Germany, July 1991.
- \*76. Bacon BR, Britton RS, O'Neill R, Doyle JT. Verapamil and ruthenium red have antioxidant properties and reduce damage in iron-loaded hepatocytes. Presented at the Tenth International Conference on Iron and Iron Proteins, Oxford, England, July 1991.
- \*77. Britton RS, O'Neill R, Singh R, Bacon BR. Dietary supplementation with vitamin E suppresses hepatic malondialdehyde levels in rats with chronic iron overload. *Hepatology* 14:158A, 1991. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1991.
- \*78. Tector AJ, Britton RS, O'Neill R, Bacon BR. Additive effect of iron overload and ethanol on hepatic damage. *Gastroenterology* 102:A944, 1992. Presented at the annual meeting of the American Gastroenterological Association, May 1992.
- \*79. Parkkila S, Niemelä O, Ylä-Herttua S, Bacon BR, Singh R, Britton RS. Dietary supplementation with vitamin E decreases hepatic levels of fluorescent peroxidation products in rats with iron overload. *Gastroenterology* 102:A867, 1992. Presented at the annual meeting of the American Gastroenterological Association, May 1992.
- \*80. Li SCY, O'Neill R, Britton RS, Kobayashi Y, Bacon BR. Lipocytes from rats with chronic iron overload have increased collagen and protein production. *Gastroenterology* 102:A841, 1992. Presented at the annual meeting of the American Gastroenterological Association, May 1992.
- \*81. Kobayashi Y, Britton RS, O'Neill R, Li SCY, Bacon BR. Protein kinase C isoforms in rat hepatic lipocytes. *Hepatology* 16:143A, 1992. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1992.
- \*82. Britton RS, Li SCY, O'Neill R, Kobayashi Y, Bacon BR. Chronic iron overload in rats results in activation of hepatic lipocytes. Presented at the Fourth International Conference on Hemochromatosis and Clinical Problems in Iron Metabolism, April 1993.
- \*83. Bacon BR, Britton RS. Pathophysiology of iron toxicity. Presented at the Fourth International Conference on Hemochromatosis and Clinical Problems in Iron Metabolism, May 1993.
- \*84. Bacon BR, O'Neill R, Britton RS. Hepatocellular respiration and hepatic ATP levels are decreased in experimental iron overload. Presented at the Fourth International Conference on Hemochromatosis and Clinical Problems in Iron Metabolism, May 1993.
- \*85. Ramm GA, Britton RS, O'Neill R, Bacon BR. Characterization of a receptor for ferritin on rat hepatic lipocytes. Presented at the Eleventh International Conference on Iron and Iron Proteins, May 1993.
- \*86. Singh R, Walsh D, Britton RS, Epperly NA, Tredway TL, Bacon BR, Matuschak GM. Ischemia-reperfusion down regulates *E. coli*-induced tumor necrosis factor-alpha gene expression in isolated perfused rat liver. *Gastroenterology* 104:A996. Presented at the annual meeting of the American Gastroenterological Association, May 1993.
- 87. Li SCY, Britton RS, O'Neill R, Kobayashi Y, Bacon BR. The effect of malondialdehyde on collagen production by rat hepatic lipocytes. *Gastroenterology* 104:A939, 1993.
- \*88. Kobayashi Y, Britton RS, O'Neill R, Bacon BR. Regulation of protein kinase C isoforms in rat hepatic lipocytes. *Gastroenterology* 104:A929, 1993. Presented at the annual meeting of the American Gastroenterological Association, May 1993.

- \*89. Ramm GA, Britton RS, O'Neill R, Bacon BR. Identification and characterization of a membrane bound ferritin receptor on rat hepatic lipocytes. *Gastroenterology* 104:A977, 1993. Presented at the annual meeting of the American Gastroenterological Association, May 1993.
- \*90. Kowdley KV, Kaur S, Hassanien T, Farrell FJ, Sorrell MF, Van Thiel DH, Keefe EB, Bacon BR, Weber FL, Tavill AS. Prevalence of primary liver cancer (PLC) and survival in hereditary hemochromatosis (HHC) patients undergoing orthotopic liver transplantation. *Hepatology* 18:57A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*91. Olynyk J, Reddy R, Di Bisceglie AM, Jeffers LJ, Parker T, Radick J, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to alpha-interferon therapy in chronic hepatitis C. *Hepatology* 18:90A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*92. Ramm GA, Britton RS, O'Neill R, Raechal LJ, Luxon BA, Milliano MT, Bacon BR. Further characterization of the rat lipocyte ferritin receptor: Internalization of ferritin. *Hepatology* 18:126A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*93. Singh R, Britton RS, Epperly NA, Lechner AJ, Bacon BR, Matuschak GM. Down-regulation of *E. coli*-induced cytokine gene expression by ischemia-reperfusion in isolated perfused rat liver is independent of transforming growth factor-beta. *Hepatology* 18:132A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*94. Bacon BR, Rebholz AE, Fried M, Di Bisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon-alpha. *Hepatology* 18:150A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*95. Kobayashi Y, Britton RS, O'Neill R, Bacon BR. Platelet-derived growth factor activates protein kinase C in rat hepatic lipocytes. *Hepatology* 18:168A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*96. Singh R, Britton RS, Epperly NA, Tredway TL, Bacon BR, Matuschak GM. *E. coli* acutely upregulates procollagen I gene expression in isolated perfused rat liver. *Hepatology* 18:170A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- \*97. Farahvash MJ, Janney CG, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: An expanded clinical entity. *Hepatology* 18:174A, 1993. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1993.
- 98. Olynyk J, Tracy TF, Goerke ME, Britton RS, Bacon BR. The effect of Kupffer cell blockade with gadolinium on fibrosis and ductal proliferation in an experimental model of biliary obstruction. *Hepatology* 18:205A, 1993.
- 99. Ramm GA, Britton RS, O'Neill R, Bacon BR. Vitamin A-poor lipocytes: Differential collagen production, ferritin receptor expression, and cellular activation. *Hepatology* 18:207A, 1993.
- 100. Ramm GA, Britton RS, Singh R, O'Neill R, Janney CG, Bacon BR. Parenteral iron-dextran increases hepatic collagen gene expression in the gerbil: Involvement of iron-loaded Kupffer cells in hepatic fibrosis. *Hepatology* 18:207A, 1993.
- 101. Farahvash MJ, Ghosh S, Osborn TG, Bacon BR. Cryoglobulinemia is common in patients with chronic hepatitis C. *Hepatology* 18:231A, 1993.
- 102. Olynyk J, Britton RS, Bacon BR. Two types of hepatic iron overload in patients with genetic hemochromatosis (GH): Linear and nonlinear relationship with total body iron stores. *Hepatology* 18:273A, 1993.

103. Olynyk J, O'Neill R, Britton RS, Bacon BR. Measurement of hepatic iron concentration (HIC) in fresh and paraffin-embedded tissue. *Hepatology* 18:273A, 1993.
104. Olynyk J, Matuschak GM, Tredway TL, O'Neill R, Britton RS, Bacon BR. Differential production of tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) by rat Kupffer cells (KCs) after phagocytosis of *E. coli* (EC) vs. *C. albicans* (CA). *Hepatology* 18:320A, 1993.
105. Olynyk J, Stephenson AH, O'Neill R, Britton RS, Bacon BR. Phagocytosis of damaged hepatocytes by Kupffer cells results in prostaglandin I<sub>2</sub> secretion *in vitro*. *Hepatology* 18:320A, 1993.
- \*106. Olynyk J, Stephenson AH, O'Neill R, Britton RS, Bacon BR. A novel *in vitro* model for the study of phagocytosis of damaged hepatocytes by Kupffer cells. *Clinical Research* 41:668A, 1993. Presented at the annual meeting of the Central Society for Clinical Research, November 1993.
- \*107. Ramm GA, Britton RS, O'Neill R, Luxon BA, Milliano MT, Bacon BR. The rat lipocyte ferritin receptor: Further binding studies and determination of ferritin internalization. *Clinical Research* 41:687A, 1993. Presented at the annual meeting of the Central Society for Clinical Research, November 1993.
- \*108. Ramm GA, Britton RS, O'Neill R, Bacon BR. Ferritin receptors are expressed on activated, but not quiescent lipocytes: An early marker of lipocyte activation. *Gastroenterology* 106:A967, 1994. Present at the annual meeting of the American Gastroenterological Association, May 1994.
109. Ramm GA, Britton RS, O'Neill R, Kohn HD, Petersen PF, Bacon BR. Vitamin A-poor lipocytes: A desmin-negative lipocyte subpopulation, with a decreased rate of *in vitro* activation. *Gastroenterology* 106:A968, 1994.
- \*110. Kaur S, Carey WD, Bacon BR, Gollan JL, Rustgi VK. Risk factors for viral hepatitis (VH) B and C exposure in subjects presenting to a voluntary large scale screening program (LSSP) - Results of the National Hepatitis Surveillance Program. *Gastroenterology* 706:A916, 1994. Presented at the annual meeting of the American Gastroenterological Association, May 1994.
111. Kaur S, Carey WD, Bacon BR, Gollan JL, Rustgi VK. Symptoms of viral hepatitis (VH) B and C in subjects presenting to a voluntary large scale screening program (LSSP) - Results of the National Hepatitis Surveillance Program. *Gastroenterology* 106:A916, 1994.
- \*112. Kaur S, Carey WD, Bacon BR, Gollan JL, Rustgi VK, Sandha GS. Performance characteristics of a large scale screening program (LSSP) for viral hepatitis (VH) B and C - Results of the National Hepatitis Surveillance Program. *Gastroenterology* 106:A916, 1994. Presented at the annual meeting of the American Gastroenterological Association, May 1994.
- \*113. Kohn HD, Ramm GA, Britton RS, O'Neill R, Bacon BR. The effect of alpha-tocopherol on lipocyte activation, *in vitro*. *Clinical Research* 42:420A, 1994. Presented at the annual meeting of the Central Society for Clinical Research, September 1994.
- \*114. Brown KE, Rice J, O'Neill R, Ramm GA, Britton RS, Bacon BR. Vitamin E suppresses lipid peroxidation but not hydroxyproline accumulation in chronic iron overload. *Hepatology* 20:270A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*115. Fimmel CJ, Kladney RD, Bacon BR. Dietary iron overload increases gene expression in rat hepatic lipocytes *in vivo*. *Hepatology* 20:286A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*116. Kohn HD, Ramm GA, Britton RS, O'Neill R, Bacon BR. Alpha-Tocopherol inhibits the expression of alpha-smooth muscle actin in cultured rat lipocytes. *Hepatology* 20:117A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.

- \*117. Ramm GA, Britton RS, O'Neill R, Kohn HD, Bacon BR. Ferritin inhibits alpha-smooth muscle actin expression in cultured rat lipocytes. *Hepatology* 20:287A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*118. Ramm GA, Britton RS, O'Neill R, Li L, Kohn HD, Petersen PF, Bacon BR. Chronic iron overload causes activation of rat lipocytes, *in vivo*. *Hepatology* 20:287A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*119. Ramm GA, Britton RS, O'Neill R, Li L, Kohn HD, Bacon BR. The role of protein kinase C in lipocyte activation, *in vitro*. *Hepatology* 20:287A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*120. Ramm GA, Li L, Carr SC, Vogler CA, Britton RS, Bacon BR, Tracy TF. Rapid de-differentiation of myofibroblasts during hepatic repair following chronic cholestatic liver injury. *Hepatology* 20:287A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*121. Olynyk JK, Luxon BA, Jeffrey GP, Reed WD, Bacon BR. Predicting phlebotomy requirements in the treatment of iron overload. *Hepatology* 20:323A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*122. Olynyk JK, Fox ES, Stephenson AH, Matuschak GM, Britton RS, O'Neill R, Bacon BR. A novel *in vitro* model for the study of phagocytosis of iron-loaded hepatocytes by Kupffer cells. *Hepatology* 20:181A, 1994. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 1994.
- \*123. Bellezzo JM, Britton RS, Bulla GA, Bacon BR, Matuschak GM, Tracy TF, Fox ES. N-Acetylcysteine suppresses endotoxin-induced tumor necrosis factor production by rat Kupffer cells. Presented at the annual meeting of the American Society of Cell Biology, December 1994.
- \*124. Bellezzo JM, Bulla GA, Britton RS, Bacon BR, Fox ES. NF- $\kappa$ B activity in lipopolysaccharide (LPS) stimulated Kupffer cells is induced by a CD14-independent mechanism. Presented at the annual meeting of the American Society of Cell Biology, December 1994.
- \*125. Olynyk JK, Fox ES, Stephenson AH, Matuschak GM, Britton RS, O'Neill R, Bacon BR. Kupffer cell-hepatocyte interactions in iron overload. Presented at the fifth conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, April 1995.
- \*126. Brown KE, O'Neill R, Ramm GA, Britton RS, Bacon BR. Effects of vitamin E on hepatic lipid peroxidation and hydroxyproline in chronic iron overload. Presented at the fifth conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, April 1995.
- \*127. Ramm GA, Li L, Britton RS, O'Neill R, Bacon BR. *In vivo* activation of hepatic lipocytes in an animal model of genetic hemochromatosis. Presented at the fifth conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, April 1995.
- \*128. Ramm GA, Britton RS, O'Neill R, Kohn HD, Bacon BR. The role of ferritin and the ferritin receptor in lipocyte activation. Presented at the fifth conference of the International Association for the Study of Disorders of Iron Metabolism, Boston, April 1995.
- 129. Khan NA, Brown KE, O'Neill R, Kohn HD, Bacon BR. Aldehydic products of lipid peroxidation do not directly activate rat hepatic lipocytes. *Gastroenterology* 108:A1096, 1995.
- 130. Khan NA, Ramm GA, Britton RS, O'Neill R, Blaner WS, Bacon BR. Lipocyte heterogeneity: Subpopulations of rat lipocytes differ both in vitamin A content and in the expression of vimentin and desmin. *Gastroenterology* 108:A1097, 1995.



- \*131. Bacon BR, Sadiq SA. Hereditary hemochromatosis: Diagnosis in the 1990's. *Hepatology* 22:372A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*132. Bacon BR, Farrell G, Benhamou JP, Hopf U, Barcena R, Feinman V, Rizzetto M, Wright T, Warwick S, Horton J, the Wellferon Study Group. Lymphoblastoid interferon improves long-term response to a six-month course of treatment when compared with recombinant interferon alfa 2b: Results of an international trial. *Hepatology* 22:152A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*133. Bellezzo JM, Britton RS, Bacon BR, Fox ES. LPS mediated NF- $\kappa$ B activation in Kupffer cells can be induced independent of CD14. *Hepatology* 22:365A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*134. Bellezzo JM, Fox ES, Bulla GA, Britton RS, Bacon BR. Antioxidants suppress endotoxin-induced tumor necrosis factor production by rat Kupffer cells. *Hepatology* 22:365A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*135. Li L, O'Neill R, Brown KE, Soweid AM, Britton RS, Poulos JE, Bacon BR. Vitamin E suppresses lipocyte activation in chronic iron overload. *Hepatology* 22:279A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*136. Neuschwander-Tetri BA, Bellezzo JM, Britton RS, Bacon BR, Fox ES. Thiol regulation of endotoxin-induced tumor necrosis factor release from isolated Kupffer cells. *Hepatology* 22:236A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*137. Niemelä O, Parkkila S, Britton RS, Ramm GA, O'Neill R, Janney CG, Brunt EM, Bacon BR. Hepatic lipid peroxidation in patients with hereditary hemochromatosis. *Hepatology* 22:372A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*138. Poulos JE, Brunt EM, Janney CG, Bacon BR, Di Bisceglie AM. Hepatic expression of alpha-smooth muscle actin in chronic hepatitis C: Correlation with disease activity and changes with therapy. *Hepatology* 22:278A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*139. Poulos JE, Di Bisceglie AM, Bellezzo JM, Weber JD, Britton RS, Bacon BR, Baldassare JJ. Stimulation of c-Jun kinase by fibronectin and interleukin-1-beta is associated with increased gene expression of stromelysin in lipocytes. *Hepatology* 22:293A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*140. Hogan C, Caplan B, Bacon BR, Di Bisceglie AM, Babbitt B. Antigen independent activation of T cells obtained from chronic hepatitis B patients results in enhanced responses upon restimulation by HBV antigens. *Hepatology* 22:264A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*141. Reddy KR, Bacon BR, Tzakis A, Neuschwander-Tetri BA, Jeffers LJ, Di Bisceglie AM, Bernstein DE, Weppler D, Webb M, Nery J, de Medina M, Vioana A, Schiff ER. Hepatic iron concentration (HIC) in end stage liver disease (ESLD) 2° to chronic hepatitis C (HCV) and/or alcoholic liver disease (ALD). *Hepatology* 22:275A, 1995. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1995.
- \*142. Di Bisceglie AM, Bacon BR, Neuschwander-Tetri BA, Yun A, Kim JP. Role of hepatitis G virus in cryptogenic liver disease. *Gastroenterology* 110:A1181, 1996. Presented at the annual meeting of the American Gastroenterological Association, San Francisco, May 1996.

- \*143. O'Neill R, Li L, Britton RS, Bacon BR. Transforming growth factor-beta accelerates the myofibroblastic transformation of cultured hepatic stellate cells. *Gastroenterology* 110:A1286, 1996. Presented at the annual meeting of the American Gastroenterological Association, San Francisco, May 1996.
- \*144. Bacon BR, Tsuchihashi Z, Thomas W, Britton RS, Wolff RK. Genetic analysis in hereditary hemochromatosis. *Hepatology* 24:249A, 1996. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1996.
- \*145. Britton RS, O'Neill R, Brady LM, Fox ES, Bacon BR. Platelet-derived growth factor activates extracellular signal-regulated kinase (ERK) independently of protein kinase C in rat hepatic stellate cells. *Hepatology* 24:456A, 1996. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1996.
- \*146. Li L, Britton RS, Bulla GA, Bacon BR. Transforming growth factor-beta activates the transcription factors AP-1 and Sp1 in rat hepatic stellate cells. *Hepatology* 24:456A, 1996. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1996.
- \*147. Poulos JE, Bellezzo JM, Weber JD, Di Bisceglie AM, Britton RS, Bacon BR, Baldassare JJ. Fibronectin and interleukin-1beta stimulate AP-1-dependent gene expression in rat hepatic stellate cells. *Hepatology* 24:459A, 1996. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1996.
- \*148. Ramm GA, Crawford DHG, Bridle KR, Britton RS, Bacon BR, Tracy Jr TF. Biliary decompression results in rapid reversal of procollagen alpha<sub>1</sub>(I) gene expression in experimental biliary fibrosis. *Hepatology* 24:463A, 1996. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1996.
- 149. Dhar SC, Solomon H, Bacon BR, Di Bisceglie AM. Liver transplantation in patients with chronic hepatitis C and alcoholism. *Hepatology* 24:502A, 1996.
- \* 150. Farrell G, Bacon BR, Goldin R. Final results of an international controlled trial comparing lymphoblastoid interferon-alpha-n1 with recombinant interferon-alpha2b in chronic hepatitis C (HCV). *Journal of Hepatology* 1997 (in press). Presented at the annual meeting of the European Association for the Study of the Liver, London, April 1997.
- \* 151. Bacon BR, Schratz CL, Britton RS, Wolff RK. Presence of the hemochromatosis genotype in patients with liver disease. *Gastroenterology* 112:A1218, 1997. Presented at the annual meeting of the American Gastroenterological Association, Washington, May 1997.
- \* 152. Poulos JE, Weber JD, Baldassare JJ, Li L, Britton RS, Bacon BR. Activation of mitogen-activated protein kinase pathways by tumor necrosis factor-alpha and fibronectin in rat hepatic stellate cells. *Gastroenterology* 112:A1361, 1997. Presented at the annual meeting of the American Gastroenterological Association, Washington, May 1997.
- \* 153. Parkkila S, Waheed A, Britton RS, Feder JN, Tsuchihashi Z, Schatzman RC, Bacon BR, Sly WS. The normal gastrointestinal distribution and cellular localization of the novel MHC class-I-like HLA protein defective in hereditary hemochromatosis. *Gastroenterology* 112:A1355, 1997. Presented at the annual meeting of the American Gastroenterological Association, Washington, May 1997.
- \* 154. Shaheen NJ, Bacon BR, Grimm IS. Clinical characteristics of patients diagnosed with hereditary hemochromatosis who lack the Cys282Tyr mutation. *Gastroenterology* 112:A1381, 1997. Presented at the annual meeting of the American Gastroenterological Association, Washington, May 1997.

- \* 155. Di Bisceglie AM, Babbitt BP, Miesowicz F, Schratz CL, Osmack PA, Bacon BR. A pilot study of autologous lymphocyte therapy for chronic hepatitis B. *Gastroenterology* 112:A1257, 1997. Presented at the annual meeting of the American Gastroenterological Association, Washington, May 1997.
- \*156. Di Bisceglie AM, Bonkovsky H, Krawitt E, Grace N, Killenberg P, Hunt C, Chopra S, Reddy RK, Flamm S, Tavill AS, Ferguson R, Tamburro C, Osmack P, Bacon BR. Iron reduction therapy in chronic hepatitis C. *Hepatology* 26:214A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*157. Tung BY, Tabasco-Minguillan J, Bacon BR, Farrell FJ, Gish RG, McCashland TM, Kowdley KV. Long-term follow-up after liver transplantation for hereditary hemochromatosis. *Hepatology* 26:343A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*158. Fiel MI, Schiano TD, Bodenheimer HC Jr, Thung SN, Miller CM, Bacon BR. Genotypic, biochemical and histological analysis for hereditary hemochromatosis in liver transplant patients. *Hepatology* 26:159A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*159. Minguillan JT, Lee RG, Britton R, Wolff R, Demetris AJ, Bacon BR, Rakela J. Genetic markers for hemochromatosis in patients with cirrhosis and iron overload. *Hepatology* 26:158A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*160. Poulos JE, Weber JD, Neuschwander-Tetri BA, Wells LD, Petersen PE, Baldassare JJ, Britton RS, Bacon BR. Activation of AP-1 dependent gene expression by RGD in hepatic stellate cells is dependent on Ras, and is suppressed by N-acetylcysteine. *Hepatology* 26:184A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*161. O'Neill R, Li L, Britton RS, Bacon BR. Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression on hepatic stellate cells by TNF and endotoxin is suppressed by N-acetylcysteine. *Hepatology* 26:832A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- \*162. Leicester KL, Olynyk JK, Fox ES, Yeoh GC, Brunt EM, Britton RS, Bacon BR. Hepatic macrophages in primary biliary cirrhosis. *Hepatology* 26:440A, 1997. Presented at the Annual Meeting of the American Association for the Study of Liver Diseases, Chicago, November 1997.
- 163. Olynyk JK, Yeoh GC, Ramm GC, Clarke SL, Hall PM, Britton RS, Bacon BR, Tracy TF. Kupffer cell blockade with gadolinium suppresses hepatic oval cell proliferation in rats with biliary obstruction. *Hepatology* 26:576A, 1997.
- \*164. Zhou XY, Tomatsu S, Fleming RE, Parkkila S, Waheed A, Sly WS, Brunt EM, Tsuchihashi Z, Feder JN, Schatzman RC, O'Neill R, Britton RS, Bacon BR. Knockout of the mouse HFE gene produces hemochromatosis. *Gastroenterology* 114:A1372, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.
- \*165. Li JJ, O'Neill R, Chen S, Bora PS, Britton RS, Bacon BR. The ethanol metabolites, fatty acid ethyl esters, activate rat hepatic stellate cells. *Gastroenterology* 114:A1289, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.
- \*166. Li JJ, Bora PS, Chen S, O'Neill R, Guruge BL, Britton RS, Bacon BR. Hepatic stellate cells contain fatty acid ethyl ester synthase, an enzyme that converts ethanol to lipophilic bioactive metabolites. *Gastroenterology* 114:1288, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.

- \*167. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. Hepatic macrophages are associated with fibrosis in hereditary hemochromatosis. *Gastroenterology* 114:A1286, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.
- \*168. Shaheen NJ, Braun MH, Grimm IS, Sandler RS, Downs SM, Bacon BR. Liver biopsy versus genetic testing for the C282Y mutation: A comparison of diagnostic strategies for hereditary hemochromatosis using decision analysis. *Gastroenterology* 114:A1339, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.
- \*169. Di Bisceglie AM, Bassett SE, Bacon BR, Lanford RE. Effect of dietary iron loading in chimpanzees with chronic hepatitis C virus infection. *Gastroenterology* 114:A1234, 1998. Presented at the annual meeting of the American Gastroenterological Association, New Orleans, May 1998.
- \*170. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. A proposal for grading and staging the histopathologic findings in nonalcoholic steatohepatitis (NASH). *Modern Pathology* 11:151A, 1998. Presented at the annual meeting of the United States and Canadian Academy of Pathology, Boston, MA, March 1998.
- 171. Varma CR, Mistry B, Ramrakhiani S, Bacon BR, Neuschwander-Tetri BA, Garvin PJ, Burton FR. Post-transplant lymphoproliferative disorder presenting as biliary obstruction. *Transplantation*.
- \*172. Varma CR, Aridge D, Mistry B, Garvin PJ, Bacon BR, Solomon H. Obesity and liver transplantation: Is there an adverse outcome? *Hepatology* 28:226A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*173. Khan CM, Bacon BR. Treatment of chronic hepatitis C in patients with normal aminotransferases. *Hepatology* 28:282A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*174. Li JJ, Hu W, Baldassare JJ, Poulos JE, Chen S, Li L, Bora PS, Neuschwander-Tetri BA, O'Neill R, Britton RS, Bacon BR. The ethanol metabolite, linolenic acid ethyl ester, stimulates mitogen-activated protein (MAP) kinase and cyclin signaling in hepatic stellate cells. *Hepatology* 28:302A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*175. Ramrakhiani S, Solomon H, Varma CR, Osmack P, Bacon BR, Di Bisceglie AM. Prevalence of immunity to hepatitis A and B in patients undergoing orthotopic liver transplantation. *Hepatology* 28:345A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*176. Bacon BR, Rauscher JA, Smith-Wilkaitis NL, Randall DC, Koehler KM, Di Bisceglie AM. Interferon-ribavirin combination is successful in eliminating hepatitis C virus in non-responders to interferon alone including patients with normal aminotransferases. *Hepatology* 28:372A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*177. Brunt EM, Britton RS, Olynyk JK, Di Bisceglie AM, Bacon BR. Iron grading: a proposal for a histologic system that includes the pattern, location and grade of stainable iron. *Hepatology* 28:423A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*178. Li JJ, Hu W, Baldassare JJ, Li L, Chen S, Poulos JE, O'Neill R, Britton RS, Bacon BR. Extracellular signal-regulated kinase (ERK) links platelet-derived growth factor (PDGF) signaling to the cell cycle machinery in hepatic stellate cells. *Hepatology* 28:435A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
- \*179. Li L, Britton RS, Bacon BR. Transforming growth factor- $\beta$  increases mitogen-activated protein kinase signaling and AP-1 dependent gene expression in rat hepatic stellate cells. *Hepatology* 28:538A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.

- \*180. Sponseller CA, Smith-Wilkaitis N, Bacon BR, Di Bisceglie AM. Clinical improvement in patients with decompensated liver disease due to hepatitis B following treatment with lamivudine. *Hepatology* 28:589A, 1998. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Chicago, November 1998.
181. Leicester KL, Olynyk JK, Brunt EM, Britton RS, Bacon BR. Hepatic CD14-positive cells are associated with fibrosis in hereditary hemochromatosis. *Hepatology* 28:614A, 1998.
182. Solomon H, Burton FR, Dunphy II FR, Petruska PJ, Varma CR, Mistry B, Garvin PJ, Ramrakhiani S, Bacon BR. Lymphoproliferative disease masquerading as biliary obstruction. *Hepatology* 28:747A, 1998.
183. Solomon S, Varma CR, Garvin PJ, Ramrakhiani S, Burton FR, Bacon BR. Portal vein arterialization after hepatic artery occlusion in liver transplantation. *Hepatology* 28:747A, 1998.
- \*184. Naeem M, Bacon BR, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile with interferon therapy in chronic hepatitis C. *Gastroenterology* 116:A1203, 1999. Presented at the annual meeting of the American Gastroenterological Association, Orlando, May 1999.
- \*185. Li JJ, Hu W, Baldassare JJ, Chen S, Li L, Poulos JE, O'Neill R, Britton RS, Bacon BR. Pentoxifylline inhibits the effect of platelet-derived growth factor on regulatory cell-cycle proteins in hepatic stellate cells. *Gastroenterology* 116:A1238, 1999. Presented at the annual meeting of the American Gastroenterological Association, Orlando, May 1999.
186. Younossi ZM, Gramlich TL, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Iron in nonalcoholic fatty liver disease: Myth or reality? *Gastroenterology* 116:A1292, 1999.
187. Bacon BR, Fazel A, Baumann M. Treating iron deficiency in colon carcinoma: Are we disabling a natural defense mechanism? *Gastroenterology* 116:A374, 1999.
188. Bacon BR, Fazel A, Baumann M. The impact of iron deficiency on the growth of colon carcinoma cells. *Gastroenterology* 116:A374, 1999.
189. Kew MC, Klein AS, Abrams RA, Sitzmann JV, Jones L, Sharma S, Bacon BR, Di Bisceglie AM, Groopman JD. Increased hepatic oxidative DNA damage in patients with hepatocellular carcinoma. *Hepatology* 30:279A, 1999.
190. Bacon BR, Rauscher JA, Smith-Wilkaitis NL, Koehler KM, Antal MJ. Interferon-ribavirin combination: Sustained response in previous monotherapy non-responders. *Hepatology* 30:372A, 1999.
191. Bridle KR, O'Neill R, Britton RS, Bacon BR. ERK and PI3-kinase mediate the mitogenic effect of insulin-like growth factor on hepatic stellate cells. *Hepatology* 30:490A, 1999.
- \*192. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Hereditary hemochromatosis patients with hepatitis C presented with advanced hepatic fibrosis at a younger age and at a lower hepatic iron concentration. *Gastroenterology* 118:P64, 2000. Presented at the annual meeting of the American Gastroenterological Association, San Diego, May 2000.
- \*193. Bridle KR, O'Neill R, Britton RS, Bacon BR. Down regulation of protein kinase C does not abrogate the stimulatory effects of PDGF or IGF-1 on extracellular signal-regulated kinase, phosphatidylinositol 3-kinase or p70 S6 kinase in rat hepatic stellate cells. *Hepatology* 32:35A, 2000. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, October 2000.
- \*194. Bridle KR, Li L, O'Neill R, Britton RS, Bacon BR. Potential crosstalk between extracellular signal-regulated kinase, phosphatidylinositol 3-kinase and p70-S6 kinase signaling induced by IGF-1 and PDGF in rat hepatic

- stellate cells. *Hepatology* 32:35A, 2000. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, October 2000.
- \*195. Fontana RJ, Perrillo R, Hann H-WL, Wright T, Rakela J, Bacon BR, Anschuetz G, Gardner SD, Brown NA. Determinants of survival in 133 patients with decompensated chronic hepatitis B treated with lamivudine. *Hepatology* 32:52A, 2000. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, October 2000.
- \*196. Kowdley KV, Brandhagen DJ, Crippin JS, Gish RG, Bacon BR, Keeffe EB, Sterling R, Fontana RJ, Cotler S, Emond MJ. NHTR Investigators (various). Survival after orthotopic liver transplantation among patients with hepatic iron overload: Preliminary results from the national hemochromatosis transplant registry. *Hepatology* 32:56A, 2000. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, October 2000.
- \*197. Sjogren MH, Wu G, Herrine S, Raufman J-P, Bacon BR, Epstein M, Medoff J, Chen S, Waters B, Krawitt E, Sjogren RW, Herrera J. High-dose interferon alfacon-1 is a treatment option for non-responders and relapsers to combined therapy with interferon and ribavirin. *Hepatology* 32: 112A, 2000. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Dallas, October 2000.
- \*198. Neuschwander-Tetri BA, Sponseller C, Bacon BR, Wehmeier K, Brunt EM. Exaggerated insulin response to an oral glucose challenge in non-diabetic patients with biopsy evidence of NASH. *Gastroenterology* 120:A-107, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*199. Neuschwander-Tetri BA, Li L, Wells LD, Bacon BR, Britton RS. Inhibition of p70 S6 kinase by rapamycin does not reverse the activated phenotype of pancreatic stellate cells. *Gastroenterology* 120:A-720, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*200. Ramrakhiani S, Bacon BR. Response to combination therapy with alfa-interferon and ribavirin in patients with chronic hepatitis C and normal aminotransferases. *Gastroenterology* 120:A-571, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*201. Ramrakhiani C, Bacon BR, St. Vrain J, Befeler AS, Ramrakhiani S, Labovitz AJ. 2-D and dobutamine stress echocardiography in the pre-operative evaluation of patients undergoing orthotopic liver transplantation. *Gastroenterology* 102:A-371, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*202. Ramrakhiani S, Befeler AS, Bacon BR. Nonalcoholic steatohepatitis is associated with increased histological activity and fibrosis in patients with chronic hepatitis C. *Gastroenterology* 120:A543, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*203. Ramrakhiani S, Befeler AS, Bacon BR. Dyslipidemia and other major coronary risk factors in liver transplant recipients. *Gastroenterology* 120:A-562, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*204. Habib A, Bacon BR, Befeler AS, Ramrakhiani S. Rapamycin for treatment of renal insufficiency related to calcineurin inhibitors in liver transplant recipients. *Gastroenterology* 120:A-92, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*205. Habib A, Bacon BR, Ramrakhiani S. Hyperhomocysteinemia in liver transplant recipients. *Gastroenterology* 120:A-562, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*206. Ramrakhiani S, Bacon BR, Varma SC, Ramrakhiani S, Di Bisceglie AM. Hepatitis C virus genotype 4 infection in the United States; Clinical features and response to therapy. *Gastroenterology* 120:A-381, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.

- \*207. Merriman RB, Bacon BR, Brunt EM, Tetri BA, Peters MG, Strauss AW. A common mutation of the long-chain hydroxyacyl-co-A dehydrogenase enzyme of mitochondrial fatty acid beta-oxidation is not associated with non-alcoholic steatohepatitis. *Gastroenterology* 120:A-543, 2001. Presented at the annual meeting of the American Gastroenterological Association, May 2001.
- \*208. Kowdley KV, Tung BY, Brandhagen DJ, Schilsky M, Han SH, Cotler S, Weinstein JS, Gist RG, Bass N, Bacon BR, Sterling R, Fontana RJ. Prevalence of hepatic iron overload and *HFE* mutations among patients undergoing orthotopic liver transplantation (OLT): Interim results from the National Hemochromatosis Transplant Registry (NHTR). *Hepatology* 34:205A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*209. Kowdley KV, Brandhagen DJ, Gish RG, Bass N, Weinstein JS, Schilsky M, Fontana RJ, McCashland T, Cotler S, Bacon BR, Keefe, EB, Polissar N. Survival after orthotopic liver transplant (OLT) among patients with hepatic iron overload: Interim results for the National Hemochromatosis Transplant Registry (NHTR). *Hepatology* 34:236A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*210. Merriman RB, Aouizerat BE, Molloy MJ, Kane JP, Bacon BR, Bass NM. A genetic mutation in the peroxisome proliferator-activated receptor alpha gene in patients with non-alcoholic steatohepatitis. *Hepatology* 34:441A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*211. Bridle KR, Li L, O'Neill R, Britton RS, Bacon BR. Insulin-like growth factor-1 and platelet-derived growth factor induce anti-apoptotic signaling in rat hepatic stellate cells. *Hepatology* 34:892A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*212. O'Neill R, Bridle KR, Khan MA, Li L, Britton RS, Bacon BR. Rapamycin inhibits collagen production and proliferation during early activation of hepatic stellate cells. *Hepatology* 34:405A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*213. Leicester KL, Brunt EM, Britton RS, Bacon BR, Olynyk JK. Hepatic CD14 expression is not elevated in nonalcoholic steatohepatitis. *Hepatology* 34:463A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*214. Sponseller CA, Goudey KL, Brass CA, Bacon BR. Efficacy of human recombinant interleukin 10 (IL-10) prior to re-treatment with interferon  $\alpha$ -2b and ribavirin in chronic hepatitis C patients who failed to respond to a previous course of interferon  $\alpha$ -2b and ribavirin. *Hepatology* 34:578A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*215. Sponseller CA, Koehler KM, Bacon BR. Use of interferon  $\alpha$ -2b and ribavirin for treatment of patients with chronic hepatitis C with normal ALT levels. *Hepatology* 34:596A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*216. Bacon BR, Di Bisceglie AM, Thompson JA, Koehler KM. Long-term durability of sustained virologic response to antiviral therapy of hepatitis C. *Hepatology* 34:606A, 2001. Presented at the annual meeting of the American Association for the Study of Liver Diseases, November 2001.
- \*217. Neuschwander-Tetri BA, Sponseller C, Hampton KK, Karadaghy AA, Bacon BR, Wehmeir K, Brunt EM. Rosiglitazone improves insulin sensitivity ALT and hepatic steatosis in patient with nonalcoholic steatohepatitis. *Gastroenterology* 122:1, 2002. Presented at the annual meeting of the American Gastroenterological Association, April 2002.
- \*218. Loomba R, Brunt EM, Luxon BA, Bacon BR, Neuschwander-Tetri BA. Long-term outcome of patients with autoimmune hepatitis treated with high or low dose Prednisone as initial therapy is equal. *Gastroenterology* 122:109, 2002. Presented at the annual meeting of the American Gastroenterological Association, April 2002.

- \*219. Sponseller CA, Wehmeier K, Hampton K, Bacon BR, Brunt EM, Neuschwander-Tetri BA. Serum iron studies, *HFE* genotype, and their relationship to insulin sensitivity in patients with nonalcoholic steatohepatitis. *Gastroenterology* 122:145, 2002. Presented at the annual meeting of the American Gastroenterological Association, April 2002.
- \*220. Chelamcharla M, Ramrakhiani S, Bacon BR, Befeler AS. Do patients with hepatitis C and porphyria cutanea tarda respond to treatment with interferon and ribavirin? *Gastroenterology* 122:218, 2002. Presented at the annual meeting of the American Gastroenterological Association, April 2002.
- \*221. Gordon SC, Bacon BR, Jacobson IM, Shiffman ML, Afdhal NH, McHutchison JG, Kwoh TJ, Door FA. A phase II, 12-week study of ISIS 14803, an antisense inhibitor of HCV for the treatment of chronic hepatitis C. *Hepatology* 36:362A, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*222. Neuschwander-Tetri BA, Brunt EM, Bacon BR, Sponseller C, Wehmeier KR, Hampton KK. Histological improvement in NASH following reduction in insulin resistance with 48-week treatment with the PPAR $\gamma$  agonist rosiglitazone. *Hepatology* 36:379A, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*223. Iftikhar R, Havilioglu N, Kladney RD, Luxon BA, Solomon H, Bacon BR, Fimmel CJ. Hepatocyte expression of GP73 is upregulated in non-cirrhotic liver disease. *Hepatology* 36:440A, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*224. Loomba R, Brunt EM, Luxon BA, Bacon BR, Neuschwander-Tetri BA. Autoimmune hepatitis and overlap syndromes respond equally to immunosuppressive therapy. *Hepatology* 36:502A, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*225. Sponseller CA, Koehler KM, Hoffmann JA, Strinko JM, Bacon BR. Use of interferon  $\alpha$ -2b and ribavirin for treatment of patients with chronic hepatitis C with normal ALT levels. *Hepatology* 36:579, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*226. Bacon BR, Zeuzem S, Albrecht JK. Weight-based interferon (IFN) dosing is more efficacious than fixed dosing in chronic hepatitis C (CHC). *Hepatology* 36:602A, 2002. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2002.
- \*227. Gordon SC, Bacon BR, Jacobson IM, Shiffman ML, Afdhal NH, Yu RZ, McHutchison JG, Kwoh TJ. Treatment of chronic hepatitis C with ISIS 14803, an antisense inhibitor of HCV, given for 12 weeks. *Hepatology* 38:306A, 2003. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2003.
- \*228. Harrison SA, Brunt EM, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. The presence of severe steatosis or steatohepatitis impairs response to antiviral therapy in patients with chronic hepatitis C. *Hepatology* 38:626A, 2003. Presented at the annual meeting of the American Association for the Study of Liver Diseases, October 2003.
- \*229. Bacon BR, Freilich BL, Siegner JM, O'Neill R, Kissinger J, Hoffmann JA, Britton RS, Di Bisceglie, Brass C. Antioxidant treatment does not substantially ameliorate the fall in hemoglobin in HCV patients treated with pegylated interferon alfa-2b and ribavirin. *Gastroenterology* 126:A233, 2004. Presented at the annual meeting of the American Gastroenterological Association, May 2004.
- \*230. Leicester KL, Olynyk JK, Milliano MT, O'Neill R, Luxon BA, Brunt, EM, Britton RS, Bacon BR. Knockout of CD14 suppresses early activation of hepatic stellate cells after carbon tetrachloride-induced liver injury. *Hepatology* 40:535A, 2004. Presented at the annual meeting of the American Association for the Study of Liver Diseases. October 2004.



- \*231. McHutchison JG, Bacon BR, Gordon SC, Afdhal NH, Jacobson IM, Muir A, Krieg AM, Efler Sal-adhami M, Davis HL, Schmalbach TK. Human pharmacologic activity of a new TR9 agonist antiviral Cpg 10101 (ACTILON™). *Hepatology* 40:697A, 2004. Presented at the annual meeting of the American Association for the Study of Liver Diseases. October 2004.
- \*232. Bacon BR, Mchutchison JG, Gordon SC, Afdhal NH, Jacobson IM, Shiffman M, Muir A, Krieg AM, Efler S, Morris ML, Whisnant J, Al-Adhami M, Davis H, Schmalbach T. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilon-TM), a novel TLR9 agonist: Comparison in normal volunteers and HCV infected individuals. *Gastroenterology* 128:P91, 2005. Presented at the annual meeting of the American Gastroenterological Association, April 2005.
- \*233. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Efler SM, Myette VK, Ahluwalia N, Murzenok PP, Lipford G, Schmalbach TK, Krieg AM, Davis HL. Immunophenotyping profile of CPG 10101, a new TLR9 agonist antiviral for hepatitis C. *Hepatology* 42:148A, 2006. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October 2005.
- \*234. McHutchison JG, Ghalib R, Lawitz E, Freilich B, Kwo P, Masciari F, Himes JL, Al-adhami M, Bacon BR. Early virologic response to Cpg 10101, a new investigational antiviral Tlr9 agonist to combination with pegylated Interferon and/or ribavirin in prior relapse HCV responders: Preliminary report of a randomized phase 1 study. *Gastroenterology* 130:S1062, 2006. Presented at the annual meeting of the American Gastroenterological Association, May 2006.
- \*235. Di Bisceglie AM, George SL, Mihindukulasuriya KL, Hoffman J, Bacon BR. Clinical, biochemical, virologic and histologic outcomes of chronic hepatitis C following sustained virologic response (SVR) to HCV therapy: A prospective 5 year cohort study. *Hepatology* 44:315A, 2006. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October 2006.
- \*236. Shiffman ML, Suter F, Bacon BR, Nelson DR, Harley H, Sola R, Shafran SD, Barange K, Lin A, Hooper G, Zeuzem S. Peginterferon alfa-2a (40KD) plus ribavirin for 16 or 24 weeks in patients with HCV genotype 2/3 infection and advanced fibrosis/cirrhosis. *Gastroenterology* 123:A-740, 2007. Presented at the annual meeting of the American Gastroenterological Association, April 2007.
- \*237. Novozhenov V, Zakharova N, Vinogradova E, Nikitin I, Gorbakov V, Yakovley A, Pak S, Rafalski V, Bogomolov P, Alessi T, Blanchett D, McNally J, Bacon BR. Phase 2 study of Omega interferon alone or in combination with ribavirin in interferon-naïve subjects with genotype-1 chronic hepatitis C. *Gastroenterology* 123:A-778, 2007. Presented at the annual meeting of the American Gastroenterological Association, April 2007.
- 238. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, Shafran SD, Barange K, Lin A, Soman A, Zeuzem S. A randomized controlled trial evaluating 16 and 24 weeks of PEG-interferon alfa-2A plus ribavirin in patients with HCV genotypes 2 or 3. *Journal of Hepatology* 46:S245, 2007. Presented at the European Association for the Study of the Liver, April 2007.
- \*239. Bacon BR, Regev A, Ghalib RH, Morelli G, Rothstein KD, Shiffman ML, Hassanein T, Hammond J. The DIRECT trial (daily dose consensus interferon and ribavirin: Efficacy of combined therapy): Treatment of nonresponders to previous pegylated interferon plus ribavirin: Sustained virologic response data. *Hepatology* 46:90A, 2007. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2007.
- \*240. Mason AL, Lindor KD, Bacon BR, Vincent C, Neuberger JM, Wasilenko ST. Multi-center, double blind, randomized controlled trial of zidovudine and lamivudine (Combivir) therapy for patients with primary biliary cirrhosis. *Hepatology* 46:68A, 2007. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2007.

- \*241. Britton RS, Morgan HL, Migas MC, Palmer GM, O'Neill R, Sly WS, Bacon BR, Fleming RE. Functional loss of transferrin receptor 2 decreases basal hepcidin expression, but does not abolish regulation by iron or erythropoietin. *Hepatology* 46:227A, 2007. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2007.
- \*242. Schiff E, Poordad FF, Jaconson IM, Flamm SL, Bacon BR, Lawitz EJ, Gordon SR, McHutchison JH, Ghalib R, Poynard T, Sulkowski MS, Trepo C, Rizzetto M, Zeuzem S, Marcellin P, Mendez TP, Brass CA, Albrecht J. Role of interferon response during re-treatment of null responders with boceprevir combination therapy: Results of phase II trial. *Gastroenterology* 134:A755, 2008. Presented at the annual meeting of the American Gastroenterological Association, April 2008.
- \*243. Lindsay K, Manns MP, Gordon SC, Pockros P, Haussinger D, Hadziyannis SJ, Schmidt WN, Jacobson IM, BARCENA R, Shiff E, Shaikh OS, Bacon BR, Marcellin P, Smith CI, McHutchison JG, Deng W, Pedicone LD, Albrecht J. Clearance of HCV at 5 year follow-up for peginterferon alfa-2b ± ribavirin is predicted by sustained virologic response at 24 weeks post treatment. *Gastroenterology* 134:A772, 2008. Presented at the annual meeting of the American Gastroenterological Association, April 2008.
- \*244. McGeeney E, Bacon BR, Kanwal F. Prevalence of celiac disease in established liver disease and cryogenic transaminase elevation: A systematic review. *Gastroenterology* 134:A312, 2008. Presented at the annual meeting of the American Gastroenterological Association, April 2008.
- \*245. Cai CX, O'Neill R, Britton R, Bacon BR. Insulin-mediated signaling events in the activation of hepatic stellate cells. *Gastroenterology* 134:A797, 2008. Presented at the annual meeting of the American Gastroenterological Association, April 2008.
- \*246. Kanwal F, Asch SM, Schnitzler M, Pinsky B, Bacon BR. Quality of care in patient with chronic hepatitis C virus infection. *Gastroenterology* 134:A815, 2008. Presented at the annual meeting of the American Gastroenterological Association, April 2008.
- \*247. Schiff E, Poordad F, Jacobson I, Flamm S, Bacon BR, Lawitz E, Gordon S, McHutchison J, Ghalib R, Poynard T, Sulkowski M, Trepo C, Rizzetto M, Zeuzem S, Marcellin P, Mendez P, Brass D, Albrecht JK. Boceprevir combination therapy in null responders: Response dependent on interferon responsiveness. *Journal of Hepatology* 48:S46, 2008. Presented at the annual meeting of the European Association for the Study of the Liver, April 2008.
- \*248. Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, Nyberg L, Lee WM, Ghalib R, Schiff E, Galati J, Bacon BR, Davis M, Mukhopadhyay P, Noviello S, Pedicone L, Albrecht J, McHutchison J. Final results of the ideal (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. *Journal of Hepatology* 48:S370-371, 2008. Presented at the annual meeting of the European Association for the Study of the Liver, April 2008.
- \*249. Kanwal F, Asch SM, Schnitzler MS, Bacon BR. Predictors of quality care among patients with chronic hepatitis C virus infection. *Hepatology* 48:84A, 2008. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2008.
- \*250. Nyberg LM, Shiffman ML, Bonilla H, Hu KQ, Morgan TR, Levine RA, Lawitz EJ, McHutchison JG, Muir AJ, Galler GW, McCone J, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis M, Herrine SK, Gibas A, Freilich B, King JW, Rossaro L, Sulkowski MS, Mukhopadhyay P, Noviello S, Albrecht JK, Poordad F. Predicting the ability to achieve a sustained virologic response (SVR) in the first 12 weeks: Results from the IDEAL study. *Hepatology* 48:295A, 2008. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2008.
- \*251. Pockros P, Jacobson IM, Bacon BR, Afdhal MH, Poordad F, chun E, Hammond J. Taribavirin exposure analysis from a previous phase 3 trial correlates with phase 2b weight based dosing interim results. *Hepatology* 48:296A, 2008.

- \*252. Poordad F, Brau N, Lawitz EJ, Shiffman ML, McHutchison JG, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis M, Herrine SK, Gibas AL, Freilich B, King JW, Rossaro L, Mukhopadhyay P, Noviello S, Brass CA, Albrecht JK, Sulkowski MS. Hematologic safety data from the IDEAL trial: Neutropenia, anemia and thrombocytopenia profiles of peginterferon alfa/ribavirin. *Hepatology* 48:298A, 2008. Presented at the annual meeting of the American Association of the Study of Liver Diseases, October, 2008.
- \*253. Poordad F, Lawitz FE, Pozza R, Shiffman M, Bacon BR, Godofsky E, Halliman D, Heise J, Chun E, Hammond J. Efficacy and safety of weight-based regimens of taribavirin or ribavirin, given with peginterferon alfa-2b, at 12 weeks after treatment (SVR12) in naive patients with genotype 1 chronic-hepatitis c. *Journal of Hepatology* 2009;50:S8. Presented at the European Association for the Study of Liver Disease, April 2009.
- \*254. Edmundowicz A, Sanyal AJ, El-Serag HB, Dominitz JA, McQuaid KR, Martin P, Keeffe EB, Friedman LS, Ho SB, Durazo FA, Bacon BR. Measuring quality of care in patients with cirrhosis: Development of an explicit quality indicator set. *Gastroenterology* 2009;136:P35. Presented at the annual meeting of the American Gastroenterological Association, May 2009.
- \*255. Afdhal NH, Bacon BR, Patel K, Lawitz EJ, Gordon SC, Nelson DR, Challies T, Nasser I, McHutchison J. United States multicenter study of ultrasonic transient elastography (FibroScan) for the diagnosis of cirrhosis and fibrosis in patients with hepatitis B and C. *Gastroenterology* 2009;136:P109. Presented at the annual meeting of the American Gastroenterological Association, May 2009.
- \*256. Kanwal F, El-Serag HB, Schnitzler M, Paula Buchanan P, Bacon BR Completion of hepatitis C virus (HCV) treatment in community based practice—an insight into the effectiveness of treatment. *Gastroenterology* 2009;136:A830. Presented at the annual meeting of the American Gastroenterological Association, May 2009.
- \*257. Sulkowski MS, Zeuzem S, Lawitz E, Grigorescu M, Tice AD, Rustgi VK, Rodriguez-Torres M, Lurie Y, Cianciara J, Bacon BR, Bain VG, Kryczka W, Pulkstenis E, Subramanian GM, McHutchison, JG. Efficacy and safety of albinterferon alfa-2b in combination with ribavirin in treatment naïve patients with chronic hepatitis C genotype 1. *Hepatology* 50:73A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*258. Poordad F, Lawitz E, Hassanein T, Shiffman ML, Bacon BR, Muir A, Heise J, Halliman D, Chun E, Hammond JM. Sustained virologic response (SVR) results for weight-based-taribavirin versus weight-based-ribavirin, in naïve chronic hepatitis C, genotype 1 patients. *Hepatology* 50:73A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*259. Singal A, Waljee AK, Shiffman ML, Bacon BR, Schoenfeld P. Re-treatment of genotype 1 hepatitis C non-responders and relapsers to prior combination therapy: a meta-analysis. *Hepatology* 50:167A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*260. Cai C, O'Neill R, Britton RS, Bacon BR. Insulin as a novel stimulator for the initial activation of hepatic stellate cells. *Hepatology* 50:213A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*261. De D, Marwaha P, Mihindukulasuriya K, Bacon BR. New scoring classification for overlap syndrome. *Hepatology* 50:259A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*262. Marwaha P, De D, Mihindukulasuriya K, Bacon BR. Treatment of patients presenting with autoimmune hepatitis-primary biliary cirrhosis overlap syndrome. *Hepatology* 50:259A, 2009. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2009.
- \*263. Bacon BR, Shiffman ML, Lim JK, Berman A, Rustgi VK, Keeffe EB. 2001 phase 2 randomized, double-blind,

- placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in hcv genotype 1 naive patients: week 12 sustained virologic response rate. *Journal of Hepatology* 52:S463, 2010. Presented at the European Association for the Study of the Liver, April, 2010.
- \*264. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Boparai N, Sniukiene V, Brass CA, Albrecht JK, Bronowicki, j-p. Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naïve patients with hepatitis c virus (HCV) genotype (g) 1: SPRINT-2 final results. *Hepatology* 52:402A, 2010. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2010.
- \*265 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous non-responders and relapsers to peginterferon/ribavirin when re-treated with boceprevir plus peginteron (peginterferon alfa-2b)/ribavirin. *Hepatology* 52:430A, 2010. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2010.
- \*262. Poordad F, Sulkowski MS, McHutchison JG, Bacon BR, McCone J, Vierling JM, Noviello S, Boparai N, Janice K, Albrecht JK, Brass CA. High correlation between week 4 and week12 as the definition for null response to peginterferon alfa (PEG) plus ribavirin (R) therapy: Results from the IDEAL trial. *Hepatology* 52:700A, 2010. Presented at the annual meeting of the American Association for the Study of Liver Diseases, Boston, October, 2010.
- \*263. Chhatwal J, Ferrante SA, Dasbach EJ, El Khoury A, Burroughs M, Bacon BR, Esteban R, Brass CA. Projecting the Long-Term Clinical Impact of Boceprevir in Patients With Chronic Hepatitis C Genotype-1 Who Failed Prior Treatment With Peginterferon/Ribavirin. *Gastroenterology* 2011;140:S-947. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May, 2011.
- \*264. Esteban R, Gordon SC, Lawitz EJ, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Boparai N, Burroughs M, Albrecht JK, Brass CA, Bacon BR. Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR). *Gastroenterology* 2011;140:S-944. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May, 2011.
- \*265. Gordon SC, Lawitz EJ, Bacon BR, Sulkowski M, Yoshida EM, Davis MN, Boparai N, Sniukiene V, Burroughs M, Brass CA, Albrecht JK, Reddy R. Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin. *Gastroenterology* 2011;140:S-944. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May, 2011.
- \*266. Manns MP, Poordad F, Bacon BR, Bruno S, Esteban R, Silva MO, Buti M, Burroughs M, Sniukiene V, Boparai N, Brass CA, Albrecht JK, Bronowicki J-P. Response-Guided Therapy With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin Reduces Treatment Duration in NaïVE and Peginterferon Alfa-2B/Ribavirin Previous-Treatment-Failure Patients With HCV Genotype 1. *Gastroenterology* 2011;140:S-942. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May, 2011.
- \*267. Poordad F, Bronowicki J-P, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski M, Poynard T, Morgan TR, Burroughs M, Sniukiene V, Boparai N, Brass CA, Albrecht JK, Bacon BR. IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy. *Gastroenterology* 2011;140:S-941. Presented at the annual meeting of the American Gastroenterological Association, Chicago, IL, May, 2011.
- \*268. Bacon BR, Bruno S, Schiff ER, Kwo PY, Buti M, Pedicone L, Deng W, Burroughs M, Brass CA, Albrecht JK, Flamm SL. Predictors of sustained virologic response (SVR) among poor interferon (IFN) responders when boceprevir (BOC) is added to peginterferon alfa-2b/ribavirin (PR). *Hepatology* 54:76A, 2011. Presented at the

- annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
- \*269. Kanwal F, Kramer JR, Buchanan P, Asch S, Assioun Y, Gary J, Li J, Bacon BR, El-Serag H. The quality of care provided to patients with cirrhosis and ascites. *Hepatology* 54:88A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*270. McGowan CE, Monis A, Bacon BR, Mallolas J, Goncales FL, Goulis I, Poordad F, Afdhal NH, Zeuzem S, Piratvisuth T, Marcellin P, Fried MW. Barriers to hepatitis c treatment: a global analysis of physician perceptions. *Hepatology* 54:88A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*271. Hirschfield GM, Xie G, Lu E, Juran BD, Mason AL, Milkiewicz P, Myers RP, Luketic VA, Bacon BR, Bodenheimer HC, Odin JA, Liakina V, Vincent C, Levy C, Coltescu C, Lazaridis K, Amos C, Siminovitch K. Identification of *SOCS1* as a risk locus for patients with primary biliary cirrhosis. *Hepatology* 54:102A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*272. Thompson AJ, Clark PJ, Tillmann HL, Patel K, Naggie S, Poordad F, Lawitz E, Bacon BR, Vierling JM, Noviello S, Brass CA, Albrecht JK, Goldstein DB, McHutchison JG, Sulkowski MS, Muir AJ. IL28B C/C genotype is predictive of  $\geq 1 \log_{10}$  IU/mL reduction in plasma HCV RNA after 4 weeks of peginterferon (PEGIFN) and ribavirin (RBV) therapy: implications for the use of the lead-in strategy for direct-acting antiviral-based treatment regimens. *Hepatology* 54:104A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*273. Barnard RJ, Zeuzem S, Vierling JM, Sulkowski MS, Manns MP, Long J, Hazuda D, Bacon BR. Analysis of resistance-associated amino acid variants (RAVS) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase 3 clinical studies. *Hepatology* 54:105A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*274. Cai CX, Nidimusili A, Talkad VT, Bacon BR, Neuschwander-Tetri BA. Insulin is a novel anti-apoptotic factor for hepatic stellate cells. *Hepatology* 54:188A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*275. Chhatwal J, Ferrante SA, Erik J, Dasbach EJ, El Khoury A, Brass CA, Burroughs M, Bacon BR, Esteban R, Elbasha E. Cost-effectiveness of boceprevir use in patients with chronic hepatitis C genotype-1 who failed prior treatment with peginterferon/ribavirin. *Hepatology* 54:200A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*276. McCone J, Jacobson IM, Bacon BR, Pedicone L, Goteti VS, Burroughs M, Brass CA, Albrecht JK, Reddy KR. Treatment-naive black patients treated with boceprevir combined with peginterferon alfa-2b + ribavirin: results from HCV SPRINT-2. *Hepatology* 54:205A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*277. Flamm SL, Lawitz E, Jacobson IM, Bourliere M, Hezode C, Vierling JM, Niederau C, Sherman M, Bacon BR, Pedicone L, Goteti VS, Burroughs M, Brass CA, Albrecht JK, Poordad F. Overall safety profile of boceprevir (BOC) plus peginterferon alfa-2a/ribavirin in genotype 1 previous non-responders and relapsers to peginterferon/ribavirin. *Hepatology* 54:210A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*278. Lalezari JP, Hazan L, Kankam M, Lawitz E, Poordad F, Araya V, Ghalib R, Bacon BR, Flamm SL, Godofsky E, Hinestrosa F, Olek E, Robison H, Robarge L. High rapid virologic response(RVR) with ACH-1625 daily dosing plus PEGIFN-alpha 2a/RBV in a 28-day phase 2a trial. *Hepatology* 54:249A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.
  - \*279. Rodriguez-Torres M, Hillson JL, Bacon BR, Box TD, Hassanein T, Greenbloom S, Eric Lawitz E, Vargas HE,

Vierling JM, Horga M, Ramos E, Fontana D, Freeman JA, Gray TE, Bittner R, Xu D, Ishak L, Lopez-Talavera JC. Safety and efficacy of pegylated interferon lambda (PEG-lambda) compared to pegylated interferon  $\alpha$ -2a (PEG-alfa) in HCV-infected patients (g1/2/3) with compensated cirrhosis: emerge phase IIB efficacy and safety results through week 12. *Hepatology* 54:250A, 2011. Presented at the annual meeting of the American Association for the Study of Liver Diseases, San Diego, CA, November, 2011.